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A bstract
Hepatitis C virus (HCV) infection is a major public health problem worldwide yet little 
is known about mother-to-child transmission of HCV. This thesis aims to investigate 
mechanisms of mother-to-child transmission of HCV and the consequences for children 
bom to HCV infected women and is based on data from the European Paediatric HCV 
Network (EPHN) prospective study. Since 1999, over 1800 HCV infected pregnant 
women have been enrolled at 33 EPHN clinical centres in 7 countries. Their children 
were followed up every 3-6 months until 18 months of age and thereafter infected 
children were seen at least every six months, with clinical and laboratory information 
collected at each visit as per protocol.
The overall risk of mother-to-child transmission of HCV was 6.2% (95% Cl 5.0 -  
7.5%). Girls were twice as likely to be infected as boys but neither mode of delivery or 
breastfeeding were associated with the risk of transmission. Among 266 vertically 
infected children (aged up to 15 years) the prevalence of clinical signs and symptoms 
was low; hepatomegaly was reported in 10% (25), frequently with abnormal alanine 
aminotransferase results. An estimated 21% (95% Cl 15 -  29%) of infected children had 
evidence of HCV-RNA clearance. Lymphocyte levels up to age 2 years were 
significantly higher in HCV infected children, girls and children bom to HCV/HIV co­
infected women. In a survey of parents/carers of children enrolled in the EPHN, a major 
shortfall in provision of information was identified. The preferred option for long-term 
follow-up of infected children was to continue visiting the paediatrician regularly and 
later transfer to adult care, rather than postal or telephone contact or data linkage.
This work will inform the clinical management of HCV infected women and their 
children and provides evidence regarding the most appropriate approach to monitor the 
long-term consequences of vertically acquired HCV infection.
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Chapter 1 Mother-to-child transmission of hepatitis C virus
1.1 Introduction
The hepatitis C virus (HCV) was first identified in 1988 (Choo et al. 1989) as the major 
causal agent of blood-borne non-A, non-B hepatitis. Although non-A, non-B hepatitis 
was first reported in blood transfusion recipients in the early 1970s, there is evidence 
that the virus, later identified as HCV, has been present in human populations for at 
least 60 years (Seeff et al. 2000).
HCV is a non-cytopathic, hepatotropic member of the Flaviviridae and the HCV 
genome is a 9.6-kilobase single-stranded, positive-sense ribonucleic acid (RNA) 
molecule (Chisari 2005). There are six major HCV genotypes ( 1 - 6 )  and more than 50 
subtypes (Farci and Purcell 2000). The predominant subtypes in western Europe and 
north America are la  and 3a, and subtype lb  is common in southern and eastern Europe 
and Japan. Genotypes 4 and 5 are mainly found in Africa (Farci and Purcell 2000). 
Around 70-75% of acute HCV infections persist (Poynard et a l 2003;Flamm 2003), in 
contrast to around 10% chronicity in hepatitis B infection (Poynard et al. 2003). 
Chronic HCV infection is a major cause of liver disease and death worldwide (Butt 
2005) and there is currently no vaccine available.
The first diagnostic tests for HCV infection became available in 1989 soon after the 
virus was identified. However, the sensitivity of these serological assays was only 64% 
for ELISA (enzyme-linked immunosorbent assay) and 55% for the confirmatory 
recombinant immunoblot assay (RIBA), resulting in a high proportion of false negative 
tests (Colin et al. 2001). The second and third generation assays, available since 1991 
and 1993 respectively, have much improved sensitivity and specificity, estimated at
16
99% and 100%, respectively (Colin et a l 2001). Anti-HCV can also be detected in oral 
fluid specimens with a modified ELISA, with 92% sensitivity and 99% specificity (Judd 
et a l  2003). This method is particularly suited to large population-based studies to 
estimate prevalence (Judd et a l 2005).
Presence of HCV-RNA is detected by polymerase chain reaction (PCR) and indicates 
active viral infection. Qualitative PCR assays are used to diagnose infection while 
progression of disease and response to treatment are often monitored with quantitative 
assays which measure viral load. The second version assays have a lower detection limit 
of about 50 IU/ml for qualitative assays and 600 IU/ml for quantitative assays (Lee et 
a l 2000), although the quantitative assays vary and results are not always directly 
comparable (Erensoy 2001). Two commercial assays have also been developed which 
detect HCV core antigen rather than viral nucleic acids. Although not as sensitive as 
PCR, they are considerably cheaper and do not require sophisticated laboratory 
equipment (Seme et a l  2005). These assays are therefore of potential value in resource- 
poor settings as an alternative to PCR but this may not be possible as active marketing 
by the manufacturer has now stopped due to lack of interest in western countries (Seme 
et a l 2005).
The development of assays to detect anti-LJCV antibody enabled the introduction of 
blood supply screening, a crucial first step in preventing further nosocomial infections, 
although many individuals, particularly those with haemophilia, were already infected. 
Blood supply screening started in the UK in September 1991 and in most other 
developed countries around this time, but there were considerable delays in the 
introduction of effective screening in some countries, such as Italy and Canada, which 
has led to convictions of negligence and compensation programmes (Weinberg et a l
17
2002). In recent years HCV-RNA testing of blood donations has been introduced in 
several countries to further improve the security of the blood supply (Soldan et al. 
2003;Gonzalez et al. 2005a).
Progress in understanding host-virus interactions has been hindered by the lack of a 
non-primate animal model and, until recently, cell culture. The first robust cell culture 
systems for HCV were only reported in June 2005 (Lindenbach et al. 2005;Zhong et al. 
2005). The development of a vaccine has been hampered by the considerable genetic 
heterogeneity of the virus (Farci and Purcell 2000) among other factors, but recent work 
on mechanisms of spontaneous viral clearance and chimpanzee models, in combination 
with the new cell culture systems, indicate that a vaccine could be available within the 
next decade (Houghton and Abrignani 2005).
Although an HCV small-animal model is not available, the veterinary pestiviruses, 
including bovine viral diarrhoea virus (BVDV), have genome homology to HCV. Work 
on BVDV, including transplacental infection, may contribute to understanding the 
genetic diversity of HCV and future development of vaccines (Stokstad et al. 
2004;Young et al. 2005).
Thus, over the last 18 years there have been considerable advances in understanding 
HCV from a basic science perspective, alongside increasing recognition of the 
significance of HCV infection as a major public health problem worldwide (Butt 
2005;Chisari 2005). The first documented case of mother-to-child transmission of HCV 
was reported in 1991 (Thaler et al. 1991). With the risk of infection through 
contaminated blood products now negligible, mother-to-child, or vertical, transmission 
is the main route of infection in children.
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1.2 Prevalence of HCV infection
The estimated global prevalence of HCV infection is 3%, that is, more than 170 million 
infected individuals (WHO 2002;Poynard et al. 2003). Table 1.1 shows prevalence 
estimates for a range of populations, both general and antenatal. Most estimates come 
from specific studies, often of selected groups, such as blood donors or pregnant 
women. While prevalence estimates from antenatal populations are usually a good 
proxy for prevalence in the general population, estimates from blood donors often 
underestimate the overall population prevalence as high risk groups are excluded from 
donating (Touzet et al. 2000). Population-based surveys provide more reliable age and 
sex specific estimates.
Overall the prevalence o f HCV infection in general populations is about 1 % in Europe 
but marked geographical variations exist both between and within countries (Table 1.1). 
The prevalence is generally higher in southern than northern Europe and higher in 
eastern than western Europe (Nalpas et al. 1998;Tiribelli et al. 2003;Touzet et al. 2000). 
In the UK, more than 200,000 individuals are estimated to be infected, a prevalence of 
around 0.5% (Health Protection Agency, 2005). Although low compared to southern 
Europe, this is four times the number living with human immunodeficiency virus (HIV) 
infection (The UK Collaborative Group for HIV and STI Surveillance. 2005).
Italy has one of the highest prevalences in Europe (Table 1.1) and there is a strong 
north-south gradient. In one national study the age-adjusted prevalence in northern Italy 
was 1.6%, in line with other southern European countries, but 6.1% and 7.3% in central 
and southern Italy, respectively (Ansaldi et al. 2005). In central and southern regions, a 
cohort effect is evident with much higher prevalence in individuals older than 30 years 
which has been linked to iatrogenic transmission during polio vaccination campaigns in
19
the 1950s and 1960s (Montella et a l  2003). Even in population groups considered to be 
at low risk for HCV, the prevalence in Naples was 8.5% (95% Cl 7.2 -  9.7) among 
general practice patients and 6.4% (95% Cl 4.7 -  8.2) among employees o f the National 
Cancer Institute (Montella et a l  2005).
Estimates of the antenatal prevalence of HCV infection range from less than 1% to 
about 2.5% in Europe (Newell and Pembrey 2002) and reflect the overall prevalence in 
each country, although higher prevalence has been reported among certain sub-groups, 
such as injecting drug users (Goldberg et a l  2001) and women from areas of high HCV 
prevalence (Rao et a l  2002) (Table 1.1).
Some geographical variation exists within specific risk groups; for example, the 
prevalence of HCV infection was 35% and 57% in London and Glasgow, respectively, 
among recent initiates to injecting drug use (IDU) (Judd et a l 2005). Of nearly 2000 
HIV infected patients in France, 42% were HCV infected (95% Cl 40 -  45%) (Saillour 
et a l 1996). The HCV prevalence among HIV infected patients in London was 
considerably lower at 8.9% but varied from 1.8% among those who acquired HIV 
through heterosexual transmission to 82% among those who acquired HIV through IDU 
(Mohsen et a l  2005).
The prevalence in north and south America is in line with the upper range of European 
estimates (Table 1.1). The prevalence in Brazilian army recruits is rather high 
considering the young age of this group and may be associated with injecting drug use 
in some cases. In the Chilean study the prevalence increased with age, a similar finding 
to studies in Europe.
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Moderate to high prevalences have been reported for African and Asian populations 
(Table 1.1) (Wada et al. 2002;Madhava et al. 2002). Recent evidence indicates that the 
high prevalence in some regions is likely to be due to iatrogenic transmission during 
vaccination campaigns 20 or 30 years ago or other unsafe medical practices, some of 
which may still occur. The best documented of these is Egypt with the highest reported 
prevalence in a general population of 15-20%, due to transmission of the virus through 
infected needles used during mass treatment campaigns for schistosomiasis (Rao et al. 
2002). Pakistan also has high prevalence in some areas (Ahmad 2004), hypothesised to 
be associated with smallpox vaccination (Aslam et al. 2005).
The HCV prevalence estimates for antenatal African populations vary (Table 1.1) and 
may be due to true differences in exposure between regions. However, seroprevalence is 
difficult to assess in sub-Saharan Africa even with 3rd generation assays because of the 
high frequency of false-positive results (note the apparent lower proportion o f viraemia 
among anti-HCV positive subjects from African studies in Table 1.1); intercurrent 
infections leading to hyperglobulinemia may contribute to the high false positive rate 
(Rouet et al. 2004).
National population-based studies have been conducted in Japan and the prevalence is 
high in some regions (Table 1.1). In Australia, HCV is the leading notifiable infectious 
disease (Amin et al. 2004) with an estimated prevalence of 1-2% in women of 
childbearing age (Sfameni et al. 2000).
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Table 1.1 Prevalence of HCV infection in a range of general and antenatal 
populations
Subjects and setting Prevalence of HCV infection 
(% of anti-HCV antibody 
positive subjects)
Proportion of anti- 
HCV antibody positive 
subjects with HCV- 
RNA positivity
General population estimates
Estimate for EU countries overall* 0.9% -
(Nalpas et al. 1998) range 0.1% -  3%
3393 general population >2 yrs 
(hospital laboratory samples), Italy 
(Ansaldi et al. 2005)
2.6% (2.1 -3 .2 ) 
age-adjusted 4.4%
56%
Estimate for England based on 
seroprevalence studies 1995/96 
(HPA 2005)
0.5%
11,456 adults, general population, 
Oslo, Norway (Dalgard et al. 2003)
0.8% 72%
21,241 participants ofNHANES III 
1988-1994 (representative of general 
U.S. population) (Alter et al. 1999)
1.8% 74%
5508 Army conscripts, Brazil 
(Toledo, Jr. et al. 2005)
1.5% (95% Cl 1.2- 1.8) -
959 adults, general population, Chile 
(Gonzalez et al. 2005b)
1.1% (95% Cl 0 .48- 1.82) 
0.8% RIBA confirmed
63%
2042 subjects from rural Republic of 
Equatorial Guinea (Basaras et al. 
1999)
1.7% overall
5.6% in subjects >40 yrs
966 blood donors & antenatal clinic 
attenders, Kumasi, Ghana
2.7% (RIBA confirmed) 27%
(Wansbrough-Jones et al. 1998)
8499 Egyptians,
10-50 years old (Frank et al. 2000)
21.9% (95% Cl 21.0-22.8) 
overall age-adjusted
-
523 volunteers, Lahore, Pakistan 14.9% -
(Aslam et al. 2005)
2973 individuals, community-based 
study, West Bengal, India 
(Chowdhury et al. 2003)
0.87% 81%
2036 voluntary blood donors, 
Hyderabad, India (Khaja et al. 2005)
2.4%
161,307 subjects >30 years old, Saga 
Prefecture, western Japan (Wada et 
al. 2002)
8.1% 60%
459 residents, Masago community, 
Taiwan (Wang et al. 1999)
5 7 .9%  age- & sex-adjusted -
2800 samples in a national 
serosurvey, Australia (Amin et al. 
2004)
2.3% (95% Cl 1 .8-2 .9) 
age-standardised
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Table 1.1 continued:-
Subjects and setting Prevalence of HCV infection 
(%  of anti-HCV antibody 
positive subjects)
Proportion of anti- 
HCV antibody positive 
subjects with HCV- 
RNA positivity
Antenatal populations
15,250 pregnant women, Bergamo, 
Italy (Conte et al. 2000)
2.4% 72%
5000 anti-HIV negative pregnant 
women, Florence, Italy (La Torre et 
al. 1998)
1.6% (RIBA confirmed) 70%
3631 pregnant women, Obstetrics 
Dept., Bologna, Italy (Bellu et al. 
1999)
1.8% (ELISA) 70%
3003 pregnant women, Granada, 
Spain (Salmeron et al. 1998)
0.63% (ELISA) 
0.53% (RIBA)
74%
2929 pregnant women, Salamanca, 
Spain (Gutierrez-Zufiaurre et al. 
2004)
0.4%
4729 pregnant women, St Mary’s 
hospital, London, UK (Ward et al. 
2000)
0.8%
Overall UK estimate from unlinked
anonymous testing of neonatal dried 
blood spot samples (Ades et al. 
2000)
0.16% (range 0.09-0.25) -
30,259 neonatal dried blood spot 0.29% -0.40% -
samples, Scotland (Hutchinson et al. 
2004)
1098 pregnant women, Moldova 
(eastern Europe) (Drobeniuc et al. 
1999)
2.3%
150 pregnant women, rural Malawi 16.5% -
(Ahmed et al. 1998)
980 pregnant women, District 
Hospital, Ifakara, Southern Tanzania 
(Menendez et al. 1999)
5% (ELISA)
2.3% (RIBA confirmed)
31%
35%
501 HIV positive and 501 HIV 
negative pregnant women, Abidjan, 
Cote d’Ivoire (Rouet et al. 2004)
HIV positive: 1.2% (95% Cl 
0.44 -  2.59)
HIV negative: 0.8% (95% Cl 
0.22-2.03)
131 pregnant women; IDUs, 
methadone maintenance programme, 
NSW, Australia (Spencer et al. 1997)
95.4% 62%
* individual country estim ates from studies o f  representative sam ples o f  the population (B elgium , France 
and Spain) or from official estim ates derived from blood donors or selected groups (Austria, Denmark, 
Finland, Germany, G reece, Ireland, Italy, Luxembourg, The Netherlands, Portugal, Sw eden, UK )
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1.3 HCV infection in adults
Most HCV infections in adults are acquired through percutaneous exposure to infected 
blood via injecting drug use, receipt of blood products or transfusions before 1991 when 
screening was introduced, tattooing or piercing. Sexual and household transmission of 
HCV does occur but rarely (Wejstal 1999;Ackerman et al. 2000) and there are reports 
of occupational transmission in health care workers (Sulkowski et al. 2002). Most 
studies investigating the risk o f sexual transmission have estimated prevalence or 
incidence of HCV infection in sexual partners of HCV infected individuals and indicate 
a low risk (Rooney and Gilson 1998;Vandelli et al. 2004). However, these are usually 
monogamous relationships likely to be at low risk of sexually transmitted infections in 
general. Genito-urinary medicine (GUM) clinic attenders are more representative of 
those at high risk for sexually transmitted infections. In a national UK study Balogun et 
al. (Balogun et al. 2003) found a low HCV prevalence of 0.65% among non-IDU GUM 
clinic attenders, confirming a low risk of sexual transmission of HCV.
HCV infection persists in 70% to 85% of adults who acquire infection and causes 
slowly progressive disease which can lead to liver cirrhosis and hepatocellular 
carcinoma (Poynard et al. 2003;Flamm 2003). The first natural history studies of HCV 
tended to overestimate the rate of disease progression to cirrhosis and hepatocellular 
carcinoma as they were biased by the inclusion of symptomatic patients, often without 
known date of acquisition (Alter 2005). More recent prospective studies and long-term 
follow-up of cohorts with known date of acquisition have shown that in many cases 
progression to serious disease can take decades. Dore et al. (Dore et al. 2002) developed 
a Markov model based on a review of adult natural history studies and estimated the 
risk of progression to cirrhosis to be 7% after 20 years and 20% after 40 years of
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infection. Estimates for hepatitis C-related mortality were 1% after 20 years and 4% 
after 40 years.
In the UK, an adult cohort of transfusion recipients with known date of acquisition of 
infection was identified and HCV related disease and mortality described after 10 years 
of infection (Harris et al. 2002). 117 of 924 (13%) patients had died, 29 (25%) of whom 
had one or more liver related conditions on their death certificate. This represented a 
higher risk of death from liver disease than controls but was not statistically significant. 
Clinical follow-up of 826 patients showed abnormal liver function in 307 (37%), and 
115 (14%) reported physical signs or symptoms of liver disease.
Irish women infected with anti-D immunoglobulin constitute another cohort with 
known date of acquisition of infection. After 22 years of follow-up the course o f HCV 
infection was described as benign with a lack of disease progression and low incidence 
o f extra-hepatic manifestations, although high levels of psychological distress and poor 
quality of life were reported (Barrett et al. 2001). Another group of Rhesus-negative 
women were infected with HCV through contaminated anti-D immunoglobulin in 
Germany in 1978/9. A similar mild course of disease was observed after 25 years 
follow-up: nearly half o f the women (883/1833) were HCV-RNA negative without 
treatment, 30 (1.6%) had pre-cirrhotic stage-disease, only nine (0.5%) had cirrhosis and 
one had hepatocellular carcinoma. Ten women (0.5%) had died from HCV-related 
complications (Wiese et al. 2005). A Spanish study showed a higher rate of progression; 
37 of 94 patients (39%) had progressed to cirrhosis and 7 of 100 patients had developed 
hepatocellular carcinoma 20 years after diagnosis (Foms et al. 2001). However, many 
of the patients may have become infected up to 20 years before diagnosis.
25
There is now good evidence to show that progression of fibrosis is not linear but J- 
shaped, i.e. the rate of progression increases over time (Ryder et al. 2004). Duration of 
infection, age, male sex, alcohol consumption, HIV co-infection and being overweight 
have been associated with a greater rate of fibrosis progression (Poynard et al. 
2003;Freeman et al. 2003;Poynard et al. 1997).
Cirrhosis and hepatocellular carcinoma are the most obvious consequences of HCV 
infection but there is some evidence to suggest that certain extra-hepatic conditions may 
also be associated with HCV infection. Fatigue, arthralgia, paraesthesia, myalgia, 
pruritus and sicca syndrome have often been reported among HCV infected individuals 
at a higher prevalence than expected in the general population (Poynard et al. 2003). 
Lichen planus has been associated with HCV infection (Ghodsi et al. 2004) and a 
significantly higher prevalence of autoantibodies has been observed in individuals with 
chronic HCV infection compared to unselected healthy adults (Zusinaite et al. 2005). A 
U.S. study of male veterans found that HCV infected patients were significantly more 
likely to have skin disorders (porphyria cutanea tarda, vitiligo, lichen planus) and 
cryoglobulinaemia (an autoimmune disorder) than controls (El-Serag et al. 2002). 
Individuals with chronic HCV infection may be at increased risk o f non-Hodgkin’s 
lymphoma (Cowgill et al. 2004;Paydas 2002;Negri et al. 2004;Duberg et al. 2005).
The treatment options for chronically infected individuals have improved substantially 
in recent years. Sustained virological response (HCV-RNA negative at least 6 months 
after cessation of therapy) is achieved by more than 50% of patients receiving 
combination therapy of peg-interferon alpha and ribavirin (Poynard et al. 2003;Manns 
et al. 2001) with higher rates of up to 80%-90% in adults infected with genotypes 2 and 
3 (Zeuzem et al. 2004). Interferon treatment has been shown to improve survival in
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people with a biochemical as well as a virological response by preventing liver-related 
deaths (Kasahara et al. 2004). New treatment options are being developed; the efficacy 
of an NS3 protease inhibitor has recently been investigated with promising results and 
further development is underway (Lamarre et al. 2003) and novel immunomodulatory 
agents are being explored (De Francesco and Migliaccio 2005).
There is evidence from a recent study to suggest that HCV may persist at very low 
levels in individuals with sustained virological response to treatment (Pham et al. 2004). 
HCV-RNA was detected in serum and peripheral blood mononuclear cells with a highly 
sensitive assay in 16 patients up to 5 years after recovery. In 9 o f 12 patients, the HCV- 
RNA negative strand was detected suggesting viral replication. It is unclear whether 
these trace amounts could reactivate infection or pose a risk of transmission to others 
and further investigation is needed.
1.4 HCV infection and pregnancy
HCV infection is not a contraindication for pregnancy. No increase in spontaneous 
miscarriage or obstetric complications was observed in subsequent pregnancies among 
the cohort of women infected by contaminated anti-D immunoglobulin in Ireland 
(Jabeen et al. 2000). Results from an Italian study (Conte et al. 2000) may even suggest 
a favourable temporary effect of pregnancy on HCV infection; ALT levels decreased 
during pregnancy in viraemic women and then increased again after delivery and this is 
unlikely to be completely explained by haemodilution. In a study from Japan, HCV- 
RNA became undetectable in 3 of 22 (14%) pregnant HCV infected women and only 2 
of 120 (2%) non-pregnant controls (Hattori et al. 2003). However, results of a case- 
control study in which liver biopsy samples taken before and after delivery from 12 
HCV infected women were compared with biopsies from 12 non-pregnant HCV
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infected women, suggest that pregnancy may exacerbate HCV-related liver damage 
(Fontaine et al. 2000). This may be mediated by immunological changes which 
normally occur during pregnancy and post-partum and the longer-term impact on liver 
disease is unknown (Fontaine et al. 2000). These studies were small and further work is 
needed to clarify the effect of pregnancy on HCV infection.
1.5 Antenatal screening
The most commonly reported risk factors for acquisition of HCV infection among 
pregnant women are injecting drug use and receipt of blood transfusions or blood 
products. Other factors often reported include surgical procedures and sexual partner of 
an HCV infected person or injecting drug user but a substantial proportion of infected 
women do not report any specific risk factor (Ward et al. 2000;Conte et al. 2000).
Infected women are identified by detection of anti-HCV antibodies in a blood sample. 
Routine antenatal screening for HCV infection is widespread in Italy since first being 
recommended by the Ministry of Health in 1995 (Decreto Ministeriale - Ministero della 
Sanita 1995) and universal antenatal screening has been recommended by the Royal 
Australian and New Zealand College of Obstetricians and Gynaecologists (Hardikar et 
al. 2006). However, in most countries there is not a national policy of offering screening 
to all pregnant women but women may be -tested if they are considered at high risk of 
being HCV infected, for example, if they have a history of injecting drug use or 
received blood products before 1991. Routine testing of pregnant women may occur in 
specific centres, but this is usually limited to inner city hospitals which serve 
populations with a high proportion of women with risk factors for acquisition of HCV 
(European Paediatric HCV Network et al. 1999;Ward et al. 2000). As women are in 
contact with medical services during pregnancy the antenatal period represents a good
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opportunity to test those who may not otherwise be tested. Several studies have shown 
that a high proportion of infected women are first identified in pregnancy. For example, 
two thirds of infected women were newly identified by antenatal screening in a research 
setting in an inner London hospital (Ward et al. 2000) and in Scotland diagnosis 
occurred before pregnancy in only a quarter of infected women (Hutchinson et al. 
2004).
Generally, before the introduction o f a policy to routinely offer testing to all pregnant 
women, the balance of benefits and risks of such a screening programme must be 
considered. The criteria often used to do this are adapted from Wilson and Jungner 
(Wilson and Jungner 1968) and state that the condition must be an important public 
health problem; the natural history is well understood; a safe, valid and reliable 
screening test is available which is acceptable to those being tested; treatment or an 
intervention of proven effectiveness is available; the risk of harm, both physical and 
psychological, is less than the chance of benefit.
HCV infection is an important public health problem and the 3rd generation ELISAs are 
a safe screening test with high sensitivity and acceptable specificity. However, the 
natural history of infection in children is not well understood and there are currently no 
interventions to prevent mother-to-child transmission so the chance o f benefit is 
outweighed by the likely anxiety and other psychological costs associated with a 
positive test. Thus, in the case of HCV infection, only 2 of the 5 criteria for routine 
screening are satisfied (Pembrey et al. 2003a). On the basis of these considerations, the 
UK Department of Health National Screening Committee did not recommend the 
introduction of national routine antenatal screening for HCV in 2001/2; this policy is in
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line with European (Consensus Panel 1999) and US guidelines (American Academy of 
Pediatrics 1998).
1.6 Risk of and risk factors for mother-to-child (vertical) transmission of HCV
1.6.1 Timing of transmission
Mother-to-child transmission of HCV infection can occur before or during delivery. To 
date, there is no evidence that it occurs postnatally during breastfeeding. In a recent 
analysis of 54 infected children from the European Paediatric HCV Network (EPHN) 
with a PCR result in the first 3 days of life it was estimated that at least one-third but 
possibly up to half of infected children acquire HCV in utero with the remainder 
infected in the peripartum (late intrauterine, intrapartum) period (European Paediatric 
HCV Network et al. 2005b). Detection of HCV-RNA by PCR soon after birth is 
assumed to indicate in utero transmission (Bryson et al. 1992). This finding was in line 
with an Italian study of 403 mother-child pairs with 6 of 13 infected children HCV- 
RNA positive immediately after birth (Resti et al. 1998). The combined evidence 
suggests that an estimated 40% of children acquire infection around the time of delivery 
which would indicate a potential role for elective caesarean section delivery in reducing 
the risk of mother-to-child transmission of HCV (Gibb et al. 2000a;European Paediatric 
HCV Network et al. 2001). Results of the EPHN work suggest that patterns of PCR 
results (age at first positive PCR) in infants-which by some may be taken as evidence of 
transmission through breastfeeding are also consistent with late intrapartum 
transmission (European Paediatric HCV Network et al. 2005b).
1.6.2 Risk of transmission
Estimates of the risk of HCV vertical transmission range from about 3% to 10% 
(Pembrey et al. 2003a) (Figure 1.1). This variation is due to the small size of most
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studies and to differences in the distribution of risk factors between the populations 
studied. However, the confidence intervals overlap suggesting few statistically 
significant differences between study estimates. The most precise estimates are obtained 
from large prospective studies: the risk of transmission was 7.1% (95% Cl 5.8 -  8.6) in 
a recent Italian multi-centre study of 1372 mother-child pairs (Resti et a l 2002a).
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Figure 1.1
Estimates of HCV vertical transrrisson risk 
(with 95% confidence intervals) from studies of 
over 100 mother-child pairs
1.6.3 Risk factors
Table 1.2 summarises the design and main findings of all studies investigating risk 
factors for mother-to-child transmission of HCV which included over 100 mother-child 
pairs.
Maternal HIV co-infection
Maternal HIV co-infection has consistently been associated with an increased risk of 
HCV vertical transmission, probably through higher HCV viral load in these women 
due to maternal immunosuppression (European Paediatric HCV Network et al. 
2001;Tovo et al. 1997;Zanetti et al. 1998). In a meta-analysis of 10 studies including a 
total of 2382 mother-child pairs, the overall combined odds ratio for HCV vertical 
transmission was 2.82 (95% Cl 1.78 -  4.45, p<0.001) for co-infected women compared 
to women with only HCV infection. In a sub-analysis including only HCV viraemic 
women, the pooled estimate was 1.97 (95% Cl 1.04 -  3.74, p=0.04) indicating that 
maternal HIV co-infection was a significant risk factor for HCV transmission even 
when controlling for maternal viraemia (Pappalardo 2003). However, in one study of 
155 mother-child pairs, none of the 15 HCV/HIV co-infected women transmitted HCV 
to their infants and this was thought to be due to receipt o f antenatal anti-retroviral 
therapy in all the co-infected women which may have reduced their HCV as well as the 
HIV viral load.
Maternal HCV RNA viral load
Maternal HCV RNA viral load is likely to be the predominant risk factor for vertical 
transmission of HCV. Although presence of viraemia or high viral load during 
pregnancy have been associated with an increased risk of transmission in some studies 
(Table 1.2, (Steininger et al. 2003;0kamoto et al. 2000;Giacchino et al. 1998;Ferrero et
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al. 2003)), this has not been reliably quantified in large studies. Although the risk of 
transmission seems to increase with increasing viral load (Mast et al. 2005), the 
distributions of viral load in transmitting and non-transmitting mothers overlap in 
several studies (Resti et al. 1998;Zanetti et al. 1998) and it is not possible to identify a 
level below which transmission is very unlikely.
Maternal injecting drug use
Maternal injecting drug use has been associated with an increased risk of transmission 
in one study (adjusted odds ratio (OR)=1.53, 95% Cl 1.21 -  1.93, p=0.0003) (Resti et 
al. 2002a). The risk of transmission in current and past IDUs was similar. However, this 
has not been confirmed in any other studies (Table 1.2) and concerns have been 
expressed about possible inadequate adjustment for confounders (Armstrong et al. 
2003).
Gestational age
Gestational age has been investigated as a potential risk factor for HCV vertical 
transmission following the increased risk of HIV mother-to-child transmission among 
premature infants (Kuhn et al. 1997;Italian Register for HIV Infection in Children 
1994;European Collaborative Study 2005). However, there is no evidence to suggest 
that gestational age is significantly associated with HCV transmission (Tovo et al. 
1997;Spencer et al. 1997;Resti et al. 2002a). There was no significant difference in risk 
of transmission between term and premature infants in a large Italian study (OR=1.08, 
95% Cl 0.69 -  1.47, p=0.68) (Resti et al. 2002a).
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Table 1.2 Design and main findings of studies investigating risk factors for mother-to-child transmission of HCV 
(all published studies including at least 100 mother-child pairs)
Setting and 
time of 
study 
(reference)
Total no. of 
mother- 
child pairs
Study design Definition of 
infant HCV 
infection
Risk of 
vertical 
transmission 
% (95% Cl)
No. (%) of 
HCV/HIV 
co-infected 
mothers
Factors significantly 
associated with 
vertical transmission
Comments
Europe
(European
Paediatric
HCV
Network et 
al. 2001)
24 centres
1992- 1998
1474 Retrospective 
analysis of 
prospectively 
collected data
>2 positive HCV- 
RNA PCR tests 
and/or anti-HCV 
positive >18 
months
9.2%
(7.8-10.8)
503 (35%)
- Maternal HIV co- 
infection
- In HCV/HIV co- 
infected women only: 
reduced risk with 
caesarean section; 
increased risk with 
breastfeeding
- Infant HIV infection
Risk of vertical 
transmission could be an 
overestimate -  possible 
bias towards increased 
reporting of infected 
children
Italy (Resti 
et al.
2002a)
24 centres
1993 - 1996
1372 Prospective; all 
pregnant women 
tested
1 positive HCV- 
RNA PCR or anti- 
HCV positive >2 
years
7.1%
(5 .8 -8 .6 )
194(14%) - Maternal IDU
- Maternal HCV RNA
Maternal HIV and IDU 
strongly correlated;
One infected child bom to 
an HCV-RNA negative 
woman;
Vertical transmission risk 
similar in active and past 
IDUs
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Table 1.2 continued
Setting and 
time of 
study 
(reference)
Total no. of 
mother- 
child pairs
Design Definition of 
infection
Risk of 
vertical 
transmission 
% (95% Cl)
No. (%) of 
HCV/HIV 
co-infected 
mothers
Factors significantly 
associated with 
vertical transmission
Comments
UK and 
Ireland 
(Gibb et al. 
2000a)
1994- 1999
441 i) Prospective: 
Jan 94 -  Apr 99, 
3 Dublin 
hospitals
ii) active 
surveillance 
through BPSU 
Mar 97 -  Apr 99
Definitive 
diagnosis or 
exclusion of 
infection not 
possible for most 
children*
6.7%
(4.1-10.2)
estimated 
from sum of 
individual 
probabilities*
22 (5%)
unknown 
HIV status 
for 91 (21%)
- Mode of delivery: 
elective CS 0% vs. 
other modes 7.4%
- Maternal HIV co- 
infection (borderline)
* Infant infection status 
imputed - probability of 
infection estimated for 
each child based on time 
to antibody loss and 
sensitivity and specificity 
of PCR at different ages. 
Only 31 elective CS 
deliveries
Italy (Resti 
et al. 1998) 
19 centres
possible 
overlap 
with (Resti 
et al. 
2002a)
442
(403
completed 
the study)
Prospective; all 
women tested
>1 positive HCV- 
RNA PCR test or 
anti-HCV positive 
> 2 years
3.2%
(1 .7 -5 .5 )
4.7% in HCV- 
RNA positive 
women
none: HIV 
infected 
women not 
included
- Maternal acquisition 
through blood 
transfusion or IDU 
(higher risk of VT than 
mothers with no known 
risk factor)
No multivariable analysis
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Table 1.2 continued
Setting and 
time of 
study 
(reference)
Total no. of 
mother- 
child pairs
Study design Definition of 
infant HCV 
infection
Risk of 
vertical 
transmission 
% (95% Cl)
No. (%) of 
HCV/HIV 
co-infected 
mothers
Factors significantly 
associated with 
vertical transmission
Comments
Lombardy
region,
Italy
(Zanetti et 
al. 1998)
1990 -
291 Prospective >1 positive HCV- 
RNA PCR test or 
anti-HCV positive 
>18 months
5.8%
(3 .4 -9 .2 )
40(14%) - Maternal HIV co- 
infection
- Median HCV viral 
load higher in 
transmitting than non­
transmitting mothers 
but ranges overlap
Italy (Tovo 
etal. 1997)
12 centres
245 Prospective >2 positive HCV- 
RNA PCR tests 
and/or anti-HCV 
positive >18 
months
11.4%
(7.5-15.3)
165 (67%) - Elective CS -  lower 
risk (borderline)
USA
(Houston
and
Honolulu) 
(Mast et al. 
2005)
1993 - 1998
244 Prospective >2 positive HCV- 
RNA PCR tests 
and/or anti-HCV 
positive >24 
months
3.7%
(1.8 -  7.1)
11 (5%) - Maternal HIV co- 
infection
- Internal fetal 
monitoring
- Membrane rupture >6 
hours
Multivariable analysis 
restricted to HCV-RNA 
positive mothers
332 of 567 women agreed 
to participate, of these 244 
completed >12 months 
follow-up
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Table 1.2 continued:-
Setting and 
time of 
study 
(reference)
Total no. of 
mother- 
child pairs
Study design Definition of 
infant HCV 
infection
Risk of 
vertical 
transmission 
% (95% Cl)
No. (%) of 
HCV/HIV 
co-infected 
mothers
Factors significantly 
associated with 
vertical transmission
Comments
Southern 
France 
(Marine- 
Barjoan et 
al. 2005)
multicentre
1998-2002
240 Prospective HCV-RNA PCR 
positive at 3 
months with same 
genotype as 
mother
5.6%
(2.9 -  9.5)
62 (26%) - Maternal HIV co- 
infection
- High maternal HCV 
viral load
France 
(Poiraud et 
al. 2001)
1992-2000
161 Case-control HCV-RNA 
positive after one 
month of age
Cannot 
estimate from 
case-control 
study
none - Vaginal delivery with 
forceps
All women were HCV- 
RNA positive and HIV 
negative
USA/Puerto
Rico
(Thomas et 
al. 1998)
4 centres
1989- 1994
155 Prospective >1 HCV-RNA 
PCR positive test
8.4%
(4.5-13.9)
155 (100%) - High maternal HCV 
viral load
- Infant HIV infection
All women HIV infected 
and enrolled in the 
Women and Infants 
Transmission Study
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Table 1.2 continued:-
Setting and 
time of 
study 
(reference)
Total no. of 
mother- 
child pairs
Study design Definition of 
infant HCV 
infection
Risk of 
vertical 
transmission 
% (95% Cl)
No. (%) of 
HCV/HIV 
co-infected 
mothers
Factors significantly 
associated with 
vertical transmission
Comments
Bergamo, 
Italy (Conte 
et al. 2000)
155
(followed to 
12 months)
Prospective >1 HCV-RNA 
PCR positive test
5.1%
(2.2 -  9.9)
15(10%) None
New York 
City, USA 
(Granovsky 
et al. 1998)
5 clinics
1986- 1991
122 Prospective >2 positive HCV- 
RNA PCR tests 
and/or anti-HCV 
positive >18 
months
5.7%
(2.3-11.5)
73 (60%) None All infants followed for at 
least 12 months
Japan
(Tajiri et al. 
2001)
7 hospitals 
in Osaka 
area
1993 - 1998
114 Prospective >2 positive HCV- 
RNA PCR tests
7.8%
(3.7-14.4)
none - Maternal HCV 
viraemia
- High maternal HCV 
viral load
All infants followed for at 
least 6 months
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Table 1.2 continued:-
Setting and 
time of 
study 
(reference)
Total no. of 
mother- 
child pairs
Study design Definition of 
infant HCV 
infection
Risk of 
vertical 
transmission 
% (95% Cl)
No. (%) of 
HCV/HIV 
co-infected 
mothers
Factors significantly 
associated with 
vertical transmission
Comments
Trieste,
Italy (Dal 
Molin et al. 
2002)
1994 - 2000
105 Prospective >1 HCV-RNA 
PCR positive test
4.8%
(1.6-10 .8)
6.6% in HCV- 
RNA positive 
women
12(11%) Among HCV-RNA 
positive mothers:
- High maternal HCV 
viral load
- Maternal IgM anti- 
HCV
All infants followed for at 
least 12 months
No transmission from 
HCV-RNA negative 
women
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Gender
Most studies have not considered the effect of gender. One found a higher proportion of 
infected children among girls but not a statistically significant difference (Granovsky et 
al. 1998).
Mode of delivery
Avoidance of contact between maternal blood and genital secretions and the infant 
could theoretically reduce the risk o f intrapartum HCV transmission. Elective caesarean 
section delivery has therefore been considered as a potential protective factor for 
vertical transmission.
However, a lack of effect of elective caesarean section on the risk o f mother-to-child 
transmission of HCV was suggested by findings from Belec et al. (Belec et al. 2003) 
who did not detect replicating HCV-RNA in any cervicovaginal secretion samples from 
15 chronically infected women who were HCV-RNA positive in serum. HCV-RNA was 
not detected in the acellular fractions o f any samples although non-replicating HCV- 
RNA was detected in the cellular fractions of 4 of 15 samples. These results would 
suggest that transmission to the infant during normal vaginal delivery would be 
relatively inefficient.
A higher proportion of infected children bom by vaginal delivery has been observed in 
some studies, although most lacked the statistical power to detect or exclude an effect 
(Conte et al. 2000;0kamoto et al. 2000;Tajiri et al. 2001). A significant increased risk 
of transmission among vaginally delivered infants (32% vs. 6% among caesarean 
deliveries) was found in one study involving a total of 70 infants (Paccagnini et al.
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1995) and a similar association but of borderline statistical significance was observed in 
an Italian multi-centre study (Tovo et al. 1997).
In a larger study of 441 mother-child pairs from centres in the UK and Ireland, a 
protective effect of elective CS section was claimed on the basis o f no cases o f vertical 
transmission among 31 elective CS deliveries compared to an estimated 7.4% 
transmission risk among 393 vaginal or emergency CS deliveries (Gibb et al. 2000a). 
However, definitive infection status was not available for most children so HCV 
infection status was imputed using a method developed for HIV infection and could 
thus be unreliable (Fiore et al. 2001). As the risk of transmission was estimated from the 
sum of individual probabilities it was not possible to stratify the analysis by HCV/HIV 
co-infection.
In contrast, in a retrospective analysis of data from EPHN centres involving 1474 
mother-child pairs bom between 1992 and 1998, there was no evidence for a protective 
effect of elective CS in women with only HCV infection (adjusted OR=1.17, 95% Cl 
0.59 -  2.31, p=0.66) although there was for the women with HCV/HIV co-infection 
(adjusted OR=0.36, 95% Cl 0.16 -  0.80, p=0.01) (European Paediatric HCV Network et 
al. 2001). Similarly in a multi-centre study involving 1372 mother-child pairs, vaginal 
delivery was not associated with an increased risk of vertical transmission (adjusted 
OR=1.20, 95% Cl 0.93 -  1.55, p=0.15) (Resti et al. 2002a).
Other obstetric factors
Procedures which increase contact between maternal and fetal blood could theoretically 
be associated with a greater risk of mother-to-child transmission but few studies have 
quantified this. There is little evidence available about the risk of HCV transmission to
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the fetus during procedures such as amniocentesis, although this issue is increasingly 
relevant as women become pregnant at older ages and are at greater risk of 
chromosomal abnormalities and are thus offered amniocentesis. HCV-RNA has been 
detected in amniotic fluid, although rarely (Delamare et al. 1999). Amniocentesis was 
considered a likely explanation for a case of diamniotic twins discordant for HCV 
infection, where the needle punctured the sac of only one fetus (Minola et al. 2001). 
However, among another pair of diamniotic twins only the second baby was HCV 
infected and amniocentesis was not performed, suggesting the involvement of other 
factors (Inui et al. 2002).
Having reviewed the limited evidence, Davies et al. (Davies et al. 2003) concluded that 
amniocentesis does not appear to significantly increase the risk of vertical transmission 
but women should be advised that few studies have addressed this issue. They suggest 
that the use of non-invasive methods of prenatal screening may reduce the need for 
amniocentesis. There is no indication that women of unknown HCV status should be 
tested for HCV infection before amniocentesis.
The occurrence o f perineal or vaginal laceration during vaginal delivery was 
significantly associated with an increased risk of vertical transmission in one study of 
75 mother-child pairs, although there was nasuch effect of episiotomy (Steininger et al.
2003). Poiraud et al. observed a significant 3-fold increased risk among forceps 
deliveries in a case-control study of 51 infected children and 110 uninfected controls 
(Poiraud et al. 2001). In a recent larger U.S. study, use of internal fetal monitoring 
during delivery was associated with an increased risk of vertical transmission (adjusted 
OR=6.7, 95% Cl 1.1 -  35.9) (Mast et al. 2005).
43
Rupture of membranes
In an Australian study the duration from rupture of membranes (ROM) to delivery was 
significantly longer among mothers o f infected than of uninfected infants, despite the 
lack of a mode of delivery effect; median duration of ROM was 18 hours among the 6 
transmitting women and 5.5 hours among the 57 women with an uninfected child 
(p=0.03) (Spencer et al. 1997). However, this was not the case in a U.S. cohort (Thomas 
et a l 1998), which included 11 infected children and where categories (< 4 hours vs. > 
4 hours) rather than median duration of ROM were compared; in this latter study lack of 
statistical power may explain the lack of significance. In a more recent U.S. study 
membrane rupture more than 6 hours before delivery was associated with vertical 
transmission in multivariable analysis (adjusted OR 9.3, 95% Cl 1.5 -  179.7) (Mast et 
al. 2005).
Infant feeding
HCV-RNA has been detected in colostrum and breast milk in some studies (Kumar and 
Shahul 1998;Lin et al. 1995;Mast et al. 2005) but not others (Polywka et al. 
1999;Spencer et al. 1997). In one study women with HCV-RNA positive breast milk 
samples were significantly more likely to have an infected child than those with 
negative breast milk samples, but this finding may simply reflect higher plasma HCV 
viral load in the transmitting women (Ruiz-Extremera et al. 2000). In a study in the 
United Arab Emirates it was reported that five women with primary and symptomatic 
HCV infection post partum had high HCV-RNA levels in their breast milk (Kumar and 
Shahul 1998). Three of their infants became infected and breastfeeding was suggested 
as the likely route of transmission. The authors concluded that while breastfeeding is 
likely to pose no increased transmission risk among asymptomatic women, those with 
symptomatic liver disease, especially with high viral loads should not breastfeed. No
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significant associations have been observed between type of infant feeding and mother- 
to-child transmission of HCV in any other studies (Table 1.2, (Zanetti et al. 1998;Tovo 
et al. 1997;Spencer et al. 1997;Resti et al. 1998)). Many of these studies were small and 
lacked statistical power although an effect of breastfeeding has not been observed in 
larger studies either. The adjusted odds ratio for breastfeeding was 0.95 (95% Cl 0.58 -
1.40, p=0.74) in the Italian multi-centre study (Resti et al. 2002a) and 1.52 (95% Cl 
0.35 -  5.12, p=0.5) in the UK/Ireland study (Gibb et al. 2000a). There was no effect of 
breastfeeding among 916 women with only HCV infection (adjusted OR=1.07, 95% Cl 
0.57 -  2.02, p=0.83) in the EPHN retrospective analysis, although an increased risk was 
observed among the few HCV/HIV co-infected women who breastfed (adjusted OR=
6.41, 95% Cl 1.25 -  32.94, p=0.03) (European Paediatric HCV Network et al. 2001).
Other factors
Women with advanced liver disease could be more likely to transmit HCV to their 
infants but this has not been investigated as most HCV infected pregnant women are 
asymptomatic. Duration of maternal HCV infection, a proxy for disease progression, 
was not associated with risk of vertical transmission in one study (Resti et al. 2000) 
although elevated maternal ALT, a marker for liver damage, was associated with an 
increased risk of transmission in another study (Xiong et al. 1998).
A higher risk o f vertical transmission was reported among women with positive IgM 
anti-HCV in one study (Dal Molin et al. 2002) but has not been investigated elsewhere. 
IgM is likely to indicate acute primary infection which could be associated with high 
HCV viral load.
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Table 1.3 Summary of risk factor evidence
Risk factor Findings Strength of the 
evidence
(strong>sufficient>
insufficient)
Maternal HIV co-infection 2-3 fold increased risk (European 
Paediatric HCV Network et al. 
1999;Zanetti et al. 1998;Tovo et al. 
1997)
Strong
Maternal HCV viraemia/ 
viral load
Very low risk from non-viraemic 
women; high viral load increases risk 
(Steininger et al. 2003 ;Dal Molin et 
al. 2002;0kamoto et al. 2000;Tajiri et 
al. 2001;Zanetti et al. 1998;Giacchino 
et al. 1998;Ferrero et al. 2003)
Sufficient
Maternal injecting drug use Increased risk reported in one study 
(Resti et al. 2002a)
Insufficient
Mode of delivery Conflicting results (Gibb et al. 
2000a;European Paediatric HCV 
Network et al. 2001 ;Resti et al. 
2002a)
Insufficient
Obstetric procedures Prolonged rupture of membranes may 
increase risk (Spencer et al.
1997;Mast et al. 2005)
Insufficient
Prematurity No evidence of an effect (Tovo et al. 
1997;Spencer et al. 1997;Resti et al. 
2002a)
Sufficient
Infant feeding No evidence of an increased risk 
through breastfeeding (Zanetti et al. 
1998;Tovo et al. 1997; Spencer et al. 
1997;Resti et al. 1998;Resti et al. 
2002a;Gibb et al. 2000a)
Sufficient
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1.7 Identification of infected and uninfected children born to infected women
Diagnosis of HCV infection in children depends on the same assays as used for adults, 
ELISA or RIBA to detect anti-HCV and PCR for HCV-RNA. However, diagnosis or 
exclusion of vertically acquired HCV infection is hindered by the presence of passively 
acquired maternal anti-HCV antibodies in the first year o f life in exposed infants 
(European Paediatric HCV Network et al. 1999). Detection of HCV-RNA by PCR 
assays is therefore required for early diagnosis. While both qualitative and quantitative 
HCV-RNA PCR assays have improved in recent years, they are still limited by low 
sensitivity. Samples from young children are often of much lower volume than in adults 
which can compound the technical difficulties with assays. In an inter-laboratory 
comparison study involving laboratories of EPHN centres, false positive results were 
rare but there were several false negative results suggesting that infected children may 
not be identified if viral load is low (Pembrey et a l 2003b). New highly sensitive real 
time PCR-based assays may help to overcome these problems in the future (Cook et al.
2004).
A recent EPHN analysis of 193 infected children and 354 uninfected children, all with 
infection status confirmed by anti-HCV antibody status at or after 18 months, showed 
that sensitivity of HCV-RNA PCR was low at birth but increased to about 80% from 1 
month of age, and specificity was high from birth at 98% (European Paediatric HCV 
Network et al. 2006), consistent with results elsewhere (Dunn et al. 2001).
Children are considered to be infected if they have two or more positive qualitative PCR 
results and/or are anti-HCV antibody positive beyond 18 months of age (European 
Paediatric HCV Network et al. 2000). Infection is usually excluded on the basis of two 
or more negative qualitative PCR results and/or a negative anti-HCV antibody result at
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or after 18 months. Analysis o f data for 1104 uninfected children bom to HCV infected 
women estimated that 95% of uninfected children will lose maternal antibody by 12 
months of age. This suggests that absence of infection could be confirmed earlier than 
18 months of age in most children, and allay parents’ anxieties, if they are tested 
between 9 and 12 months (European Paediatric HCV Network et al. 2005a).
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1.8 Key points
• HCV infection is a major public health concern worldwide and is the cause of 
considerable morbidity and mortality among chronically infected adults.
• Mother-to-child (vertical) transmission is now the predominant route of HCV 
infection in children.
• Current estimates of the risk of mother-to-child transmission of HCV range from 3% 
to 10%.
• Maternal HIV co-infection has been consistently associated with a higher risk of 
HCV vertical transmission.
• Research has focussed on mode of delivery and type of feeding as these are 
amenable to intervention. The protective role of elective caesarean section remains a 
matter of debate, whereas existing data indicate that breast feeding is not associated 
with an increased risk of transmission.
• Diagnosis or exclusion o f vertically acquired HCV infection relies on detection of 
HCV-RNA by PCR and anti-HCV antibody by ELISA and RIBA assays. Passive 
transfer of maternal antibodies, which can remain detectable for up to 18 months, 
hinder the early diagnosis or exclusion of infection.
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Chapter 2 Vertically acquired HCV infection
2.1 Natural history of vertically acquired HCV infection
Among the many small studies o f mother-to-child transmission of HCV, some have 
included a brief description o f the clinical, virological and biochemical features o f the 
infected children. However, only a few reports focus on the natural history of vertically 
acquired HCV infection. Table 2.1 summarises the results of three studies o f vertically 
infected children only, and a further five studies which included both vertically infected 
children and those infected through other routes (predominantly blood transfusions). 
Four more studies (Guido et a l  1998;Guido et a l 2003;Kage et a l  1997;Murray et a l
2005), which included children infected vertically and by other routes, reported only 
liver biopsy results with little data on clinical, virological or biochemical parameters 
and are described in the text only.
Clinical manifestations
Despite average follow-up periods of about 3 to 7 years, vertically infected children 
were asymptomatic in most studies, with just two cases o f hepatomegaly, which is a 
non-specific sign, in the EPHN retrospective study (European Paediatric HCV Network 
et a l 2000) (Table 2.1). Clinical symptoms were observed in a few of the children with 
horizontally acquired infection but some - of these children had other underlying 
conditions or were referred for follow-up because they were symptomatic or had 
elevated liver enzymes.
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Table 2.1 Natural history studies
All children vertically infected
Setting
(reference)
Number of
children
studied
Identification 
of children
Definition of 
infection
Duration of
follow-up,
years
mean (range)
Findings
Clinical Clearance ALT Liver
histology
Italy
(Palomba et 
al. 1996)
7 Bom to 
HCV/HIV co­
infected 
women, 
prospectively 
followed
Anti-HCV 
positive beyond 
18 months
5.4 (2 .2 -7 .5 )
normal no wide variation 
-peaked in 1st 
year, normal 
for long 
periods but 
exacerbations 
in some
in 5 children: 
all chronic 
persistent 
hepatitis; mild 
(n=l) or 
intermediate 
(n=4)
Europe
(European
Paediatric
HCV
Network et 
al. 2000)
104 Prospectively 
followed from 
birth; data 
retrospectively 
collected from 
22 participating 
centres
Anti-HCV 
positive >18 
months and/or 
>2 HCV-RNA 
PCR positive 
tests
4.1 (0.5-12.8) 2 children had 
hepatomegaly
possibly in 18 
(17%)
wide variation 
-  high in 1st 2 
years, declined 
thereafter
in 20 children: 
steatosis, portal 
lymphoid 
aggregates 
most common 
findings, mild 
to moderate
Italy, Spain 
(Resti et al. 
2003)
70
(62
followed 
for >24 
mths)
Referred for 
follow-up 
related to 
maternal 
infection; all 
followed from 
1st year
Anti-HCV 
positive >18 
months and/or 
>2 HCV-RNA 
PCR positive 
tests (1 in 1st 
year)
in 62 children 
followed for 
>24 mths:
4 .8 (2 -1 1 )
asymptomatic 19% (12/62); 
significantly 
associated with 
high ALT in 
first year
variable; 
normalized in 
18 children, 
lower from 2nd 
year
in 11 children: 
minimal in 4, 
mild in 7
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Table 2.1 continued:-
Some children vertically infected (VT); others infected through parenteral routes >[mostly blood transfusions/blood products) (other/BT)
Setting
(reference)
Number of
children
studied
VT: other
Identification of 
children
Definition of 
infection
Duration of
follow-up,
years
mean (range)
Findings
Clinical Clearance ALT Liver histology
Australia 
(Rerksuppap 
hoi et al. 
2004)
16:15
Follow-up of 
children born to 
HCV infected 
women (VT) 
and ‘lookback’ 
programme (BT)
VT: Ab pos > 
18m or >1 
pos HCV- 
RNA at >1 
mth of age
median 
VT: 3.7 
(0.1 -7 .3 )
BT: 3.9 
(0.1 -9 .4 )
no signs or 
symptoms
VT: 2/16 
(13%)
BT: 4/15 
(27%)
higher in VT 
than BT in 1st 5 
yrs
4 children (1 VT, 3 
BT) -  mild to 
moderate fibrosis
Europe (Jara 
et al. 2003) 35:165
NB. some 
overlap 
with (Resti 
etal. 2003)
Referred to ■ 
paediatric and 
hepatologic 
centres
VT: HCV- 
RNA pos in 
1st year, Ab 
pos, mum 
identified at 
delivery
6.2
(1 -17 .5 )
all VT children 
asymptomatic. 
A minority of 
other children 
had anorexia, 
asthenia, 
abdominal pain
VT: 3/35 
(17%)
Other modes: 
6/165 (3.6%)
usually 
persistently or 
intermittently 
abnormal;
in VT ALT 
greater in 151 
yrs among 
clearers
92 children -  
70 (76%) minimal 
to mild hepatitis;
20 (22%) moderate 
hepatitis; 1 severe 
hepatitis; 1 
cirrhosis.
Fibrosis score 
higher in older 
children
UK, Ireland 
(Gibb et al. 
2000b)
40:142
VT: 6/40 
HIV co­
infected
active
surveillance 
through BPSU 
(Apr 97 -  Dec 
98)
Ab pos > 18 
mths and/or 2 
pos PCR at 
any age
6.7
(0.04-15.6) 
VT: 0 -  15
no clinical 
symptoms 
except in 1 
child infected 
by transfusion
29(16%)
overall
VT: 2/40, 5%
Other:
27/142, 19%
VT: normal in 
13/34 tested 
(38%)
Other modes: 
normal in 
74/118(63%)
VT: 10 children: 1 
normal, 6 mild, 3 
moderate hepatitis 
Other modes: 43 
children: 3 normal, 
33 mild, 6 
moderate, 1 severe
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Table 2.1 continued:-
Setting
(reference)
Number of
children
studied
VT: other
Identification of 
children
Definition of 
infection
Duration of
follow-up,
years
mean (range)
Findings
Clinical Clearance ALT Liver histology
Argentina 
(Gismondi 
et al. 2004)
17:31
4/48 HIV 
co-infected
Retrospective &
prospective
study-
hepatology units
Ab pos >18 
mths and/or 2 
pos PCR
22 had only 
one blood 
sample each; 
26 followed 
up for 3 mths 
-  8.9 yrs
all
asymptomatic
Among 26: 
19% (5); 
maximum 
31% (8)
Elevated in 
about half
No biopsies done
Naples, Italy 
(Iorio et al. 
2005)
54:71 Children 
attending the- 
liver unit 1986 -  
2004.
Retrospective
evaluation.
Ab pos for 
>6 months
median 9 
(3.4-20.9)
all
asymptomatic
9% (7) in 
untreated 
children
Variable;
>50 IU/1 at 
baseline in 
50/75 untreated 
children
64 children: 
median hepatitis 
grade 4.4 (1 -  8), 
median fibrosis 
stage 1.6 (0 -  4), 
no cirrhosis
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Some children bom to HCV/HIV co-infected women may also have vertically acquired 
HIV. There is evidence from HCV/HIV co-infection in adults that HIV infection 
increases progression of HCV-related liver disease but little is known about the impact 
of co-infection on disease progression in children (England et a l 2006). Co-infected 
children were excluded from some natural history studies (European Paediatric HCV 
Network et a l  2000).
Viraemia
Several different patterns of viraemia have been observed in vertically infected children. 
In the EPHN study (European Paediatric HCV Network et a l 2000), 54 (52%) were 
persistently RNA PCR positive, 6 (6%) were negative at every test while a substantial 
proportion (44, 42%) had both positive and negative results. Resti et al. (Resti et a l 
2003) showed similar results and 3 of 7 children in the other Italian study (Palomba et 
a l 1996) had at least one negative PCR during follow-up but all were HCV-RNA 
positive at the last visit.
Interpretation of these patterns is limited by the frequency and timing of HCV-RNA 
PCR tests. A child classed as persistently viraemic may have had undetectable viraemia 
during a period when they were not tested. A negative PCR test may indicate low viral 
load rather than absence of the vims from serum.
Clearance of viraemia
Around 15% - 25% of infected adults have evidence of spontaneous clearance of HCV 
(Thomas et a l  2000;Alter 2005). Repeatedly negative PCR results in children with 
previous positive findings may also indicate clearance of HCV-RNA from plasma 
(European Paediatric HCV Network et a l 2000;Resti et a l 2003) (Table 2.1).
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Following a case report o f viral clearance by 2 years of age in a vertically infected child 
(Padula et al. 1999) further evidence has been presented. Data from an Israeli study 
(Ketzinel-Gilad et al. 2000) suggest that children who clear HCV may not be identified 
if they are not tested in first few days of life. Of 23 children bom to HCV infected 
women, HCV-RNA was detected in the serum of 5 children at 2 days old but by 6 
months HCV-RNA was undetectable in all children and none seroconverted.
A high rate of spontaneous clearance was reported in an Italian study (Ceci et al. 2001) 
in which 8 of 60 vertically exposed children were HCV-RNA positive on at least two 
consecutive occasions in the first year and considered to be HCV infected. At 18 and 24 
months of age, 6 of the 8 infected children were HCV-RNA and RIBA negative which 
was taken to indicate clearance.
Most vertically HCV infected children remain anti-HCV positive throughout follow-up, 
although some children are transiently antibody negative reflecting delayed antibody 
production subsequent to loss of passively acquired maternal antibody (European 
Paediatric HCV Network et al. 2000). Some children with evidence o f viral clearance 
do not seroconvert, i.e. they remain antibody negative after loss of maternal antibody, 
although this seems to be uncommon; only 4 of 18 clearers in one study (European 
Paediatric HCV Network et al. 2000) and none of the clearers in the other study (Resti 
et al. 2003) did not seroconvert.
Thus, HCV-RNA negative results consistent with viral clearance have been observed in 
a few children with vertically acquired HCV infection but it remains unclear what 
proportion of vertically acquired infections will resolve spontaneously and at what age.
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Alanine aminotransferase (ALT)
In adults, levels of serum liver enzymes, particularly alanine aminotransferase (ALT), 
are used as markers o f liver damage (Hui et al. 2003). In vertically acquired infection, 
ALT values vary between children and over time and some children have consistently 
normal levels (European Paediatric HCV Network et al. 2000, Table 2.1). The reference 
ranges for ALT vary a little between laboratories and most reports state that values 
twice the upper limit of normal were considered high without providing specific ranges 
(Piton et al. 1998). Generally the normal range in the first year of life is 5 to 50 or 80 
IU/1 and thereafter 5 to 40 or 45 IU/1 (Behrman et al. 2004). As few liver biopsies are 
done in children it has been difficult to correlate the extent of liver damage with serum 
ALT. In one study involving 80 children (19 with vertically acquired infection) ALT 
levels were significantly associated with severity of intralobular focal necrosis but not 
with any other necroinflammatory lesion (Guido et al. 1998). In adults there is 
conflicting evidence about the value o f serum ALT levels to predict severity of liver 
disease. Elevated serum ALT levels were independently associated with progression to 
cirrhosis in a systematic evaluation of published studies (Freeman et al. 2003), yet a 
study of HCV infected haemodialysis patients found no significant correlation between 
fibrosis score and serum ALT (Boyacioglu et al. 2004) and progression to fibrosis has 
been reported in patients with persistently normal ALT (Hui et al. 2003).
Liver histology
Liver biopsies are considered the ‘gold standard’ for assessing liver damage but they 
have some limitations; each biopsy is usually only a few centimetres at most, a very 
small proportion of the whole liver and may not accurately reflect the state of the rest of 
the liver. Liver biopsies are not usually performed in vertically infected children if 
asymptomatic and are more often done to inform decisions regarding initiation of
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treatment. Biopsies are assessed according to standardised scoring systems for grade, an 
indication of the activity or amount of inflammation, and stage, the level o f fibrosis. The 
METAVIR system (Poynard et al. 1997) scores the grade from 0 to 4 with 0 
representing no activity and 3 or 4 considered severe activity, and the stage (fibrosis 
score) from 0 (no fibrosis) to 4 (cirrhosis). The Knodell score or histological activity 
index is composed of four individually assigned numbers, three o f which combine to 
give an inflammation score and the fourth to indicate the level of fibrosis (Murray et al. 
2005).
The results in vertically infected children who have undergone biopsy indicate mild to 
moderate hepatitis in most cases (Table 2.1). In one study involving both vertically and 
horizontally infected children, fibrosis was absent in 22 (28%), mild in 44 (55%), 
moderate in 13 (16%) with cirrhosis in one child. The fibrosis score was associated with 
patient age and duration of disease but the spectrum of lesions was independent of the 
route of infection (Guido et al. 1998). Although liver biopsy results were not reported 
separately for vertically and horizontally infected children, it was noted that histological 
findings seemed to be independent o f the route of infection in three further studies (Jara 
et al. 2003;Guido et al. 2003;Iorio et al. 2005). The results of one of these studies, 
which included 13 paired biopsies, suggested that fibrosis progression is not linear and 
the rate of progression over age is variable and unpredictable (Guido et al. 2003).
A recent study compared progression of disease in 21 children (half (10) of whom were 
vertically infected) with 52 adults (Murray et al. 2005). In a multivariable analysis 
controlling for gender, duration of infection, HCV-RNA level and genotype, liver 
biopsies from children had substantially less inflammatory activity and fibrosis than 
adults.
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Summary
The typical picture among vertically HCV infected children, followed on average for 
about 5 years, appears benign, generally asymptomatic with evidence of mild to 
moderate liver damage in some cases. The course of disease seems to be milder than in 
adults. Some children have consecutive negative HCV-RNA PCR results which may be 
taken to indicate spontaneous viral clearance. However, this is based on limited 
evidence as very few studies have been conducted on vertically acquired HCV infection 
and each included a relatively small number o f children.
2.2 Treatment of infected children
Children are considered good candidates for treatment as they tend to have 
characteristics associated with a good response in adults, such as lack of cirrhosis, 
shorter duration of infection, and good tolerance to antiviral medications (Jacobson et 
a l  2002;Delgado-Borrego and Jonas 2004). To date there have been no randomised 
clinical trials in children so current evidence relies on observational studies.
Until recently interferon (IFN) alpha was the only treatment licensed for children with 
HCV infection. It is not recommended for children less than 3 years old because of 
possible adverse effects on growth (Strader et a l  2004). In children over 3 years, IFN- 
alpha is usually given at a dosage of 3-5 million units (MU) per square metre o f body 
surface, intramuscularly or subcutaneously, three times a week for 6-12 months. A 
review of 19 published studies of interferon monotherapy involving 366 treated children 
found a mean sustained virological response rate (HCV-RNA negative at least 6 months 
after cessation of therapy) of 36% (0%-73%) (Jacobson et a l  2002).
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In July 2003 the US Food and Drug Administration granted marketing approval to 
Rebetol (ribavirin manufactured by Schering-Plough) for use in combination with 
interferon alpha-2b for paediatric hepatitis C (Schering-Plough 2003). It is 
recommended for the treatment of children who are 3 years o f age or older with 
compensated liver disease previously untreated with interferon alpha. The 
recommended duration o f combination therapy is 24 weeks for patients with genotype 2 
or 3 and 48 weeks for patients infected with genotype 1.
The efficacy and safety o f interferon-alpha and ribavirin in older HCV infected children 
has been assessed in several studies. In one, 6 of 12 children had a sustained virological 
(RNA) and biochemical (ALT) response (Lackner et al. 2000) and in another, 7 of 11 
children had sustained virological responses 6 and 12 months after stopping treatment 
(Christensson et al. 2000). In a German study, 25 (61%) of the 41 children and 
adolescents enrolled (21 vertically infected) showed a sustained virological response to 
interferon-alpha in combination with ribavirin (15mg/kg/d) (Wirth et al. 2002). The 
largest study enrolled children at 26 centres in Europe, Canada, Israel and the USA 
(Gonzalez-Peralta et al. 2005). O f 118 children who received ‘optimal therapy’ with 
interferon-alpha-2b and ribavirin, 64 (54%) of whom were vertically infected, 46% (54) 
achieved sustained virological response. Children infected with genotypes 2 and 3 had 
significantly higher response than those infected with genotype 1 (84%, 21/25 vs. 36%, 
33/92).
Both interferon and ribavirin have side effects including flu-like symptoms, tiredness, 
lack of appetite and weight loss, which are usually mild or moderate and rarely 
necessitate early cessation of treatment (Kelly et al. 2001; Wirth et al. 2002). A fifth of
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children (23) in the large international study experienced severe adverse events 
(Gonzalez-Peralta et al. 2005), although this was similar to that observed in adults.
Pegylated interferon, shown to be effective in combination with ribavirin in adults 
(Zeuzem et al. 2004), would be particularly suitable for children as it requires less 
frequent injections than standard interferon-alpha. Evaluation of this therapy in children 
has started recently. A small Polish study reported early virological response (HCV- 
RNA negative 12 weeks after initiation of treatment) in 8 of 10 children with chronic 
HCV infection who were treated with pegylated interferon-alpha-2b and ribavirin 
(Kowala-Piaskowska et al. 2005). In an open label pilot study of pegylated interferon 
alpha-2b and ribavirin 22 of 46 (48%) patients with genotype 1 had a sustained 
virological response as did all 13 patients with genotype 2 or 3 and 1 o f 2 patients with 
genotype 4 (Wirth et al. 2005).
2.3 Medium to long-term outcomes of vertically acquired HCV infection
Very little is known about the medium- to long-term outcomes of vertically acquired 
HCV infection. Long-term clinical outcome was investigated in children who had 
acquired HCV during cardiac surgery at a mean age o f 2.8 years (Vogt et al. 1999). 
After 20 years of follow-up on average, more than half of the patients were still positive 
for HCV-RNA but only a few showed histological signs of liver damage. None of them 
had clinical signs or symptoms. A similar mild course of infection and slow rate of 
progression was observed among a cohort of 35 year old adults who had been infected 
with mini transfusions of blood neonatally (Casiraghi et al. 2004).
In a study of 224 HCV infected children, 39 of whom were definitely vertically 
infected, liver biopsy specimens were available for 92. Children who were 15 years or
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older (n=25) had a significantly higher fibrosis score than children less than 15 years of 
age (n=67), suggesting that liver disease does progress over time in HCV infected 
children, although slowly (Jara et al. 2003).
A UK retrospective study was able to assess fibrosis progression in elderly HCV 
infected patients who were infected in childhood (D'Souza et al. 2005). Liver biopsies 
from 143 HCV infected Asian patients (64% with a documented blood product or high 
risk procedure before 20 years o f age) were compared with biopsies from 239 HCV 
infected Caucasian patients, 85% of whom had acquired HCV through injecting drug 
use or a documented blood product or high risk procedure in adulthood. Among the 
Asian patients aged 61 -  80 years, 78% (43/55) had cirrhosis compared to 25% (14/55) 
of Caucasian patients in the same age group, suggesting a high prevalence of cirrhosis 
after more than 60 years of HCV infection. Potential confounding by other factors was 
assessed and duration of infection was confirmed as the most likely reason for such high 
prevalence of cirrhosis.
It is unclear whether these results can be extrapolated to vertically acquired infection. 
There may be important differences in the natural history of vertically acquired 
infection and infection acquired postnatally. However, given the information available 
in adults and evidence that increased duration of infection is associated with fibrosis 
progression (Serra et al. 2003), it is likely that some vertically infected children will 
start to develop serious symptoms in their teens, twenties or thirties. It is also possible 
that they may develop extra-hepatic manifestations such as autoimmune diseases 
(Bortolotti et al. 2003) and exposure of the immature immune system to infection could 
lead to alterations in immune function (Della Bella S. et al. 2005).
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2.4 Monitoring the long-term consequences of vertically acquired HCV
While most vertically infected children will remain under regular clinical care into 
adulthood, it is important to be able to monitor the long-term consequences of vertically 
acquired HCV infection from a public health perspective, to estimate the current and 
future burden on health services and ensure that appropriate clinical services are 
provided. Existing sources o f routinely collected data could be employed for this 
purpose. A system to monitor vertically acquired HCV infection would require three 
main components; a register of individuals with vertically acquired infection, data on 
potential outcomes from sources such as cancer and other disease registries, hospital 
episode statistics and death registration, and unique identifiers to enable linkage of 
exposure and outcome data, such as health service or social security numbers.
In the UK a national register o f hepatitis C infections with known date of acquisition 
was established in 1998 (Harris et al. 2000). Children identified through a period of 
active surveillance (April 1997 - December 1998) for paediatric HCV infection, 
vertically acquired or otherwise, through the British Paediatric Surveillance Unit orange 
card reporting system were included on the national register (Gibb et al. 2000b); other 
children with vertically acquired HCV infection could also be included. Laboratory 
notifications of anti-HCV or HCV-RNA positive tests to the Health Protection Agency 
and HCV-related hospital episodes could alert new cases of vertically acquired HCV 
infection to the register. A database of individuals diagnosed with HCV infection was 
established in Scotland based on laboratory-reporting and included records for over 
13,500 individuals by the end of 2001 (Shaw et al. 2003). This and other national 
surveillance and notification systems for HCV (Robotin et al. 2004;Mazurek et al. 
2002;Mele et al. 2000) could provide the infrastructure for registers of vertically 
acquired infections.
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Thus, it is possible that routine data sources could be adapted for the purpose of 
monitoring the long-term outcomes of vertically acquired HCV infection but any 
approach will need to take into account the views of affected individuals and issues of 
ethics and confidentiality.
2.5 Immunological parameters in HCV infection
Investigation of immunological parameters in children bom to HCV infected women 
could help elucidate mechanisms involved in mother-to-child transmission of HCV, the 
initial response to infection in exposed infants and mechanisms of spontaneous viral 
clearance in vertically infected children. Early exposure of the immature immune 
system to HCV infection, especially in children who acquire infection, could have 
medium- to long-term effects on immune function.
Few studies have investigated immune parameters in children vertically exposed to 
HCV infection. In a recent study, HCV-specific CD4+ lymphocytes were present in 20 
of 28 (71%) children bom to HCV infected women although only 3 of the 28 children 
were HCV infected and the 25 uninfected children lost passively acquired antibody by 
one year of age. These results indicate the development of T-cell mediated immunity 
even in the absence of anti-HCV antibodies, suggesting that vertical exposure to HCV 
can induce antigen-specific immune responses which are protective against infection 
(Della Bella S. et al. 2005).
In another study of nine vertically HCV infected children, Giovannetti et al. found 
alterations in the distribution of T-cell subsets and cytokine production although no 
correlation was observed between individual T-cell subsets and ALT levels or HCV 
viral load (Giovannetti et al. 2001).
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Most research relating to immunological markers in children exposed to maternal 
chronic infection comes from cohorts of children bom to HIV infected women. The 
findings in infected children usually relate specifically to HIV infection (European 
Collaborative Study 2003a;European Collaborative Study 2004b) but immunological 
markers in uninfected children could provide insight into more general effects of 
maternal chronic infection on infant immune function, and are therefore relevant to 
children bom to HCV infected mothers. In uninfected children bom to HIV infected 
women, associations were observed between gender and race and lymphocyte and 
neutrophil levels over age; both lymphocytes and neutrophils were lower in males than 
females and lower in black children than white children (Bunders et al. 2005b;European 
Collaborative Study 2004b).
There is evidence that another chronic maternal disease, autoimmune disease, may 
impact on infant cellular immunity. Total lymphocyte percentages were significantly 
decreased in neonates of mothers with insulin dependent diabetes compared to neonates 
of healthy mothers. Differences in lymphocytes were also observed between children of 
diabetic mothers and the reference population up to age six (Roll et al. 1994).
An important limitation in the assessment of immune function in many paediatric 
diseases is the lack of age-related reference values for healthy children. Studies have 
been carried out to measure lymphocyte subsets (Shearer et al. 2003;Robinson et al. 
1996;Shahabuddin et al. 1998) and neutrophils (Bellamy et al. 2000) in healthy children 
and indicate substantial changes over age, confirming that adult reference ranges are 
likely to be inappropriate for use in children (Heldrup et al. 1992). The largest studies 
included about 800 children (Shearer et al. 2003;Lisse et al. 1997) but were limited by 
their cross-sectional design. Gender was associated with lymphocyte subsets in the West
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African study (Lisse et al. 1997) but not in the US study (Shearer et al. 2003) or a 
smaller African study (Kiepiela et al. 1989). Longitudinal data for uninfected children 
bom to HIV infected women, followed up for at least several years with regular 
collection of blood samples, have been used to develop age-related standards for 
lymphocytes and lymphocyte subsets (Bunders et al. 2005a). Uninfected children bom 
to HCV infected women may also provide an appropriate reference group.
In summary, very little is known about the impact of exposure to maternal HCV 
infection on infant immune function.
2.6 Psychosocial issues for families affected by HCV infection
It is important to consider the psychosocial needs of HCV infected women and their 
children alongside the medical and clinical issues. To date there are no reports of 
research into the psychological or social impact of HCV vertical transmission on 
families, nor their satisfaction with provision of care for HCV exposed children. 
However, work has been published on quality o f life in HCV infected adults and a few 
studies have focussed on women.
The results of some studies suggest considerable reduction in health related quality of 
life in individuals with chronic hepatitis C infection compared to population norms 
(Fontana and Kronfol 2004) although in some cases reductions in quality of life were 
less marked in individuals who were unaware of their infection status (Rodger et al. 
1999). This is consistent with the results from a study in rural Egypt where no 
significant reductions in quality of life were observed in HCV infected individuals 
compared with uninfected controls and all participants were unaware of their HCV 
status at the time of the quality of life survey (Schwarzinger et al. 2004). Differences in
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background morbidity and disease progression in infected individuals between Egypt 
and Western populations and differences in study design may also explain the 
discrepancy in results.
A Canadian study found that the most common concerns of chronic hepatitis C patients 
were disease progression, the possibility of premature death and infecting other family 
members (Minuk et al. 2005). Perceived stigmatization and communication problems 
with health care professionals have also been reported (Zickmund et a l 2003;Zickmund 
et al. 2004). These issues are particularly relevant for families with children.
In an Australian community-based study, HCV infected women reported significantly 
poorer physical and mental health and well-being than women representative of the 
general population (Gifford et al. 2003). Similarly, high levels o f psychological distress 
and impaired quality of life were observed in women with iatrogenic hepatitis C 
infection, regardless of viraemia status or liver histology (Coughlan et al. 2002). With 
effective treatment now available for HCV infected adults (Manns et al. 2001), therapy 
options should be discussed with women after pregnancy. However, in the Australian 
study only 17% of women had ever received HCV treatment (Gifford et al. 2003). 
Worries about stigma and transmission to children and other family members have been 
highlighted as issues particularly pertinent to women (Grundy and Beeching 
2004;Zickmund et al. 2003;Gifford et al. 2003).
There is limited evidence about the potential risk of household transmission of HCV. 
Horizontal intra-familial transmission can occur (Ackerman et al. 2000) and significant 
clustering of HCV infection within households has been demonstrated (Akhtar and 
Moatter 2004), although the risk is likely to be low, especially from asymptomatic
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individuals (Kim et al. 1998;Ackerman et al. 2000). In a recent study from Egypt which 
identified incident cases of HCV infection, children with an anti-HCV positive parent 
had the highest incidence rate of 14.1 per 1000 person-years suggesting horizontal 
intrafamilial transmission, although the exact routes were unclear (Mohamed et al. 
2005). Transmission could have occurred via small exposures to blood or saliva in the 
course of routine household contact or through the conventional parenteral route by 
sharing of needles for medical injections within the household which is common 
practice in some regions o f Egypt.
Non-medical issues will become relatively more important as HCV infected children 
grow up. Family clinics are well established for HIV (Gibb et al. 1997;Thome et al. 
1999) and are likely to be helpful for HCV affected families, as are other support 
networks. Issues such as disclosure of infection status to children and adolescents have 
been addressed in relation to HIV infection and may provide relevant insights for 
children and adolescents living with HCV infection (Miller 1995;Thome et al. 2000).
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2.7 Key points
• Little is known about the natural history of vertically acquired HCV infection.
• Clinical signs and symptoms seem to be rare in the first five years of life.
• Several different patterns o f markers of infection (HCV viraemia and liver enzymes) 
are observed among infected children and viral clearance may occur.
• Very little is known about the infant immune response to maternal chronic HCV 
infection.
• It is unclear whether the natural history of adult HCV infection can be extrapolated 
to children. There may be important differences between infections acquired 
perinatally when the immune system is immature and those acquired in adulthood.
• Given the available data for children and what is known for adults, it is likely that 
serious HCV symptoms may not occur for many years in vertically infected 
children.
68
Chapter 3 Aim and Methods
3.1 Rationale for this work
At the start o f this PhD, most studies investigating the risk of mother-to-child 
transmission of HCV and associated factors had been retrospective or of insufficient 
sample size. However, as the vertical transmission risk is low, precise estimation of the 
risk and reliable quantification of the effect of potential risk factors can only be obtained 
from large prospective studies. Identification o f factors associated with an increased risk 
is essential to inform the development of effective interventions to prevent mother-to- 
child transmission of HCV.
Only within a large prospective study will there be sufficient numbers of vertically 
infected children, followed according to a standard protocol, to allow accurate 
characterisation of the course o f infection and disease progression. This is needed to 
inform the clinical management o f infected children and to evaluate the efficacy of anti­
viral therapies.
The long-term outcomes o f vertically acquired infection remain to be clarified. It is 
possible, for example, that early exposure to infection results in sub-clinical changes to 
immunological markers which could have implications for susceptibility and response 
to infection later in life. Methods need to be developed to monitor the long-term 
consequences of vertically acquired infection to identify those at higher risk of 
progression so that appropriate and adequate care can be provided. Ascertaining the 
views of parents and carers of HCV exposed children is an essential part o f this process.
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3.2 Aim and objectives
Aim
To investigate mechanisms of mother-to-child transmission of HCV and the 
consequences for children bom to HCV infected women.
Objectives
1. To quantify the contribution of maternal, obstetric and infant factors to the risk of 
mother-to-child transmission of HCV.
2. To investigate between-study variation in risk factor estimates for mother-to-child 
transmission o f HCV.
3. To clarify the natural history of vertically acquired HCV infection by evaluating 
laboratory markers, such as HCV RNA viraemia and alanine aminotransferase, as 
predictors of clinical disease progression.
4. To investigate the effect o f maternal chronic HCV infection on infant immune 
function by examining patterns and levels of immunological parameters over age 
in infected and uninfected children bom to HCV infected women.
5. To ascertain the views of parents and carers o f children bom to HCV infected 
women on the current arrangements for follow-up and management of their 
children and the views of parents and carers of infected children on possible 
methods to monitor the long-term consequences of vertically acquired HCV 
infection.
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3.3 Methods and data
3.3.1 European Paediatric Hepatitis C Virus Network
The European Paediatric Hepatitis C Virus Network (EPHN) was established in 1998 to 
address important questions on mother-to-child transmission of HCV by pooling 
expertise and data from European clinical centres where HCV infected women and their 
children were followed. Professor Pier-Angelo Tovo, University of Turin, Turin, Italy 
was the clinical co-ordinator o f the project; the epidemiological aspects, including data 
management and analyses, were co-ordinated by Lucy Pembrey and Professor Marie- 
Louise Newell from the Centre for Paediatric Epidemiology and Biostatistics at the 
Institute of Child Health, London. Clinicians in paediatrics and obstetrics, and 
virologists and immunologists from over thirty centres were involved in the EPHN 
(Appendix 3.1 for list o f collaborators).
Initially, two analyses were carried out using data which had already been collected by 
participating centres and were requested from the clinicians retrospectively. The first 
described patterns o f viraemia and alanine aminotransferase (ALT) levels in 104 
vertically infected children (European Paediatric HCV Network et al. 2000) and the 
second investigated the effects o f mode of delivery and breastfeeding on the risk of 
mother-to-child transmission of HCV (European Paediatric HCV Network et al. 2001).
Data collection
The data analysed for this thesis are from the EPHN prospective cohort study which 
started in 1999 with enrollment and follow-up of mother-child pairs according to the 
EPHN protocol (Appendix 3.2). Mother-child pairs were eligible for inclusion in the 
study if the mother was identified as HCV infected (by 2nd or 3rd generation ELISA or
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RIBA or by HCV-RNA PCR) at or before delivery, or the child was identified as HCV 
seropositive within one month of delivery, provided that maternal HCV infection was 
confirmed. Women who were also seropositive for HIV were included.
Local ethics approval was obtained at each centre and each mother gave consent before 
enrolment.
Each mother-child pair was assigned a unique identifier which appeared on every form. 
No names or other identifiers were written on any forms or included in electronic 
records. The EPHN ID number is composed of the centre number (2 digits), the mother 
number (3 digits) and the child number (3 digits). The mother number enables 
identification of siblings and twins.
Maternal information including most likely mode of acquisition of HCV infection, 
reason for HCV testing, history o f injecting drug use and HIV infection status was 
collected at the time o f enrollment. Details of laboratory tests for HCV (anti-HCV 
antibody, qualitative and quantitative HCV-RNA PCR and ALT) carried out during 
pregnancy and at delivery were recorded, with earlier test results if available. Maternal 
HCV genotype and details o f any treatment during pregnancy for HIV infection were 
also recorded. Obstetric and infant information (mode of delivery, duration of labour 
and rupture of membranes, obstetric interventions, birth weight, gestational age, gender 
and details of neonatal anti-retroviral HIV prophylaxis, if applicable) was collected at 
delivery. All data were recorded on specific study forms (Appendix 3.3).
The recommended follow-up schedule included visits to the paediatrician at birth, 6 
weeks, 3, 6, 9, 12, 18, and 24 months, then every six months if infected or every year if
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uninfected. At each visit a clinical examination form was completed including 
information on the child’s height, weight, HIV infection status and CDC stage if 
applicable, whether the child was ever breast fed and for how long, and clinical 
manifestations in nine broad categories: growth failure, hepatomegaly, splenomegaly, 
nephropathy, cardio-pulmonary problems, skin disorders, haematological disorders, 
auto-immune disease and other. Details of hepatitis A and B vaccinations, ultrasound or 
liver biopsies since the last visit and treatment for HCV infection were also collected 
(Appendix 3.3).
Liver biopsies were performed according to local practice and interpreted by the local 
pathologist.
Blood was taken at each visit for laboratory tests, the results o f which were recorded on 
another study form. These tests included anti-HCV antibody by ELISA or RIBA assays, 
qualitative and quantitative PCR for HCV-RNA and ALT. Routine test results were also 
recorded (e.g. haemoglobin, WBC, lymphocytes, neutrophils, immunoglobulins). For 
infected children, HCV genotype, if known, and the results of any auto-antibody tests 
were also collected.
In addition to the children bom since the start of the prospective study, some older 
children with documented perinatal acquisition of infection who had been regularly 
followed at an EPHN centre were enrolled and followed in the study. Clinical and 
laboratory follow-up study forms were completed for them at each visit according to the 
above protocol.
73
Completed study forms were sent to the London co-ordinating centre by post or fax. 
Some clinicians entered their data directly onto Excel spreadsheets or onto a copy of the 
Access database and emailed the files to the London co-ordinating centre.
All forms and electronic data were checked as they were received and the appropriate 
clinician contacted with any queries. Summary information for each centre was 
recorded on Excel spreadsheets on the number of mother-child pairs enrolled and the 
dates of follow-up visits. Data from forms were entered onto the central Microsoft 
Access database or appended from Excel and Access files. The database includes range 
and internal consistency checks to ensure accurate data entry. The frequency with which 
data were sent to the London co-ordinating centre was monitored so that clinicians 
could be reminded to send their data regularly.
Laboratory methods
All laboratory tests including anti-HCV assays, HCV-RNA PCR and genotyping were 
performed locally. Second or third generation ELISA or RIBA were used to detect anti- 
HCV antibodies in all centres. All laboratories used the Roche Amplicor Cobas assay, 
except one laboratory which used a Real-time assay and two which used in-house 
assays, of whom one changed to Roche in 2001. The median lower detection limit of the 
qualitative PCR assays was 150 copies/ml (range lxlO2 to lxlO4 copies/ml). There was 
little variation in the lower detection limits of the assays used in each laboratory over 
time. For quantitative HCV-RNA PCR, the Roche Amplicor Monitor or Bayer 
Quantiplex assays were used in most centres (Pembrey et al. 2003b).
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Definitions
Infant HCV infection status
Children were considered to be HCV infected if they had two or more positive HCV- 
RNA PCR tests and/or were anti-HCV antibody positive beyond 18 months (European 
Paediatric HCV Network et al. 2000).
Uninfected children had less than two positive PCR tests and two or more negative 
HCV-RNA PCR tests and/or were anti-HCV antibody negative beyond 18 months of 
age.
In addition, for the analysis in Chapter 4, children who had no positive PCR tests and 
were antibody negative between 9 and 18 months were considered uninfected.
The remaining children were o f indeterminate infection status.
Among the children confirmed as HCV infected, those who then became antibody 
negative at or after 18 months of age and those who subsequently had two consecutive 
negative HCV-RNA PCR tests were considered to have evidence of viral clearance; this 
defines the ‘clearers’ referred to in Chapters 4 and 7. For the natural history analysis in 
Chapter 6, a more specific definition of clearance was used which incorporated data on 
symptoms and ALT; the details are provided in the methods section at the beginning of 
Chapter 6.
Other definitions
Elective caesarean section deliveries were defined as those performed before the onset 
of labour and before rupture of the membranes. Prematurity was defined as delivery at 
less than 37 weeks gestation and low birthweight as less than 2500g.
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Data analysis
Data management was carried out using Microsoft Access and statistical analyses were 
performed using STATA (version 7, 8 or 9) (Stata Corporation, Texas, USA). Methods 
specific to each analysis are provided at the beginning of each results chapter.
The analyses presented in this thesis were carried out at different times over the last few 
years. As enrollment o f mother-child pairs and follow-up of children was ongoing, the 
data available at the time o f each analysis varied (Table 3.1).
Table 3.1 Data available at the time of each analysis
Analysis Chapter (ref) Subjects Time of analysis
1. Risk factors for 
HCV vertical 
transmission
2. Between-study 
variation in risk 
factor estimates
Chapter 4 
(European 
Paediatric HCV 
Network 2005) 
Chapter 5
1787 mother-child pairs 
bom since the start of the 
prospective study (1999)
Mother-child pairs 
included in Chapter 4 and 
two other studies
July 2004
November 2005
3. Natural history
4. Immunological 
markers
Chapter 6 
(European 
Paediatric HCV 
Network et al. 
2005c)
Chapter 7
266 vertically HCV April 2003
infected children (some 
bom before 1999)
654 infected and July 2005
uninfected children, 
including infected children 
bom before 1999
5. Parent/carer survey Chapter 8 333 parents and carers o f October 2005
children enrolled in the 
EPHN
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Role of the researcher
I have worked on the EPHN since it started in 1998 and have been responsible for the 
day-to-day co-ordination o f the project. I prepared the protocol and designed the data 
collection forms for the prospective study. I played a large role in preparing a grant 
application to the European Commission which was successful in securing further 
funding for the EPHN for the period 2001-2004. Throughout the study I have been 
solely responsible for data entry, data management and liaison with EPHN clinicians. I 
carried out all the data analyses presented in the thesis and was responsible for planning 
the analysis strategies which were discussed with my supervisor and the clinical co­
ordinator of the study.
As well as preparation o f reports and manuscripts for publication, I have presented my 
work at EPHN annual meetings and at conferences. Two publications have resulted 
directly from the work in this thesis to date and submission of further papers is planned. 
I have also contributed to five other EPHN publications which are related to the work in 
this thesis (Appendix 3.4).
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Chapter 4 Risk factors for mother-to-child transmission of HCV
4.1 Introduction
Identification of maternal, obstetric and infant factors associated with the risk of 
mother-to-child transmission o f HCV is needed to inform potential interventions to 
reduce the risk o f transmission. Prospective data on a large number of HCV infected 
mothers and their infants are required to identify these risk factors and estimate their 
contribution to the overall risk of mother-to-child transmission.
4.2 Methods specific to this analysis
Only the first live-born infants from multiple pregnancies were included in the analyses 
so that each pregnancy was included only once.
Statistical analysis
X2 tests were used to compare proportions. Where continuous data were normally 
distributed, such as maternal age at delivery, the mean values in different groups were 
compared with t tests. Median values were used to describe continuous data which were 
not normally distributed (skewed), such as gestational age. The Wilcoxon rank sum test 
was used to compare median maternal HCV viral load by highly active anti-retroviral 
therapy (HAART) group and by infant’s infection status, and median duration of 
rupture of membranes by infant’s infection status. Univariable and multivariable logistic 
regression was used to obtain odds ratio (OR) estimates for the effect of putative risk 
factors on the risk of vertical transmission. Interaction terms were fitted between 
variables in the multivariable analysis and their significance tested with a likelihood 
ratio x2 test. As the HCV-RNA PCR assays used to determine infection status vary 
between centres and to allow for centre-associated unobserved differences in
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background characteristics, we incorporated a random effect in the multivariable models 
at centre level (Rabe-Hesketh et al. 2002).
4.3 Results
By July 2004, 1787 mother-child pairs had been enrolled at 33 centres of the EPHN in 
Italy, Spain, Germany, Ireland, UK, Norway and Sweden. Excluding second- and third- 
bom infants from multiple pregnancies, there were 1758 mother-child pairs (1731 
singleton infants and 27 first-bom infants from multiple pregnancies), of whom 1479 
(84%) children had confirmed HCV infection status and 279 (16%) were of 
indeterminate infection status (Figure 4.1).
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Figure 4.1 Mother-child pairs included in the analysis and HCV infection 
status of infants from multiple pregnancies and sibling pairs
1787 mother-child pairs 
enrolled
! including
I
I
i
t
2 sets of triplets 25 twin pairs 43 sibling pairs
all/both uninfected 2 20 30
1 infected, 1 uninfected 1 3
1 infected, 1 indeterminate 0 5
1 uninfected, 1 indeterminate 2 4
both indeterminate 2 1
29 second- and third-bom 
infants from multiple 
pregnancies excluded
(one uninfected and tw o  
indeterminate infants o f  the 3 
discordant pairs)
1758 mother-child pairs
(1731 singleton infants +  27 first-born 
infants from m ultiple pregnancies)
1479 (84%) children 
with confirmed 
HCV infection status
279 (16%) children 
with indeterminate 
HCV infection status
91 HCV infected 1388 HCV
children uninfected children
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4.3.1 Characteristics of the 1758 HCV infected pregnant women
Half of the women enrolled in the EPHN (664, 51%) were reported to have been 
identified as HCV infected through routine antenatal testing and a third (462, 36%) were 
tested for HCV because they were considered at high risk of infection; 66 (5%) were 
tested on the mother’s request, 56 (4%) for clinical reasons and 50 (4%) for other 
reasons including blood donation (10) and already known to be infected at enrollment
(13) (reason for HCV testing was not known or missing for the remaining 460) (Table 
4.1). The mean maternal age at delivery was 31.4 years (SD 5.26, median 31.9, range
17.1 -  45.1 years, missing for 319 women). 226 women (13.8%) were HCV/HIV co­
infected (missing for 117) and 510 (31.7%) breastfed their babies (missing for 147). The 
majority of women, 1208 (68.7%), were from Italian centres and 550 (31.3%) were seen 
in centres outside Italy; in Spain (282), Ireland (168), UK (52), Germany (33), Norway
(14) and Sweden (1).
Factors associated with mode o f  acquisition o f  HCV infection
Contaminated blood transfusions/blood products were the probable mode o f acquisition 
of HCV infection for 172 women (10.6%), for 572 (35.4%) HCV infection was 
associated with injecting drug use (IDU), while other routes were reported for 663 
women (41.1%) and mode o f acquisition was not known for 208 (12.9%) (this 
information was missing for 143 women).
Of the 663 women who reported ‘other’ modes of acquisition, these were specified for 
251 (38%); sexual transmission was reported for 86 (34%) women, surgery for 62 
(25%) and parenteral infection for 34 (13%). Intrafamilial transmission was identified as 
the route of infection for 27 (11%) women, of whom 14 had an HCV infected mother so 
were probably vertically infected, dental treatment for 17 (7%) women, occupational
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exposure for 9 (4%), tattooing for 8 (3%) and various other routes for the remaining 8 
(3%); receipt of contaminated anti-D immunoglobulin (4), ‘blood sisters’ (1), 
immunoglobulin for hepatitis A (1), blood donor (1), chiropody (1).
Fewer of the women with unknown mode of HCV acquisition were HIV co-infected 
than those with known mode of acquisition [7% (14/189) vs. 15% (202/1380), 3^ =7 .32, 
p=0.007]. Three-quarters (85) of women with unknown mode of acquisition were 
identified as HCV infected through routine antenatal screening compared to 49% (579) 
of the women with known route o f infection (x2=28.69, p<0.0001). 442 (37%) of 
women with known mode o f acquisition were tested for HCV because they were 
identified as being at high risk o f HCV infection.
IDU is an important route o f HCV infection. Women who acquire HCV infection in this 
way may differ as a group from women who became infected through blood 
transfusions and other routes. To investigate this, factors associated with acquiring HCV 
through IDU versus other routes were identified. 572 women (41.5%) had ever injected 
drugs making this the most likely route of acquisition of HCV while a total of 805 
(58.5%) women did not report a history o f IDU (IDU history not known for the 
remaining 381 women). Younger maternal age at delivery, maternal HIV infection and 
non-Italian centres were all independently and significantly associated with maternal 
acquisition of HCV infection through IDU (Table 4.1). Maternal HIV co-infection was 
most strongly associated with acquiring HCV through IDU; HCV/HIV co-infected 
women were 11 times more likely to have a history of IDU than women with only HCV 
infection. Both viruses can be transmitted via contaminated needles in IDU.
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Table 4.1 Association of maternal factors with probable acquisition of HCV infection through injecting drug use
IDU ever IDU vs. never IDU, n=1262*
n ever
n = 5 7 2
never
n=805
not known 
n=381
unadjusted OR 
( 9 5 % C I )
P adjusted for all other 
variables, OR ( 9 5 %  C l )
P
Maternal age at 
delivery (yrs)
mean, SD (range) 
missing
1 4 3 9
3 1 9
3 0 .4 ,  5 .3 7
( 1 8 . 3 - 4 2 . 9 )
7 7
3 2 . 1 , 4 . 9 7
( 1 7 . 1 - 4 5 . 1 )
2 4
3 5 . 1 , 5 . 7 4
( 1 8 . 9 - 4 3 . 9 )
2 1 8
for each year increase
0 .9 4  ( 0 . 9 2 - 0 . 9 6 ) < 0 .0 0 1 0 .9 3  ( 0 .9 1  - 0 . 9 5 ) < 0 .0 0 1
Maternal HIV co- 
infection
infected
uninfected
missing
2 2 6
1 4 1 5
1 1 7
163  ( 3 0 % )  
3 8 9  
2 0
3 2  (4 % )  
7 6 9  
4
31 ( 1 1 % )  
2 5 7  
9 3
10 .41  ( 6 . 9 2 - 1 5 . 6 6 )  
1.0
< 0 .0 0 1 1 1 .3 0  ( 7 . 3 2 - 1 7 . 4 4 ) < 0 .0 0 1
Centre
non-Italian
Italian
5 5 0
1 2 0 8
2 7 9  (4 9 % )  
2 9 3
1 1 4 ( 1 4 % )
691
1 5 7 ( 4 1 % )
2 2 4
5 . 2 7 ( 4 . 0 0 - 6 . 9 4 )
1 .0
< 0 .0 0 1 4 .6 5  ( 3 . 4 6 - 6 . 2 5 ) < 0 .0 0 1
Reason for HCV testing
mother’s request 6 6 10  (2 % ) 5 4  (7% ) 2  (2 % ) routine antenatal testing not included in the m odel
routine antenatal testing 6 6 4 71 (1 7 % ) 5 1 2 ( 6 8 % ) 81 (7 1 % ) vs. other groups, n = l 184
identified as high risk 4 6 2 3 3 1  (7 8 % ) 1 1 0 ( 1 5 % ) 21 ( 1 8 % )
0 . 1 0 ( 0 . 0 7 - 0 . 1 3 )  < 0 .0 0 1clinical 5 6 5 (1 % ) 4 7  (6 % ) 4  (4 % )
other 5 0 10  (2 % ) 3 4  (4 % ) 6  (5 % )
not known/missing 4 6 0 145 4 8 2 6 7
* information available for all variables
Region (Italy or otherwise) was included in the model as the risk factors for HCV 
infection in pregnant women may vary between regions depending on the predominant 
pattern of transmission (e.g. the high prevalence in parts of southern Italy is likely to be 
associated with iatrogenic transmission during polio vaccination campaigns in the 1950s 
and 1960s (Montella et a l 2003)). The association of less IDU-associated acquisition of 
HCV infection in Italian centres observed here may be because the predominant 
epidemic in Italy originated from unsafe medical (Montella et al. 2003) and dental 
practices and the IDU-related epidemic is smaller. This association is also likely to 
reflect differences in antenatal testing practices between centres in Italy and those 
elsewhere in Europe. 55% (544/998) o f women from Italian centres were tested for 
HCV as part of routine antenatal testing compared to 40% (120/300) of women from 
centres outside Italy (^=19.43, p<0.001). The reason for HCV testing is closely related 
to having a history of IDU so was not included in the multivariable model. Women with 
a history of IDU were likely to be tested for HCV because they were at high risk of 
infection, regardless of routine antenatal testing practices; only 15% (42/276) of women 
with a history of IDU were identified through routine testing in Italian centres as were 
19% (29/151) in non-Italian centres (^=1.12, p=0.29).
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4.3.2 Children of indeterminate infection status
Compared to the 1479 mothers o f children with confirmed HCV infection status, the 
mothers of the 279 children of indeterminate infection status were significantly less 
likely to be HCV/HIV co-infected (7.2%, p=0.001) and therefore less likely to have an 
elective caesarean section (CS) delivery (20%, p<0.001). They were more likely to have 
a history of IDU (58%, p<0.001) and less likely to breastfeed (25%, p=0.03). These 
differences are likely to reflect that the children with indeterminate infection status were 
bom significantly more recently than children with confirmed infection status; 26 (9%) 
were bom in 2003 or 2004 compared to only 59 (4%) children with confirmed infection 
status (j^= 14.49, p=0.0001). Otherwise, the distribution of characteristics was similar 
between the two groups.
4.3.3 Children with confirmed infection status
Table 4.2 shows the characteristics o f the 1479 women and children with confirmed 
infection status; this group forms the basis of the main analyses. The distribution of 
characteristics is also shown separately for HCV/HIV co-infected women and women 
with only HCV infection. As elective CS is recommended for HIV infected women to 
reduce the risk of HIV vertical transmission (Newell and Rogers 2002), the rate of 
elective CS was substantially higher in women with HCV/HIV co-infection (64%, 
123/192) than in those with HCV infection alone (29%, 333/1139) (p<0.0001). Within 
Europe Italy is known to have a high rate of elective CS (Tranquilli and Giannubilo 
2004) and this was observed here with an overall elective CS rate in Italian centres of 
38%; in non-Italian centres this increased from 14.9% (54/363) before 2001 to 22.4% 
(30/134) since 2001 (x2=3.93, p=0.05).
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Median gestational age at delivery was 39 weeks (range 25 -  42 weeks) and mean birth 
weight was 3007g (SD 564g, range 740g -  4900g). Prematurity (<37 weeks) varied by 
maternal characteristics from 12% (138/1111) among women with only HCV infection 
to 37% (72/197) among HCV/HIV co-infected women. Among active injecting drug 
users during pregnancy 25% (28/112) had a premature delivery, as did 23% (54/237) of 
women with a history of IDU, compared to 10% (73/697) of those who had never 
injected drugs (ever IDU vs. never IDU, p<0.0001).
One third of women breastfed their infants overall: 38% (428) of those with only HCV 
infection and just 1.5% (3) o f those with HCV/HIV co-infection.
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Table 4.2 Characteristics of children with confirmed infection status and their mothers (total and by maternal HIV infection status)
n=1479 Total, n (%) HCV+/HIV+ HCV+/HIV-
Maternal HIV Infected 208(15.0) - -
infection status Uninfected 1183 (85.0) - -
Missing 88
Maternal Blood transfusion/blood products 164(12.1) 3(1.5) 159(14.1) 5^=187.02,
acquisition of Injecting drug use 447 (33.1) 148 (74.7) 288 (25.6) p<0.001
HCV infection Other 571 (42.3) 34(17.2) 533 (47.3)
Not known 169(12.5) 13 (6.6) 146(13.0)
Missing 128 10 57
Maternal Ever IDU 448 (38.6) 149 (83.7) 288 (29.7) X2=186.14,
injecting drug Never IDU 714(61.4) 29(16.3) 682 (70.3) p<0.001
use Missing 317 30 213
Maternal age at Mean, SD 31.7(5.17) 32.1 (4.85) 31.6 (5.21)
delivery (years) Median, range 32.0(17.1 -45.1) 32.7 (20.5 -41.6) 32.0(17.1 -45.1) z=2.24, p=0.03
Missing 274 31 164
Mode of delivery Vaginal 764 (52.5) 31 (14.9) 693 (59.0) elective CS vs. other
Emergency caesarean section 160(11.0) 38(18.3) 113(9.6)
oo00ooIIVs
Elective caesarean section 480 (33.0) 123 (59.1) 333 (28.4) p<0.001
Caesarean section (unspecified) 51 (3.5) 16(7.7) 35 (3.0)
Missing 24 0 9
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Table 4.2 continued
Total, n (%) HCV+/HIV+ HCV+/HIV-
Gender Male 802 (54.6) 114(54.8) 646 (54.8) ^=0.0003,
Female 668 (45.4) 94 (45.2) 534 (45.2) p=0.99
Missing 9 0 3
Gestational age Very premature (<34 wks) 79 (5.7) 30(15.2) 48 (4.3) prem vs. term
Premature (35-36 weeks) 140(10.1) 42 (21.3) 90 (8.1) X2=72.27,
Term (>37 weeks) 1163 (84.2) 125 (63.5) 973 (87.6) p<0.001
Missing 97 11 72
Birth weight Low (<2500g) 215(15.8) 70 (36.1) 135(12.4) ^=66.69,
Normal (>2500g)' 1142 (84.2) 124 (63.9) 953 (87.6) p<0.001
Missing 122 14 95
Infant feeding Breastfed 452 (32.7) 3(1.5) 428 (38.4) ^=107.49,
Formula fed 930 (67.3) 202 (98.5) 686 (61.6) p<0.001
Missing 97 3 69
Child HIV Infected 10(0.7) 10(5.3) 0
infection status Uninfected 1397 (97.4) 151 (80.3) 1183 (100%)
Indeterminate 28(1.9) 27 (14.4) 0
Missing 44 20 0
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Risk of and risk factors for vertical transmission
The overall risk of HCV vertical transmission was 6.2% (91/1479, 95% Cl 5.0% -  
7.5%). HCV transmission was higher among HIV co-infected women (8.7%, 18/208) 
than among those with HCV infection alone (5.5%, 65/1183), though this difference 
was not statistically significant (unadjusted OR=1.63, 95% Cl 0.94 -  2.81, p=0.08). 
Maternal history o f IDU was not associated with risk o f transmission: 6.3% (28/448) of 
babies bom to women who were ever injecting drug users were infected compared to 
6.2% (44/714) o f those bom to women who had never injected drugs (unadjusted 
OR=1.02, 95% Cl 0.62 -  1.66, p=0.95). Similarly, there was no difference in 
transmission risk between active injecting drug users in pregnancy and those with a 
history of IDU but not during pregnancy (7.1% (8/113) vs 7.0% (17/244), x^O.0015, 
p=0.97). Risk of transmission was not associated with maternal age at delivery: the 
mean age o f the mothers of 1137 uninfected children was 31.7 years (SD 5.17 yrs) 
compared to 31.8 years (SD 5.23 yrs) for mothers of 68 infected children (t=-0.216, 2 
sided p=0.83). The transmission risk did not vary significantly by mode of delivery: 
elective CS 7.3%, (35/480) and vaginal delivery or emergency CS 5.4% (50/924; 
unadjusted OR= 1.37, 95% Cl 0.88 -  2.15, p=0.16).
However, girls were twice as likely to be HCV infected as boys: 8.2% (55/668) of girls 
vs. 4.2% (34/802) of boys (unadjusted OR=2.03, 95% Cl 1.30 -  3.15, p=0.001). Among 
premature babies, 4.1% (9/219) were HCV infected compared to 6.3% (73/1163) of 
those bom at 37 weeks or later (unadjusted OR=0.64, 95% Cl 0.32 -  1.30, p=0.21). 
Similarly, 4.7% (10/215) of low birth weight (>2500g) babies were infected compared 
to 6.2% (71/1142) of babies of normal birth weight (unadjusted OR=0.74, 95% Cl 0.37 
-  1.45, p=0.37). The proportion of infected children was similar in the breastfed (4.9%,
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22/452) and formula fed groups (5.7%, 53/930; unadjusted OR=0.85, 95% Cl 0.51 -
1.41, p=0.52).
Table 4.3 shows the results o f univariable and multivariable analyses among the 1220 
mother-child pairs with information available on all variables. The univariable odds 
ratios for the subset o f 1220 children were generally similar to those obtained using all 
available data for each variable, as above, and show significant associations between the 
vertical transmission risk and maternal HIV co-infection, mode of delivery (borderline) 
and gender. In multivariable analysis, gender remained the only risk factor significantly 
associated with HCV vertical transmission. The multivariable analysis was repeated 
adjusting for maternal IDU as this has been reported to be associated with a higher HCV 
transmission risk by others (Resti et al. 2002a). Here, maternal IDU was not 
significantly associated with vertical transmission (unadjusted OR=0.99, 95% Cl 0.59 -
1.67, p=0.97; adjusted OR=1.33, 95% Cl 0.71 -  2.50, p=0.38) and the estimated odds 
ratios for the other variables were not altered substantially, although the adjusted odds 
ratio for maternal HIV co-infection increased to 2.18 and became statistically significant 
(95% Cl 1.02 -  4.65, p=0.04).
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Table 4.3 Associations between maternal and infant characteristics and
vertical transmission for 1220 children (65 infected, 1155 uninfected) 
with information available on all variables
n=1220 unadjusted OR 
(95%CI)
P adjusted for all 
other variables, OR 
(95% Cl)
P
Maternal HIV co-infection
Uninfected
Infected
1.0
1.89 (1 .05-3 .40) 0.03
1.0
1.82 (0 .9 4 -3 .5 2 ) 0.08
Mode of delivery
Vaginal & emergency CS 
elective CS
1.0
1.66 (1 .00-2 .74) 0.05
1.0
1.46 (0 .86 -2 .48 ) 0.16
Gender
Male
Female
1.0
2.12 (1 .27-3 .56) 0.004
1.0
2.07 (1 .23 -3 .48 ) 0.006
Prematurity
Term
Premature
1.0
0.54 (0 .2 3 - 1.26) 0.15
1.0
0.45 (0 .1 9 - 1.08) 0.07
Infant feeding
Formula fed 
Breastfed
1.0
0.74 (0 .4 2 - 1.31) 0.30
1.0
0.88 (0 .4 8 -  1.61) 0.68
Further investigation of the association of gender and risk of transmission
Odds ratios for gender were calculated -separately for vaginal or emergency CS and 
elective CS deliveries to investigate whether girls were more likely to become infected 
than boys in utero and/or during delivery. Transmission is assumed to have occurred 
before delivery in infected infants delivered by elective CS as contact between maternal 
and infant blood and other fluids is reduced compared to vaginal or emergency CS 
deliveries. Using all available data, girls were significantly more likely to be infected 
than boys, regardless of mode of delivery. Among vaginal and emergency CS
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deliveries, 31 (7.4%) o f 420 girls were HCV infected compared to 19 (3.8%) of 502 
boys (OR=2.03, 95% Cl 1.12 -  3.65, p=0.02) and among elective CS deliveries 22 
(10.2%) of 216 girls were infected as were 13 (4.9%) of 263 boys (OR=2.18, 95% Cl 
1.07 -  4.46, p=0.03). Restricting the analysis to the 1220 mother-child pairs with 
information available on all variables (as in Table 4.3), gender was no longer 
significantly associated with risk of transmission among the vaginal and emergency CS 
deliveries although the trend was the same (OR= 1.75, 95% Cl 0.87 -  3.52, p=0.11) but 
remained significant among the elective CS deliveries (OR=2.68, 95% Cl 1.22 -  5.88, 
p=0.01). However, mode of delivery did not significantly modify the effect of gender on 
vertical transmission (interaction term in the multivariable model in Table 4.3: LRT 
X2=0.50, p=0.48), suggesting that reduced statistical power would explain the lack of 
statistically significant differences in some sub-groups.
Differential follow-up by gender might explain the association between gender and risk 
of transmission. However, there was no evidence to suggest that boys had been 
followed up for longer or shorter periods than girls: the median age at last follow-up 
visit was 12.1 months (range birth -  59.4 months) for the boys and 12.3 months (range 
birth -  58.4 months) for the girls (z=-1.46, p=0.15) and the proportion of children with 
indeterminate infection status was similar for boys (15.5%, 147/949) and girls (15.2%, 
120/788) ( x2=0.02, p=0.88).
There were no significant interactions between gender and any of the variables in Table 
4.3.
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Maternal HCV/HIV co-infection
O f the 208 HCV/HIV co-infected women, 10 (6.2%) had an HIV infected child, one of 
whom was also HCV infected (HIV infection status was indeterminate for 27 and 
missing for 20). O f these 10 women, 2 received highly active anti-retroviral therapy 
(HAART) during pregnancy, 6 received other anti-retroviral therapy (ART) and 2 were 
not treated. All except one child received ART neonatally. Women with HCV/HIV co- 
infection differed from those with HCV infection alone for several o f the factors of 
interest (Table 4.2). For example, the former more frequently had an elective CS (64%, 
123 vs. 29%, 333, p<0.001) and a premature delivery (37%, 72 vs. 12%, 138, p<0.001), 
and only 1.5% (3) breastfed compared to 38% (428) of the latter (p<0.001). There was 
significant interaction between maternal HIV co-infection and prematurity (LRT 
X2=3.76, p=0.05) in the multivariable model shown in Table 4.3. To clarify these 
relationships and to examine the effect o f maternal ART on HCV transmission in the 
co-infected group, regression analyses were run separately for HCV/HIV co-infected 
women and those with HCV infection only (Table 4.4).
Mode o f delivery was not associated with risk o f transmission in either group. In both 
groups girls were significantly more likely to be infected than boys. Among the 
HCV/HIV co-infected women prematurity was associated with a significant decreased 
HCV transmission rate, although in multivariable analysis this was no longer 
statistically significant. Breastfeeding was not statistically significantly associated with 
transmission among women with HCV infection alone, while its effect could not be 
estimated among the HCV/HIV co-infected women as only three breastfed, all with 
uninfected children.
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Table 4.4 Associations between maternal and infant characteristics and
vertical transmission, stratified by maternal HIV infection status
HCV+/HIV+ women 
n=184
unadjusted OR P adjusted for gender, P
(95% Cl) prematurity, mode of
delivery, HAART
Mode of delivery
Vaginal & emergency CS 1.0 1.0
elective CS 1.20 (0 .40-3 .62) 0.75 0.76 (0 .23 -2 .53 ) 0.66
Gender
Male 1.0 1.0
Female 3 .8 0 (1 .1 8 - 12.26) 0.03 4 .0 0 (1 .1 8 - 13.54) 0.03
Prematurity
Term 1.0 1.0
Premature 0.11 (0 .01 -0 .83) 0.03 0 .1 4 (0 .02 -1 .13 ) 0.07
Maternal ART
Monotherapy/none 1.0 1.0
HAART 0.27 (0.07 -  0.97) 0.05 0.26 (0 .07 -1 .01 ) 0.05
HCV+/HIV- women
n=1034 unadjusted OR P adjusted for all other P
(95% Cl) variables
Mode of delivery
Vaginal & emergency CS 1.0 1.0
elective CS 1.57 (0 .88-2 .83) 0.13 1.59 (0 .88 -2 .86 ) 0.13
Gender
Male 1.0 1.0
Female 1 .79(1 .00-3 .22) 0.05 1 .80(1 .00-3 .24) 0.05
Prematurity
Term 1.0 1.0
Premature 0.83 (0 .32-2 .13) 0.69 0.83 (0 .32 -2 .15 ) 0.70
Infant feeding
Formula fed 1.0 1.0
Breastfed 0.88 (0 .4 8 - 1.61) 0.68 0.92 (0 .5 0 - 1.70) 0.80
Note: An odds ratio could not be calculated for the effect o f  infant feeding am ong the co-infected group 
because only 3 w om en breastfed and all o f  their children w ere uninfected. The infant feeding variable was 
therefore excluded from the multivariable m odel.
Highly active anti-retroviral therapy (HAART) is now widespread among HIV infected 
pregnant women and HAART in HIV/HCV co-infected women was associated with a 
substantial but marginally significant reduction in the risk of HCV transmission (Table 
4.4). However its use has been shown to increase the risk of prematurity (European 
Collaborative Study 2003b) and of the 184 HCV/HIV co-infected women, 81 received
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HAART during pregnancy, 71 received monotherapy and 32 were not treated. Women 
who received HAART delivered prematurely more frequently than those on no or 
monotherapy (36/81, 44% and 29/103, 28%, respectively; x2=5.27, p=0.02). As HAART 
reduces HIV viral load and improves the associated immunosuppression, it might also 
affect HCV viral load and thereby vertical transmission of HCV. There was a trend 
towards lower HCV viral load among HAART-treated women compared to women on 
monotherapy or no treatment (median viral load among 18 HAART-treated women was 
656,101 copies/ml vs. 850,000 copies/ml among 11 women on no or monotherapy, z=- 
0.922, p=0.36).
Maternal HCV viraemia
Of the women whose children had confirmed HCV infection status, 556 had at least one 
qualitative and/or quantitative PCR test for HCV-RNA during pregnancy, at delivery or 
in the first week postpartum (median number o f tests 1, range 1 to 5). O f these, 394 
(70.9%) were viraemic, 153 (27.5%) non-viraemic and 9 (1.6%) had both positive and 
negative PCR results. O f the 116 women who were tested more than once, 92 (79.3%) 
were always viraemic, 15 (12.9%) were always non-viraemic and 9 (7.8%) had both 
positive and negative tests.
Being tested for viraemia was not associated with particular centres or with possible risk 
factors for vertical transmission (gender of the child, maternal HIV co-infection, 
maternal IDU, mode of delivery, infant feeding or prematurity). Women with HIV co- 
infection were significantly more likely to be viraemic than those with only HCV 
infection (91% vs. 69%, %2= 16.60, p<0.001) and breastfeeding was less frequent among 
viraemic than non-viraemic women (27% vs. 43%, % =13.19, p<0.001).
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O f the 403 women who were ever viraemic, 6.2% (25) had an HCV infected child 
compared to 3.3% (5) o f the 153 never viraemic women (unadjusted OR= 1.96, 95% Cl 
0.73 — 5.22, p=0.17). Taking the PCR result closest to delivery for the 9 women with 
both positive and negative results gave similar results. Adjusting for gender, maternal 
HIV co-infection, mode o f delivery, breastfeeding and prematurity either individually or 
simultaneously did not alter the odds ratio estimate (fully adjusted OR=1.96, 95% Cl 
0.71 -  5.40, p=0.19). Limited sample size and few transmission events may explain the 
non-significant result.
Only 221 of the 403 ever viraemic women had at least one quantitative PCR result. 
Median viral load was 412,500 copies/ml (range 30 -  48,210,000) and was higher 
among mothers o f infected children (475,000 range 15,400 - 13,406,441 vs. 409,000 
range 30 -  40,550,000, z=-0.84, p=0.40). O f the 22 women with very high viral load 
(>90th centile), 3 (14%) had an infected child compared to 13 (6%) of 199 with viral 
load below the 90th centile (Fisher’s exact p=0.20). Two of 55 (3.6%) women with viral 
load below the 25th centile had an infected child and none of the 22 women with viral 
load below the 10th centile had an infected child. There was no evidence of a threshold 
above which transmission always occurred or below which transmission never occurred.
Of the five infected children bom to non-viraemic women, three had evidence of 
clearance and two were considered infected on the basis of two or more positive PCR 
results. Three children were breastfed and 2 were not. The maternal viraemia tests were 
performed one day after delivery, at delivery, at 11 weeks gestation and at 14 weeks 
gestation (2 women).
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There were no significant interactions between maternal viraemia and any of the factors 
in the multivariable analysis above.
Rupture of membranes
The time from rupture o f membranes (ROM) to delivery was reported for 466 women 
whose children had confirmed infection status and were delivered vaginally (400) or via 
emergency CS (62) (2 CS unspecified, 2 missing). Among the 19 women with an 
infected child the median duration o f ROM (DROM) was 4.5 hours (range 10 mins -  
27.25 hours) compared to 2.6 hours (range 1 min -  90 hours) among the 447 women 
with an uninfected child (z=-2.130, p=0.03). For each hour increase in DROM, the risk 
o f vertical transmission increased by about 3% (unadjusted OR=1.03, 95% Cl 0.99 -
1.06, p=0.11).
Sensitivity analyses
Our best estimate of the vertical transmission risk was 6.2% (91/1479, 95% Cl 5.0% -  
7.5%). Twenty-five infected children had evidence of clearance of the virus and became 
antibody negative after 18 months. For some of these children, although qualitative PCR 
tests were positive on two or more occasions, viraemia was undetectable by quantitative 
PCR at these times. We therefore repeated the main analysis reported in Table 4.3 
excluding these 25 infected children. The overall transmission rate decreased to 4.5% 
(66/1454, 95% Cl 3.5% -  5.7%), but the results concerning the correlates of 
transmission did not change substantially except that the odds ratio estimates for 
maternal HIV co-infection increased substantially and became statistically significant 
(adjusted OR=4.48, 95% Cl 2.10 -  9.58, p<0.001). Maternal IDU was associated with 
transmission in univariable (unadjusted OR=1.80, 95% Cl 1.01 -  3.21, p=0.04) but not 
in multivariable analysis (adjusted OR=0.91, 95% Cl 0.43 -  1.92, p=0.80). In stratified
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analysis, results for the HCV/HIV co-infected women remained as reported in Table 4.4 
as none of the 25 excluded children were bom to co-infected women. Among the 
women with only HCV infection, the adjusted odds ratio estimate for gender increased a 
little to 2.34 (95% Cl 1.03 -  5.30, p=0.04). Repeating the analyses including the 25 
children as uninfected rather than excluding them gave very similar results to those 
obtained when excluding these children.
The risk factor analyses were also repeated including only the 357 children with 
infection status confirmed by antibody status at or after 18 months (24 infected and 333 
uninfected). Results were similar to the main analysis as reported in Table 4.3 except 
that the adjusted odds ratio estimate for maternal HIV co-infection increased to 3.95 
(95% Cl 1.19 -  13.08, p=0.03) and the estimate for gender increased to 6.42 (95% Cl 
1 .40-29 .35 , p=0.02).
Several alternative vertical transmission risk estimates were calculated based on 
different assumptions about the infection status of the 279 children of indeterminate 
infection status. O f these 279 children, 180 had one negative PCR result, o f whom 25 
were anti-HCV antibody negative but before 9 months of age. Seven children had one 
positive PCR result and no negative anti-HCV antibody results; 5 had one positive and 
one negative PCR, o f whom 2 were antibody negative at 10.4 and 11.2 months. 87 
children had no PCR results, o f whom 2 were anti-HCV antibody negative but before 9 
months o f age.
The risk of vertical transmission would be 5.2% (91/1758, 95% Cl 4.2 -  6.3) if all 279 
children with indeterminate infection status were included as uninfected. Assuming the 
indeterminate children with no positive PCRs and one negative PCR and/or a negative
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antibody result are uninfected (n=182) and those with one positive PCR are infected 
(n=12), the vertical transmission risk would be 6.2% (103/1673, 95% Cl 5.1 -  7.4) 
(children with no PCR results and no negative antibody results remain as 
indeterminate).
If we exclude the 25 infected children who became antibody negative after 18 months of 
age and also assume that all 279 indeterminate children are uninfected, our minimum 
estimate would be 3.8% (66/1733, 95% Cl 3.0 -  4.8). If instead we assume that the 
indeterminate children with one negative PCR and/or a negative antibody result are 
uninfected and that those with one positive PCR are infected, the estimate would be 
4.7% (78/1648, 95% Cl 3.8 -  5.9).
Excluding 29 uninfected children who were antibody negative after 9 months with no 
positive PCRs gives a vertical transmission risk of 6.3% (91/1450, 95% Cl 5.1 -  7.6).
As mode of delivery was one of the key variables of interest and the rate o f elective CS 
delivery was higher in Italian centres, we repeated the main analysis separately for 
Italian and non-Italian centres. Mode of delivery was not associated with risk of 
transmission in either group (adjusted OR for 907 mother-child pairs in Italian centres = 
1.56, 95% Cl 0.87 -  2.80, p=0.14; adjusted OR for 261 mother-child pairs in non-Italian 
centres = 0.24, 95% Cl 0.03 -  2.20, p=0.21), although the odds ratio estimates were in 
opposite directions. There were only 10 transmission events in the latter group.
Allowing for potential centre differences
Incorporating a random effect in the multivariable models at centre level improved the 
goodness of fit o f the models for all women and for the subgroup with HCV infection
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alone, but not for the HCV/HIV co-infected women. However, in all cases, the 
association between the risk o f transmission and the various risk factors did not change 
and the odds ratio estimates and p values were similar.
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4.4 Key points
• Younger maternal age at delivery, maternal HIV infection and non-Italian centres 
were all independently and significantly associated with maternal acquisition of 
HCV infection through IDU.
• The overall risk of mother-to-child transmission of HCV was 6.2%.
• Girls were twice as likely to be infected as boys.
• There was no evidence o f a protective effect o f elective CS delivery.
• Duration of rupture o f membranes was significantly longer among mothers of 
infected children than uninfected children.
• HCV/HIV co-infected women were more likely to transmit HCV to their infants 
than women with only HCV infection, although this was not statistically significant 
in multivariable analysis.
• An increased, but not statistically significant, risk of transmission was observed 
among women who were HCV viraemic during pregnancy or around delivery, 
although a few children were infected by non-viraemic women.
• Maternal history of IDU, prematurity and infant feeding were not significantly 
associated with transmission.
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Chapter 5 Investigating between-study variation in risk factor
estimates for mother-to-child transmission of HCV
5.1 Introduction
It is unclear whether between-study variation in estimates of the risk of HCV mother-to- 
child transmission and the effect o f risk factors is due to methodological differences, 
such as sample size, or to differences in population characteristics. To investigate 
possible explanations for between-study variation, three studies for which individual 
subject data were available were compared.
5.2 Methods specific to this analysis 
Statistical analysis
To assess the validity of pooling data from different sources the heterogeneity o f the 
risk factor estimates from each study was estimated using meta-analysis methods (Sharp 
and Sterne 1998;Egger et al. 1998). The heterogeneity statistic, represented by Q, tests 
the null hypothesis that the risk factor effect on the estimated risk of mother-to-child
•y
transmission is the same in all studies, and is compared with the % distribution on 
(number of studies -1) degrees of freedom. The greater the average distance between the 
individual study odds ratios and the summary odds ratio, the more evidence there is 
against the null hypothesis. Meta-analyses provide both fixed and random effects pooled 
estimates. In fixed effects meta-analysis it is assumed that the true effect is the same in 
each study and that all of the between-study variation is due to sampling error, whereas 
in random effects meta-analysis it is assumed that the true effect is randomly, normally 
distributed between studies and a mean effect is estimated, about which it is assumed 
that the true study effects vary (Kirkwood and Sterne 2003). Random effects pooled 
estimates are presented in Table 5.3 and in the forest plots.
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In the pooled dataset, logistic regression was used to obtain pooled adjusted odds ratios 
for the risk factors which were significantly associated with risk of vertical transmission 
in the individual studies or were of particular interest because of their potential for 
clinical intervention (maternal HCV/HIV co-infection, mode of delivery, breastfeeding 
and prematurity). Interaction terms were fitted in the multivariable models and their 
significance tested using likelihood ratio tests, x tests for linear trend o f characteristics 
over time were performed using StatCalc in Epilnfo 3.3.2.
5.3 Results
The results of the three studies are described in Table 5.1. The first study (European 
Paediatric HCV Network et al. 2001) was a retrospective analysis of data from EPHN 
centres, collected prospectively within each centre, which included 1633 mother-child 
pairs, most of whom were bom between 1992 and 1998 (1454, 89%) with some earlier 
births. Data for each eligible mother-child pair were collected on a 2-page 
questionnaire, completed by the clinician at each EPHN centre from patient notes or 
local databases. Instructions regarding definitions o f infection status and eligibility 
criteria were provided (see Appendix 5.1 for copy of the questionnaire and instructions). 
Maternal HCV/HIV co-infection was the predominant risk factor for HCV vertical 
transmission. Among the HCV/HIV co-infected women caesarean section (CS) delivery 
was protective and breastfeeding was associated with an increased risk of HCV 
transmission but these associations were not observed among the women with only 
HCV infection.
The second study included 346 mother-child pairs bom between 1986 and 2000 at 
Hospital Clinic in Barcelona, Spain. I analysed these data in 2000 but the results have 
not been published. Data on socio-demographic factors, reproductive history, sexual
103
behaviour, history of sexually transmitted infections and alcohol and drug use were 
collected during an interview with each woman within 3 days o f delivery. Clinical 
details relating to delivery were noted in the patient notes and the results o f serological, 
virological, microbiological and biochemical tests during pregnancy were recorded on a 
central laboratory computer. All data were regularly entered onto the study database. 
Maternal HCV/HIV co-infection was associated with a four-fold increase in risk of 
HCV vertical transmission. There was no statistically significant effect of mode of 
delivery and breastfeeding was associated with an increased risk of borderline statistical 
significance.
The third study was the EPHN prospective study which is reported in Chapter 4; it 
included data for 1758 mother-child pairs bom between 1999 and 2004.
The definitions o f child HCV infection status were similar for the three studies (Table 
5.2). The definition of an elective CS delivery (before both onset o f labour and rupture 
of membranes) was the same for all three studies. However, for the risk factors 
analyses, the elective and emergency CS groups were combined and compared with the 
vaginal deliveries in the EPHN 2001 and Hospital Clinic studies, whereas the elective 
CS group was compared with vaginal and emergency CS deliveries in the EPHN 2005 
study. The specific categories of mode o f delivery were available for each study so the 
mode of delivery groups used to obtain estimates for each study for inclusion in the 
meta-analyses and the groups used in the pooled analysis were consistent across studies.
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Table 5.1 Results of each study
EPHN 2001 Hospital Clinic EPHN 2005
Reference BJOG 2001 (European 
Paediatric HCV Network et 
al. 2001)
unpublished JID 2005 (European Paediatric 
HCV Network 2005)(Chapter 4)
Time period of births 1981 -  1998 1986-2000 1999 -  2004
Total no. of mother-child pairs 
(excluding 2nd twins)
No. of mother-child pairs with 
confirmed infant infection status 
% HCV/HIV co-infected mothers
1633
1474 (90%)
35% (503/1419)
346
295 (85%) 
69% (203/295)
1758
1479 (84%)
15% (208/1391)
% mothers with history o f IDU 59% (817/1384) 81% (239/295) 39% (448/1162)
Estimated risk of vertical 
transmission (95% Cl)
9.2% (136/1474) 
(7.8% - 10.8%)
13.6% (40/295) 
(9.9% - 18.0%)
6.2% (91/1479) 
(5.0% - 7.5%)
Odds ratio estimate (95% Cl), p  for: 
Maternal HCV/HIV co-infection 
(infected vs. uninfected)
2.31 (1 .58-3 .37), p<0.001* 2 .88(1 .17 -7 .13 ), p=0.02* 
4.45 (1 .4 0 - 14.1 l),p=0.01
1.89 (1 .0 5 - 3.40), p=0.03* 
1.82 (0 .94-3 .52), p=0.08
Mode of delivery 
overall:
co-infected women: 
women with only HCV:
CS vs. vaginal 
0.69 (0 .41-1 .16), p=0.16 
0.36 (0 .16-0 .80), p=0.01 
1 .17(0 .59-2 .31), p=0.66
CS vs. vaginal 
1.09 (0.51 -2 .3 4 ), p=0.83 
1.11 (0 .48-2 .58), p=0.81 
0.85 (0 .09-8 .00), p=0.88
elective CS vs. vaginal/emerg CS 
1.46 (0 .86-2 .48), p=0.16 
0.76 (0.23 -  2.53), p=0.66 
1.59 (0 .88-2 .86), p=0.13
Breastfeeding
(breastfed vs. not breastfed) 
overall:
co-infected women: 
women with only HCV:
1.26 (0 .70-2 .27), p=0.44 
6.41 (1 .25-32 .94), p=0.03 
1.07 (0 .57-2 .02), p=0.83
3.75 (0 .8 8 - 15.99), p=0.07 
**
1.63 (0 .27-9 .78), p=0.59
0.88 (0 .4 8 - 1.61), p=0.68 
♦ ♦♦
0.92 (0 .5 0 - 1.70), p=0.80
Hospital C linic is an EPHN centre -  som e data contribute to EPHN 2001 & EPHN 2005 . A ll odds ratios are adjusted for potential risk factors except where indicated with * when  
unadjusted; ** only 2 co-infected  w om en breastfed & both had HCV infected children; *** only 3 co-infected  w om en breastfed & all had uninfected children
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Table 5.2 Paediatric HCV infection status definitions
EPHN 2001 Hospital Clinic EPHN 2005
HCV infected Antibody positive 
>18 mths and/or 
>2 positive HCV- 
RNA PCR tests
Antibody positive 
>18 mths and/or 
>2 positive HCV- 
RNA PCR tests in the 
first 3-6 mths
Antibody positive 
>18 mths and/or 
>2 positive HCV- 
RNA PCR tests
HCV uninfected Antibody negative 
>18 mths and/or 
>2 negative HCV- 
RNA PCR tests and 
<2 positive PCR tests 
If <18 mths old: >1 
negative PCR and 
antibody negative at 
last test
Antibody negative 
> 18 mths and/or 
>2 negative HCV- 
RNA PCR tests and 
<2 positive PCR tests
Antibody negative 
> 18 mths and/or 
>2 negative HCV- 
RNA PCR tests and 
<2 positive PCR 
tests, or
No positive PCR 
results and antibody 
negative between 9 
and 18 mths
5.3.1 Meta-analysis
The odds ratio estimates in Table 5.1 were not directly comparable between studies due 
to differences in coding of mode of delivery or allowing for different co-variables in 
multivariable analyses. Adjusted odds ratios allowing for the same variables were 
therefore calculated for each study for inclusion in meta-analyses. There were thus two 
separate meta-analyses for each risk factor (one using estimates from Table 5.1 and the 
other using adjusted estimates) and the results are presented in Table 5.3.
Some mother-child pairs were included in more than one study so adjusted odds ratios 
were also calculated excluding the duplicate records and these study-specific odds ratios 
combined in a meta-analysis for each risk factor (not shown); in each case the pooled 
estimate and Q statistic were similar to the results obtained when using the adjusted 
study-specific odds ratios presented in Table 5.3.
106
There was no evidence o f significant heterogeneity of the estimates for maternal 
HCV/HIV co-infection, mode of delivery and breastfeeding, regardless of which study- 
specific odds ratio estimates were used (Table 5.3); all of the p values associated with 
the test for heterogeneity (Q) were greater than 0.10 so there was no evidence to reject 
the null hypothesis that the risk factor effects are the same in all studies. The test for 
heterogeneity has low power so 0.10 is often used as a cut-off for significance rather 
than the conventional 0.05 (www.cochrane.dk 2006).
There was little variation in the pooled estimates when the different study-specific 
estimates were used. The study-specific adjusted odds ratios (each adjusting for the 
same variables and including the duplicate records) and their respective pooled random 
effects estimates are presented in Figure 5.1.
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Table 5.3 Results of meta-analyses of the three studies
Risk factor for 
HCV vertical 
transmission
Study-specific odds ratios 
(ORs) used
Pooled estimate
(Random effects estimate*) 
OR (95% Cl), p
Test for 
heterogeneity
Q,p
2 degrees o f  freedom  (df) 
unless otherw ise specified
Maternal HIV 
co-infection
as in Table 5.1 2 .30 (1 .68-3 .15), p<0.001 1.737, 0.42
(reference =
HIV uninfected)
adjusted ORs
(adjusted for m ode o f  delivery,
breastfeeding, prematurity)
2.53 (1 .73-3 .72), p<0.001 2.161,0.34
Mode o f delivery as in Table 5.1 1.02 (0 .6 3 - 1.65), p=0.93 3.960, 0.14
(elective CS vs. 
vaginal/em ergency  
CS, except when  
using estim ates from 
Table 5 .1)
adjusted ORs 
(adjusted for maternal HIV, 
breastfeeding, prematurity)
1.26 (0 .8 8 - 1.80), p=0.21 1.415, 0.49
Breastfeeding as in Table 5.1 1.25 (0 .70-2 .21), p=0.45 3.391,0.18
(breastfed vs. not 
breastfed) adjusted ORs
(adjusted for maternal HIV,
m ode o f  delivery, prematurity)
1.05 (0 .5 7 - 1.91), p=0.89 3.661,0.16
* Fixed effects estim ates were either identical to the random effects estim ates or sim ilar but with wider 95%  confidence intervals
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Figure 5.1 Forest plots to show study-specific and pooled odds ratio estimates 
w ith 95% confidence intervals for the association between risk of 
mother-to-child transmission of HCV and a) m aternal HCV/HIV co- 
infection, b) elective caesarean section delivery, and c) breastfeeding.
a) maternal HCV/HIV co-infection
EPHN 2001
Hosp Clinic
EPHN 2005
Combined
m
t r
1.5 2 3 4
Odds ratio
b) elective caesarean section delivery
c) breastfeeding
EPHN 2001
Hosp Clinic
EPHN 2005
Combined
Odds ratio
EPHN 2001 
Hosp Clinic 
EPHN 2005
m
The results of six other published studies (Mast et al. 2005;Resti et al. 2002a;Gibb et al. 
2000a;Resti et al. 1998;Zanetti et al. 1998;Tovo et al. 1997), which each included at 
least 200 mother-child pairs, were examined for possible inclusion in the meta-analysis. 
Adjusted odds ratio estimates were only available for two studies (Resti et al. 
2002a;Gibb et al. 2000a). In one of these (Resti et al. 2002a), mode of delivery was 
categorised as caesarean section versus vaginal without distinction between elective and 
emergency caesarean and odds ratios were adjusted for maternal IDU (current or past). 
The adjusted odds ratios in the other study (Gibb et al. 2000a) were based on estimated 
transmission rates as definitive diagnosis or exclusion of HCV infection was not 
possible for most of the children. The methods used to obtain any of these estimates 
were therefore not comparable with our three studies and could not be included in the 
meta-analysis.
5.3.2 Pooled analysis
The results in Table 5.3 indicated that it was appropriate to pool the data from the three 
studies to perform an individual-level data meta-analysis. A total of 209 records from 
the Hospital Clinic dataset were also in the EPHN 2001 study and a further one record 
was also in the EPHN 2005 dataset. There was one record included in both EPHN 2001 
and EPHN 2005. Excluding the duplicates before pooling the datasets gave a total of 
3526 mother-child pairs; 1632 from EPHN 2001, 136 from Hospital Clinic and 1758 
from EPHN 2005. This pooled dataset was used for all subsequent analyses.
Each study included some children for whom HCV infection status was not yet 
confirmed and could therefore not be included in analyses to estimate the effect of 
factors on risk of vertical transmission. To assess the potential for selection bias, this 
group of children with indeterminate infection status were compared to children who
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were confirmed as either infected or uninfected. The children with indeterminate HCV 
infection status (n=488) were not significantly different from those with confirmed 
infection status (n=3038) with respect to maternal and infant factors, except that their 
mothers were less likely to be HCV/HIV co-infected (10% vs. 26%, x2=50.01, 
p<0.001). This reflects that children bom to HIV infected women tend to be followed 
up more frequently because they are HIV exposed and are therefore more likely to be 
tested for HCV and have their infection status confirmed earlier. It may also reflect that 
the children with indeterminate infection were bom significantly more recently than 
those with confirmed status (z=6.70, p<0.0001) and maternal HIV co-infection has 
become less common.
Table 5.4 shows the characteristics o f the women and children in the pooled dataset by 
time period. The risk of HCV vertical transmission decreased significantly from 12.9% 
before 1994 to 3.1% since 2002. The proportion of HCV/HIV co-infected mothers and 
the proportion of mothers with a history o f IDU also significantly decreased over time. 
There was a significant increase in the proportion of women delivering by elective CS, 
the proportion of women breastfeeding and maternal age at delivery over time. The risk 
of prematurity did not change substantially over time although there tended to be less 
babies of low birth weight in recent years. The proportion of HIV infected infants bom 
to HCV/HIV co-infected women significantly decreased over time reflecting the 
introduction of, and improvements in, antiretroviral therapy for prevention of mother-to- 
child transmission of HIV.
Infant gender was not available for EPHN 2001 and receipt of neonatal ART was only 
available for EPHN 2005; these variables were therefore not included in Table 5.4. 
There were no time trends in gender (% for linear trend=0.048, p=0.83). For both
111
periods 1998-2001 and 2002-2004, where data on neonatal ART were available, all but 
4 infants (3%) and one infant (3%) bom to co-infected women respectively, received 
neonatal ART.
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Table 5.4 Characteristics of women and children (with confirmed HCV
infection status) by time period
births before 
1994
1994-1997 1998-2001 2002-2004 X2 linear 
trend*, p
No. of mother-child 
pairs with confirmed 489 1017 1207 325
HCV infection status 
Risk of vertical 12.9% (63/489) 7.8% (79/1017) 6.9% (83/1207) 3.1% (10/325) 25.50,
transmission (10.0%- 16.2%) (6.2% - 9.6%) (5.5% - 8.5%) (1.5%-5.6%) p<0.0001
(95% Cl)
Maternal HCV/HIV co- 260 (55%) 265 (27%) 190(17%) 34(11%) 253.70,
infection (n, %) 
missing 18(4%) 36 (4%) 66 (5%) 23 (7%)
p<0.0001
Maternal history of 350 (76%) 494 (52%) 396 (40%) 81 (35%) 162.88,
IDU (n, %) 
missing 27 (6%) 62 (6%) 224(19%) 94 (29%)
p<0.0001
Maternal age at 
delivery (yrs) 28(19-43) 30(17-45) 32 (17-45) 33 (20-44)
non-
parametric
median (range) 
missing 216(44%) 154(15%) 223 (18%) 54(17%)
test for 
trend
Mode of delivery: 
Elective CS 47(11%) 150(16%) 377 (33%) 114(36%)
z=l 1.10,
p<0.001
132.27,
missing 43 (9%) 106(10%) 67 (6%) 8 (2%) p<0.0001
Prematurity 71 (16%) 116(14%) 181 (16%) 43(13%) 0.004,
(<37 weeks) 
missing 34 (7%) 190(19%) 96 (8%) 2 (1%)
p=0.95
Low birth weight 58 (22%) 127(16%) 181 (17%) 46(14%) 3.99,
(<2500g)
missing 224 (46%) 237 (23%) 120(10%) 2 (1%)
p=0.05
Breastfed 119(26%) 232 (23%) 349 (31%) 108 (34%) 15.86,
missing 27 (6%) 25 (2%) 89 (7%) 8 (2%) P<0.0001
Child HIV infection 33(12.9%) 25 (9.7%) 10(6.7%) 0 6.74,
among those with co- 
infected mothers 
indeterminate/missing 4(1%) 8 (1%) 41 (3%) 9 (3%)
p=0.009
* unless specified otherw ise
Note: the m issing categories are not included in significance tests for trend
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It is important to consider the potential impact of missing data on observed associations. 
For the key variables (maternal HCV/HIV co-infection, mode of delivery, breastfeeding 
and prematurity) the proportion of missing data was no more than 10% in each time 
period, except for prematurity in 1994-1997 (Table 5.4). Missing data were not 
associated with infection status for any of the variables in Table 5.4, except low birth 
weight where 24% of infected children had missing birth weight compared to 19% of 
uninfected children (^=4.21, p=0.04) and breastfeeding where 9% of infected children 
had missing data compared to 5% of uninfected children (x2=8.88, p=0.03).
Results of the pooled logistic regression analyses are shown in Table 5.5. In the main 
analysis (Table 5.5a), maternal HCV/HIV co-infection was associated with a 2- to 4- 
fold increase in risk of HCV vertical transmission, adjusting for mode o f delivery, 
breastfeeding and prematurity. Neither elective CS nor breastfeeding were significantly 
associated with transmission. Prematurity was associated with a reduced risk o f vertical 
transmission; this association is explored in more depth below (page 117). Gender o f the 
infant was only available for the records from the Hospital Clinic study and EPHN 
2005; in a separate multivariable model including 1304 mother-child pairs with 
information available for all variables, girls were significantly more likely to be infected 
than boys (Table 5.5b). Maternal history of IDU was included in another model with a 
total of 2220 mother-child pairs (Table 5.5c); although significantly associated with risk 
of vertical transmission in univariable analysis, this association was shown to be 
confounded by maternal HCV/HIV co-infection (adjusting for only maternal HIV status 
reduced the odds ratio from 1.51 (95% Cl 1.10 -  2.07) to 0.89 (95% 0.60 -  1.32)) and 
there was no significant association in the full multivariable model. Current IDU may be 
more relevant for risk o f vertical transmission than past IDU. The risk of transmission 
among women who were active IDU in pregnancy was therefore compared to those who
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were not active users in pregnancy. In an analysis including 2154 mother-child pairs 
with information available on all variables (441 active users and 1713 past/never users), 
there was no significant association univariably (OR=1.16, 95% Cl 0.80 -  1.69, p=0.43) 
or when adjusting for maternal HIV co-infection, mode of delivery, breastfeeding and 
prematurity (OR=0.89, 95% Cl 0.60 -  1.33, p=0.57).
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Table §.§ Maternal and infant factors and risk of mother-to-child transmission of HCV: pooled analysis
n Unadjusted odds ratio 
95% Cl, p
Unadjusted odds ratio 
95% Cl, p
Adjusted odds ratio 
95% Cl, p
a)
Maternal HIV co-infection 
Elective caesarean section 
Breastfeeding 
Prematurity
2895
2814
2889
2716
2.33 (1 .76-3 .08), p<0.001 
1.08 (0 .7 9 - 1.48), p=0.63 
0.79 (0 .57-1 .10), p=0.16 
0.65 (0.41 -  1.03). p=0.07
n=2441*
2.63 (1 .93-3 .57), p<0.001 
1 .18 (0 .84 - 1.65), p=0.34 
0.67 (0 .46 -0 .98), p=0.04 
0.65 (0 .40-1 .06), p=0.08
adjusted for all other variables in 
m odel a)
2 .80(1 .99-3 .95), p<0.001 
1.11 (0 .7 9 - 1.57), p=0.53 
1.01 (0 .66 -1 .53), p=0.97 
0.52 (0.31 -  0.85), p=0.01
b)
Female gender 1556 1.76(1 .16-2 .66), p=0.008
n=1304*
1 .74(1 .08-2 .80), p=0.02
adjusted for maternal HIV, m ode o f  
delivery, breastfeeding, prematurity
1.69(1 .05-2 .73), p=0.03
c)
Maternal history of IDU 2631 1 .38 (1 .03 - 1.84), p=0.03
n=2220*
1.51 (1 .1 0 - 2.07), p=0.01
adjusted for maternal HIV, m ode o f  
delivery, breastfeeding, prematurity
0.91 (0 .6 0 - 1.36), p=0.63
* information available for all variables in the multivariable m odel
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There were significant interactions between maternal HIV co-infection status and mode 
of delivery (LRT x2=9.41, p=0.002), and maternal HIV co-infection status and 
breastfeeding (LRT j?=5.06, p=0.02) but not between maternal HIV co-infection and 
prematurity (LRT % =0.20, p=0.66). To elucidate these associations, the analysis was 
stratified by maternal HIV co-infection (Table 5.6).
Prematurity: stratified analysis
A significant association between prematurity and risk of vertical transmission was only 
observed among the HCV/HIV co-infected women (Table 5.6). Some elective CS 
deliveries were carried out before 37 weeks gestation and are therefore categorised as 
premature deliveries. However, as elective ‘premature’ deliveries are of a different 
nature to spontaneous premature deliveries, the analysis was repeated excluding 
children who were bom by elective CS (Table 5.6). The association between 
prematurity and vertical transmission was no longer significant when elective CS 
deliveries were excluded (Table 5.6); the association of borderline significance 
observed for the co-infected women may be explained by the use o f HA ART which has 
been linked to prematurity and is associated with a reduced risk o f HCV vertical 
transmission (Chapter 4, page 94).
117
Table 5.6 Maternal and infant factors and risk of mother-to-child
transmission of HCV: pooled analysis stratified by maternal HIV
infection status
HCV/HIV co-infected mothers 
n=676
HCV infected only mothers 
n=1765
Adjusted odds ratio 
(95% Cl)
P Adjusted odds ratio 
(95% Cl)
P
Prematurity 0.48 (0.25 -  0.92) 0.03 0 .5 8 (0 .2 6 - 1.27) 0.17
Elective CS 0.63 (0 .3 7 - 1.09) 0.10 1.79(1.15 -2 .7 7 ) 0.009
Breastfeeding 4.32 (1 .1 8 - 15.85) 0.03 0.89 (0 .5 8 - 1.39) 0.62
Excluding elective CS deliveries
Prematurity
n=471
0.54 (0 .2 6 - 1.10) 0.09
n=1342
0.83 (0 .3 5 - 1.97) 0.67
Breastfeeding 5.05 (1.31 -  19.50) 0.02 0.77 (0 .4 4 - 1.34) 0.35
Elective CS delivery: stratified analysis
The direction of the association between elective CS and risk of vertical transmission 
changed depending on maternal HIV status; elective CS was associated with a 
significantly increased risk of transmission among women with only HCV infection 
(Table 5.6). Further investigation o f this finding, which is not biologically plausible, 
revealed that a significant association was only observed for the EPHN 2001 study and 
not for the Hospital Clinic or EPHN 2005 studies. Of the 14 infected children bom by 
elective CS to women with only HCV infection in the EPHN 2001 study, 9 (64%) were 
from the same centre, strongly suggesting that the observed association between elective 
CS and vertical transmission is likely to be due to bias rather than a true biological 
effect. For example, it may be the result of clinical practice in this particular centre. It is 
possible that these women were offered an elective CS because they had clinical
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symptoms of their HCV infection and/or had high HCV viral load. High maternal HCV 
viral load could explain a higher risk of in utero vertical transmission.
Risk of transmission by mode of delivery category among the EPHN 2001 HCV 
infected only women was 27/535 (5.1%) for spontaneous vaginal deliveries, 5/27 
(18.5%) for instrumented vaginal deliveries, 7/104 (6.7%) for vaginal deliveries not 
specified as either spontaneous or instrumented, 0/44 (0%) for emergency CS, 14/113 
(12.4%) for elective CS, 1/61 (1.6%) for CS deliveries which were not specified as 
elective or emergency and 6/32 (18.8%) where mode of delivery was not reported. It is 
possible that for some women caesarean section was misclassified as elective when it 
was an emergency procedure and that some of the women for whom mode of delivery 
was not reported delivered by emergency CS.
Breastfeeding: stratified analysis
Although breastfeeding was associated with a 4-fold increased risk of transmission 
among the HCV/HIV co-infected women, the impact of this is low as only 11 co- 
infected women (2%) breastfed. There was no evidence of a breastfeeding effect among 
the women with only HCV infection (Table 5.6).
Risk factor estimates over time
The risk o f vertical transmission has decreased and the prevalence of some 
characteristics has changed significantly over time (Table 5.4) but has the effect of these 
factors on the risk of vertical transmission also changed over time? Adjusted odds ratio 
estimates for maternal HIV co-infection, elective CS, breastfeeding and prematurity are 
presented for each time period (Table 5.7). To assess whether the effects o f the risk 
factors were dependent on time period, interaction terms were fitted in the multivariable
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models between time and each factor. Two time periods (births before 1998 and 1998- 
2004) rather than four were used due to the lack of infected children in the co-infected 
group for 2002-2004. Overall there was no evidence of significant interaction with time 
for either maternal HIV co-infection (LRT x2=0.89, p=0.35), mode of delivery (LRT 
%2=0.19, p=0.66), breastfeeding (LRT x2=0.15, p=0.70) or prematurity (LRT x^O.75, 
p=0.39), indicating that the effect of these risk factors on mother-to-child transmission 
had not changed substantially over time. However, the effect of mode of delivery, 
breastfeeding and prematurity for each time period were also examined separately for 
HCV/HIV co-infected women and for women with only HCV infection (Table 5.7). For 
the HCV/HIV co-infected women, the effect of prematurity on risk of transmission did 
change significantly over time, based on the two time periods used above (births before 
1998 and 1998-2004) (LRT ^=4.29, p=0.04); prematurity was significantly associated 
with a reduced risk of transmission only in the period 1998-2001 which coincides with 
the introduction of HAART. There was no change in the effect o f prematurity over time 
in the women with only HCV infection (LRT x2=113, p=0.29).
A significant association between elective CS and increased risk of transmission was 
only observed among the women with only HCV infection for the period 1994-1997. 
The effect of mode of delivery was not significantly modified by time for either the 
HCV/HIV co-infected (LRT x2=2.24, p=0.13) or the HCV-only infected group (LRT 
X2=1.50, p=0.22). Similarly, the effect of breastfeeding did not change over time in the 
women with only HCV infection (LRT x^O.00, p=0.97) and this could not be assessed 
for the HCV/HIV co-infected women due to the lack of infected children bom to 
(breastfeeding) co-infected women in the latter time period.
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Table 5.7 Maternal and infant factors and risk of mother-to-child transmission of HCV by time period
Risk factor for vertical 
transmission births before 1994
n=412
Adjusted odds ratios (95% Cl), p value 
1994-1997 1998-2001
n=756 n=989
2002-2004
n=254*
All women
Maternal HIV co-infection 5 .6 5 (1 .8 0 - 17.75), p=0.003 1.99(1 .13-3 .53), p=0.02 1.97(1.01 -3 .8 4 ), p=0.05 _ *
Elective CS 1.14(0 .41-3 .18), p=0.80 1.37(0 .74-2 .54), p=0.32 1.48 (0 .85-2 .59), p=0.17 1.64 (0 .35-7 .59), p=0.53
Breastfeeding 1.66 (0 .46-5 .98), p=0.44 1.25 (0.61 -2 .5 6 ), p=0.53 0.93 (0 .4 9 - 1.76), p=0.82 0.65 (0 .12 -3 .53), p=0.61
Prematurity 0.53 (0.21 -  1.33), p=0.18 0.71 (0 .31 -1 .62), p=0.42 0.37 (0 .1 4 - 0.97), p=0.04 1.25 (0 .1 4 - 11.33), p=0.84
HCV/HIV co-infected women 
Elective CS 0.50 (0.11 -2 .3 5 ), p=0.38 0.75 (0 .27-2 .11), p=0.59 0.97 (0 .32-3 .00), p=0.96 _ *
Breastfeeding 3.09 (0 .26-37 .01), p=0.37 23.22 (2 .30-234.47), _** _ *
Prematurity 0.60 (0 .2 3 - 1.52), p=0.28
p=0.008
0.93 (0.31 -2 .7 3 ), p=0.89 0 .10(0 .01-0 .81), p=0.03 _ *
HCV infected only women 
Elective CS 4.28 (0 .92-19 .95), p=0.06 2.53 (1 .16-5 .53), p=0.02 1.59 (0 .85-2 .99), p=0.15 1.64 (0 .35-7 .59), p=0.53
Breastfeeding 1.13 (0 .26-5 .03), p=0.87 0.81 (0 .3 7 - 1.79), p=0.60 0.98 (0.51 -  1.87), p=0.95 0.65 (0 .12-3 .53), p=0.61
Prematurity _*** 0 .3 8 (0 .0 9 - 1.64), p=0.20 0.73 (0 .25-2 .09), p=0.56 1.25 (0 .1 4 - 11.33), p=0.84
* no infected children bom  to co-infected  w om en in this period; ** only 3 co-infected  w om en breastfed in this period and none o f  their children w ere infected
*** no infected children in the premature group in this period
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5.4 Key points
• There was no evidence of heterogeneity of the risk factor estimates from meta­
analysis of the three transmission studies; it was therefore appropriate to pool the 
data from these studies, but a further six published studies could not be added.
• The risk of HCV vertical transmission decreased significantly over time.
• The characteristics of the HCV infected women changed significantly over time; 
the proportion of HCV/HIV co-infected mothers and the proportion of mothers 
with a history of IDU decreased and the proportion of women delivering by 
elective CS, the proportion of women breastfeeding and maternal age at delivery 
increased.
• In multivariable analysis of the pooled dataset, maternal HCV/HIV co-infection 
was associated with a 2- to 4-fold increase in risk of HCV vertical transmission. 
Neither elective CS nor breastfeeding were significantly associated with 
transmission.
• Risk factor estimates varied by maternal HCV/HIV co-infection status.
• There was no evidence that the effect of maternal HCV/HIV co-infection, mode of 
delivery or breastfeeding on the risk of vertical transmission changed over time.
• The effect of prematurity among HCV/HIV co-infected women did change over 
time and is likely to reflect the increased use o f HAART since 1998.
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Chapter 6 Markers of infection and progression of disease in vertically
acquired HCV infection
6.1 Introduction
Prospective data for a large number of vertically infected children are needed to 
describe the natural history of vertically acquired HCV infection. Using data for 
vertically infected children enrolled in the EPHN, patterns of HCV-RNA viraemia and 
alanine aminotransferase (ALT) over time are described and their prognostic value for 
disease progression is investigated.
6.2 Methods specific to this analysis
All HCV infected children enrolled in the EPHN were included in this analysis, both 
those bom since the start o f the prospective study and children bom earlier who have 
been followed prospectively but enrolled in the EPHN some time after birth. To reflect 
the different starting points in the study, children were categorised into two groups; 
group 1 with information available from around the time of birth and group 2 reported 
to the study at or after 6 months of age. Results are presented separately for each group 
where appropriate and the group variable was included in multivariable analyses.
At each visit any clinical signs or symptoms were recorded on the relevant study form 
(see Methods, page 73). Hepatomegaly was identified by palpation during clinical 
examination. A diagnosis of hepatomegaly relied on clinical judgement as ultrasound 
could not be carried out at every visit. Although hepatomegaly is a non-specific sign it 
was the most appropriate sign or symptom to use as an indicator of liver inflammation 
given the lack of specific HCV-related clinical manifestations in these children.
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In the absence o f reliable age-related reference ranges for ALT in children, the most 
appropriate definition of abnormal ALT was discussed with EPHN clinicians and the 
cut-off values used in each clinical centre were taken into account. ALT values over 80 
IU/1 were considered abnormal for children aged less than 12 months and values over 40 
IU/1 considered abnormal after that age (Behrman et al. 2004).
To indicate whether children were persistently viraemic or had persistently abnormal 
ALT and to account for variation in the frequency of tests, summary variables were 
created for each child for the proportion of PCR tests which were positive and the 
proportion of ALT results over 40 IU/1. Clearance of viraemia from plasma was defined 
on the basis of being PCR negative at the last two tests, with normal ALT levels (<40 
IU/1) and without clinical signs at these times. This is a conservative definition of 
clearance; in adults negative PCR results alone are often taken as evidence of clearance.
Children were grouped into three broad categories based on their overall viraemia and 
ALT: 1) apparent clearance o f the virus; 2) chronic asymptomatic infection, with 
intermittent viraemia, usually normal ALT levels and rarely hepatomegaly; 3) chronic, 
active infection, with persistent viraemia, frequent abnormal ALT levels and 
hepatomegaly in some cases.
Statistical analysis
Time to first report of hepatomegaly and time to clearance of viraemia were estimated 
using Kaplan-Meier survival methods. Logistic regression was used to examine the 
association of viraemia and ALT levels with hepatomegaly while accounting for other 
factors, and to investigate the association between factors in the first year of life and 
those in subsequent years. Generalised linear logistic mixed models, with a random
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effect in the intercept to account for repeated measures within each child, were used to 
examine the effect o f viraemia and ALT on occurrence of hepatomegaly at each visit 
(Rabe-Hesketh et al. 2002).
6.3 Results
By the end of April 2003, data on 266 vertically HCV infected children were available 
for analysis. All children were followed from birth to a median of 4.2 years (range 3.2 
months to 15.9 years). 119 (48%) children were bom to HCV/HIV co-infected mothers 
(maternal HIV status not available for 20) and 26 (10%) children were co-infected with 
HIV. There were 98 boys (40%) and 144 girls (60%). Most children (68%, 115) were 
bom by vaginal delivery with a quarter (24%, 41) delivered by elective caesarean 
section and 14 (8%) by emergency caesarean section. Mean birth weight was 3030g (SD 
520g, range 1030 -  4840g) and median gestational age was 39 weeks (range 30 -  43 
weeks).
6.3.1 HCV only infected children 
Clinical symptoms
Fifty three (22%) of the 240 children with HCV infection alone developed at least one 
clinical sign or symptom during follow-up. The most common was hepatomegaly, 
reported in 25 (10.4%) children at least once during follow-up. Splenomegaly was 
reported for 2 of these 25 children at the same visits, and for no others. O f 240 children 
with a total time at risk o f 771.2 child-years, an estimated 13% will have developed 
hepatomegaly by 5 years and 28% by 10 years (Figure 6.1, Table 6.1). The estimated 
median age at first report of hepatomegaly was 7.1 months.
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Other symptoms and signs reported among 36 (15%) children (8 of whom also had 
hepatomegaly) were in the following categories: growth (reduced weight gain, n=4); 
cardio-pulmonary (n=8, double inlet ventricle in one child, mild heart murmurs in 3, 
tachycardia in 3, long Q-T in 1); skin disorders (n=7, mainly dermatitis); 
haematological disorders (n=2, anaemia); other (n=17, mainly minor infections and 
allergies).
To investigate whether the prevalence of clinical signs or symptoms in the infected 
children was similar to that expected in a normal population, the prevalence of each 
type of clinical sign or symptom was compared with uninfected children in the same 
study. Only 27 (2.0%) of 1343 uninfected children had hepatomegaly, a significantly 
lower proportion than observed among the infected children (x2=45.29, p<0.0001). 
However, the proportion of uninfected children with at least one sign or symptom other 
than hepatomegaly (18%, 241) was similar to that observed for infected children (15%, 
36)(x2=1.22,p=0.27).
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Figure 6.1 Estimated proportion of children remaining hepatomegaly-free by 
age in 240 prospectively followed HCV only infected children
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Table 6.1 Data included in the Kaplan Meier plot in Figure 6.1
Age
(months)
Number of 
children at 
beginning 
of time 
period
Number of 
children at 
end of time 
period
Number of 
children 
censored 
(at last 
visit)
Number of 
children with 
hepatomegaly
Estimated 
cumulative 
proportion of 
children with 
hepatomegaly
<3 42 132 0 3 2%
>3 to 6 134 146 2 1 3%
>6 to 9 147 147 8 4 6%
>9 to 12 146 151 5 0 6%
>12 to 18 150 139 19 0 6%
>18 to 24 137 125 18 1 6%
>24 to 36 124 97 35 1 7%
>36 to 48 98 83 19 2 9%
>48 to 60 82 64 20 3 13%
>60 to 72 63 51 16 4 19%
>72 to 84 50 36 17 2 23%
>84 to 96 35 26 9 2 28%
>96 to 108 27 23 6 0 28%
>108 to 120 22 19 5 0 28%
>120 to 180 20 4 21 1 35%
Note: Each child became ‘at risk’ of hepatomegaly at the time o f their first visit; variation in age at first 
visit accounted for. Age at first report of hepatomegaly not available for one child.
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Assessment of liver damage
Although difficult to justify in children with few symptoms and not always informative, 
liver biopsies were performed on 28 of 240 children. One child had two biopsies 
performed 6 years apart with evidence of progression between biopsies from very low 
activity to inflammation grade 2 o f 4. The median age at first biopsy was 5.2 years and 
ranged from 11.4 months to 12.0 years. All children who underwent biopsy had signs of 
chronic hepatitis, though to a different extent. A wide range of histopathologic 
abnormalities were found with steatosis and portal lymphoid aggregates the most 
frequent findings. Mild to moderate fibrosis was reported in 3 children.
Reported reasons for performing a liver biopsy were elevated ALT and HCV-RNA 
positivity. The 28 children who had a liver biopsy were significantly more likely to have 
persistently elevated ALT (>40 IU/1) than children who did not have a biopsy and were 
more likely to have been treated with interferon during follow-up (initiation of treatment 
is often dependent on a biopsy result). There were no statistically significant differences 
between those who had a biopsy and those who did not with respect to persistent 
viraemia, hepatomegaly, gender or HCV genotype.
87 children had at least one ultrasound examination (of whom 16 also had a biopsy); 70 
had normal results and 17 (20%) had evidence of hepatomegaly.
Treatment
Monotherapy with standard interferon (IFN), the only treatment available until recently, 
has sustained response rates o f generally less than 50% (Jacobson et al. 2002), 
unpleasant side effects and a disruptive treatment schedule (3 injections per week). It is 
contraindicated for children less than 3 years old due to possible adverse effects on
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growth (Strader et al. 2004). For these reasons clinicians are reluctant to initiate 
treatment and only nine children o f 240 have been treated. Therapy was started at a 
median age of 5.5 years (range 2.3 years -  11.7 years) and continued for a median 
duration of 6.0 months (range 24 days -  12.2 months). Twelve months treatment is 
recommended for genotype 1 and six months for genotypes other than 1 (Jacobson et al. 
2002). Treatment resulted in sustained HCV-RNA negativity in 3 of 9 children, was 
unsuccessful in 4 and uncertain in the remaining 2 children. O f these latter two, one 
became HCV-RNA negative after treatment and remained negative for 2 years but was 
positive again 3 years after the end of treatment; no PCR results were available after 
treatment for the other child, although ALT levels normalised during treatment but 
increased when treatment stopped.
Alanine aminotransferase (ALT) levels
187 of 240 children had at least one ALT result during follow-up; the median number of 
ALT tests was 5, range 1-16. ALT levels peaked in the first 2 years of life and declined 
thereafter (Figure 6.2). 140 (75%) children had at least one ALT result over 40 IU/1 and 
82 (44%) had at least one result over 80 IU/1; 49 children (26%) had increased ALT 
levels (>40 IU/1) each time they were tested and 47 (25%) had normal ALT levels (<40 
IU/1) at each test. One third o f children (62) had increased ALT levels on more than 
75% of times tested.
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Figure 6.2 ALT values by age for 187 children with at least one ALT result
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T w o outlying results (1213 and 1246 IU/1) have been excluded to show  the detail o f  the plot more clearly,
although both results have been confirm ed as correct.
Genotype
O f the 113 (47%) children for whom HCV genotype was determined, half (56) were 
genotype 1, a quarter (27) were genotype 3 (predominantly 3a), 16% (18) were infected 
with genotype 2 and 9% (10) with genotype 4. The remaining two children had mixed 
genotypes: lb/2ac and 3a/lb, respectively.
Patterns of viraemia
The number of HCV-RNA PCR tests for each child varied from 1 to 18 with a median 
of 5; all except 16 children had at least two tests. To account for this variation in testing 
frequency, the proportion o f PCR tests which were positive was calculated as a 
summary variable (Table 6.2). 105 children (44%) were persistently positive and 17 
(7%) persistently negative. O f the 118 (49%) with both positive and negative PCRs, 35
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(15% of total) were initially PCR negative and became persistently positive at a median 
age of 3.1 months (range 26 days -  10.6 years).
Table 6.2 HCV-RNA PCR results
HCV only HCV/HIV
infected children co-infected children
n 240 26
No. of children with at least 2 PCR tests 224 (93%) 24 (92%)
range of no. of tests done 1-18 1-12
Proportion of PCR tests which were
positive
0% 17 (7%) 1 (4%)
1-25% 5 (2%) 0
26-50% 47 (20%) 3(11% )
51-75% 35(14%) 4(15% )
76-99% 31 (13%) 3(11% )
100% 105 (44%) 15(58%)
Comparing the proportion o f  children with >75%  o f  PCR tests positive in the H C V +/H IV - and 
HC V +/H IV+ groups: x 2= \ . 5 2 ,  p=0.22
Clearance of viraemia
As group 2 children were followed according to the study protocol only from a median 
o f 2.4 years, clearance is reported separately by group.
Group 1
Thirty-two (21%, 95% Cl 15 -  29%) of the 155 children in this group fitted our 
definition of clearance of viraemia. An estimated 17% would have cleared by 2 years of 
age and 24% by 3 years (Figure 6.3, Table 6.3). Among the clearers, the estimated 
median age at the first negative PCR test was 14.9 months. All except 4 children were 
first negative by 36 months. For the two children who became negative last, there were
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long intervals between the last positive and the first negative PCR tests o f 12 months 
and 22 months respectively.
Figure 6.3 Estimated proportion of children remaining viraemic over age 
among 155 HCV infected children followed from birth (group 1)
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Table 6.3 Data included in the Kaplan Meier plot in Figure 6.3
Age
(months)
Number of 
children at 
beginning of 
time period
Number of 
children 
censored (at 
last visit)
Number of 
children 
who 
cleared
Estimated 
cumulative 
proportion of 
children clearing
< 6 155 4 2 1%
>6 to 12 149 12 8 7%
>12 to 18 129 16 8 13%
>18 to 24 105 9 4 17%
>24 to 36 92 32 6 24%
>36 to 48 54 9 3 28%
>48 to 60 42 8 1 30%
>60 to 120 33 30 0 30%
>120 to 180 3 3 0 30%
132
For 26 of the 32 clearers negative antibody tests confirmed the negative PCR tests; the 
median age at first negative antibody test was 12.6 months (range 3.8 months -  3.0 
years). The remaining 6 children were antibody positive when last tested at 1.5 - 5.3 
years.
In addition, six children were PCR negative at the last two tests but could not be classed 
as ‘clearers’ because ALT results were unavailable at these visits. If we assume normal 
ALT in these children had they been tested, the maximum estimate o f clearance would 
be 25% (38/155), 95% Cl 18-32%.
Group 2
Of the 85 older children, 3 fitted our definition of clearance. Excluding one child treated 
with interferon, our estimate o f clearance among group 2 children was 2.4% (2/85), 
95% Cl 0.3 -  8.2%. This is in line with four group 1 children (2.6%) who apparently 
cleared their infection after 3 years of age.
6.3.2 HCV/HIV co-infected children
Of the 26 HCV/HIV co-infected children, 7 (27%) had hepatomegaly, of whom 6 also 
had splenomegaly (no other cases o f splenomegaly were reported), a significantly 
higher prevalence o f hepatomegaly than among the children with only HCV infection 
(X2=6.04, Fisher’s exact p=0.02). Six of the 26 children had a liver biopsy at a median 
age of 2.5 years (range 8.6 months -  14.4 years). One child had acute hepatitis, while 
the others had mild to moderate chronic hepatitis, two with fibrosis. Seven children of 
26 had an ultrasound examination which was normal in 5 and showed hepatomegaly in 
2. One co-infected child was unsuccessfully treated with interferon for HCV infection.
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ALT levels ranged from 10 to 223 IU/1 with 5 children (29% of the 17 with results 
available) having abnormal results (>40 IU/1) more than 75% of the time, similar to that 
observed for HCV only infected children (x2—0.10, p=0.75). The co-infected children 
tended to have a higher proportion of positive PCR tests than children with only HCV 
infection although not significantly so (Table 6.2). Three children were initially PCR 
negative and became positive at 2.2 months, 3.1 months and 6.4 years. Two of 9 
children in group 1 (22%, 95% Cl 3 -  60) fitted our definition of HCV clearance, very 
similar to the proportion o f clearers among children with only HCV infection (x =0.01, 
Fisher’s exact p=1.00), although none of the 17 children in group 2 cleared.
6.3.3 Association of hepatomegaly and markers of infection
We investigated whether the extent of viraemia and abnormal ALT results was 
associated with the occurrence o f hepatomegaly. All 266 children were included with 
adjustment for HIV status and group in multivariable analyses. A binary viraemia 
variable was created to split the data at the median; <75% of PCR tests positive was 
considered to be a low proportion of positive tests and >75% considered a high 
proportion. A similar binary variable was created to represent a low {<15%) and a high 
(>75%) proportion of ALT test results over 40 IU/1.
Of the 112 children with a low proportion of positive PCR tests, 7 (6.3%) had 
hepatomegaly during follow-up compared to 25 (16.2%) of the 154 children with a high 
proportion of positive PCR tests (OR=2.91, 95% Cl 1.21 -  6.99, p=0.02). Among the 
137 children with a low proportion of abnormal ALT results, 12 (8.8%) had 
hepatomegaly compared to 19 (28.4%) of the 67 children with a high proportion of 
abnormal ALT results (OR=4.12, 95% Cl 1.86 -  9.14, p<0.001).
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ALT category and HIV status were the only variables significantly associated with 
hepatomegaly in multivariable analysis (Table 6.4). Children with a high proportion of 
abnormal ALT tests were about 4 times more likely to have hepatomegaly than those 
with a low proportion of abnormal tests (Table 6.4). Although hepatomegaly was 
significantly associated with a high proportion of positive PCR tests in univariable 
analysis, this effect did not remain in multivariable analysis (Table 6.4). Adjusting for 
the number of PCR tests did not substantially alter the odds ratio estimates.
The above analyses were repeated excluding the HCV/HIV co-infected children and 
excluding the 10 treated children, with similar results.
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Table 6.4 Association between hepatomegaly and viraemia and ALT, allowing for potential confounders in 204* HCV only 
and HCV/HIV co-infected children
unadjusted OR (95% Cl) P adjusted ORt (95% Cl) P
Viraemia (>75% vs. <75%) 3 .04(1 .19-7 .79) 0.02 1.81 (0 .60-5 .50) 0.29
ALT over 40 IU/1 (>75% vs. <75%) 4 .12 (1 .86 -9 .14 ) <0.001 4 .17(1 .67-10 .42) 0.002
Group (group 2 vs. group 1) 1.51 (0 .70-3 .28) 0.30 0.61 (0 .2 5 - 1.53) 0.29
Clearance (non-clearers vs. clearers) 7.34 (0.97 -  55.73) 0.05 2.78 (0.28 -  27.82) 0.38
HIV status (infected vs. uninfected) 4.75 (1 .6 5 - 13.68) 0.004 7.18(2 .15-23 .99) 0.001
* with information available on all variables in the analysis
+ multivariable m odel included viraem ia category, A LT category, group, clearance and HIV
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To investigate the temporal relationship between high ALT levels, viraemia and 
hepatomegaly, the association o f viraemia and ALT with occurrence of hepatomegaly 
at each visit was examined for the 240 children with only HCV infection, allowing for 
repeated measures within each child. The model including both viraemia and ALT 
showed significant variation among the children’s linear predictors and strong within- 
child correlation (intraclass correlation coefficient = 0.81, 95% Cl 0.64 -  0.91, LRT 
^=71.75, p<0.001), suggesting that clinical and biological evidence o f active infection 
tend to occur at the same time. The odds ratio for the effect of positive PCR on 
hepatomegaly, adjusted for ALT, was 10.94 (95% Cl 0.55 -  218.64, p=0.12), the non­
significant result probably reflecting lack of statistical power. ALT was not associated 
with hepatomegaly in this model; the odds ratio for each unit increase in ALT was 
0.996 (95% Cl 0.98 -  1.01, p=0.56). Adjusting for age did not alter the odds ratio 
estimates.
In summary, these findings suggest that around 20% of children may clear their 
infection, 50% will develop chronic asymptomatic infection, with intermittent 
viraemia, usually normal ALT levels and rarely hepatomegaly and about 30% chronic, 
active infection, with persistent viraemia, frequent abnormal ALT levels and in some 
cases hepatomegaly.
6.3.4 Can markers of infection in the first year of life predict viraemia at later 
ages?
Among children with only HCV infection, those with a low proportion of positive PCR 
tests in the first year were significantly more likely to clear the virus than children with 
a high proportion of positive tests in year one (36.5% (27) vs. 5.6% (4); OR=9.77, 95% 
Cl 2.92 -  32.67, p<0.0001). Similarly, 24 (28.9%) of the 83 children with a low
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proportion of abnormal ALT results in the first year cleared the virus compared to only 
one (12.5%) o f 8 children with a high proportion o f abnormal ALT results in the first 
year, although not statistically significant due to the small numbers involved 
(OR=2.85, 95% Cl 0.32 -  24.99, p=0.32).
In multivariable analyses including HCV-only and HCV/HIV co-infected children, 
those with a high proportion o f positive PCR tests in the first year of life were 
significantly more likely to have a high proportion of positive PCR tests in years 2 and 
3 (adjusted OR=3.59, 95% Cl 1.31 -  9.83, p=0.01) and in the longer term (years 2 and 
onwards) (adjusted OR=2.92, 95% Cl 1.09 -  7.80, p=0.03), compared to children with 
a low proportion of positive PCR tests in year one, when adjusting for HIV status and 
the proportion o f abnormal ALT tests in the first year.
6.3.5 Does timing of vertical transmission influence progression of infection?
48 o f 240 children had a PCR test result within the first 3 days of life. 15 (31.3%) were 
positive, suggesting that they were infected during the intrauterine period, while 33 
(68.7%) were negative indicating that intrapartum transmission was most likely. 
Timing o f transmission was not associated with clearance: 4 o f 15 (26.7%) children 
who were positive in the first three days o f life cleared the virus compared to 7 o f 33 
(21.2%) children who were PCR negative in the first 3 days (x2=0.17, p=0.68). 
However, children who were positive in the first 3 days were more likely to have a 
high proportion of positive PCR tests throughout follow-up (10/15, 66.7%) than those 
who were negative in the first 3 days (12/33, 36.4%, x2=3.81, p=0.05). Similarly, 
children who tested positive early (<3 days) were more likely to have a high proportion 
of very high ALT results (>80 IU/1) during follow-up than those who tested negative
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(3/13, 23.1% vs. 0/28, ^=6.91, p=0.008). HCV genotype was also associated with 
timing of transmission: 7 (58%) of 12 children infected with genotype 1 were PCR 
positive in the first three days compared to only 2 (12%) of 17 children with genotypes 
2, 3 or 4 (x2=7.13, Fishers exact p=0.01). Only one of the 48 children with an early 
PCR result had hepatomegaly and he/she was PCR negative.
6.3.6 Genotype by hepatomegaly, viraemia and ALT
There was no association between genotype and hepatomegaly, the proportion of 
positive PCR tests, clearance of the virus or the proportion of abnormal ALT.
6.3.7 Is gender associated with progression of infection?
There was no evidence that viraemia and ALT varied significantly by gender. 57 
(58%) boys had a high proportion of positive PCR tests compared to 80 (56%) girls 
(X^O.16, p=0.69). Among the group 1 children with only HCV infection, 16 of 62 
(26%) boys cleared the virus compared to 16 of 92 (17%) girls ( /2=1.59, p=0.21). 23 
(33%) boys had a high proportion of abnormal ALT results compared to 32 (29%) girls 
(X^O.29, p=0.59). However, among children with only HCV infection, a significantly 
higher proportion of girls (19/129, 15%) had hepatomegaly than boys (4/90, 4%) 
(X2=5.97, p=0.02). Among the co-infected children, boys were more likely to have 
hepatomegaly than girls (3/8, 38% vs. 1/15, 7%, x2=3.45, p=0.06).
6.3.8 Infected children identified since analysis
A further 38 HCV infected children have been enrolled in the EPHN since this analysis 
was done. They were similar to the children included in the main analysis. 11 (35%) 
were bom to HCV/HIV co-infected mothers (maternal HIV status not available for 7)
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and one child was co-infected with HIV. 9 (27%) were boys and 24 (73%) were girls. 
19 (53%) children were persistently PCR positive, 8 (22%) were PCR negative at each 
test and 9 (25%) had both positive and negative results (2 children had no PCR 
results). Two (8%, 95% Cl 1% - 25%) of 26 group 1 children (information available 
from birth) cleared the virus according to our definition. ALT levels ranged from 9 
IU/1 to 687 IU/1. 10 (28%) children had normal ALT at each test and 10 (28%) had 
high ALT (>40 IU/1) every time they were tested. One third of children (12) had 
abnormal ALT for more than 75% of tests. Hepatomegaly was reported for one child 
(3%, 95% Cl 0 -  14%) who was persistently PCR positive and had high ALT on 4 of 
14 tests.
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6.4 Key points
• The prevalence of clinical signs and symptoms was low; hepatomegaly was the 
most common clinical manifestation, reported in 10% (25) o f children.
• There was considerable variation in the extent of viraemia; 44% (105) o f children 
were persistently HCV-RNA positive, 7% (17) were persistently negative and 49% 
(118) had both positive and negative HCV-RNA PCR results.
• An estimated 21% (95% Cl 15 -  29%) of children had evidence o f HCV-RNA 
clearance, most by 3 years of age.
• Children with a high proportion of abnormal ALT tests were about 4 times more 
likely to have hepatomegaly than those with a low proportion of abnormal tests.
• Hepatomegaly was significantly associated with a high proportion o f positive PCR 
tests in univariable analysis, but this was no longer statistically significant in 
multivariable analysis.
• There was evidence that viraemia, high ALT and hepatomegaly tend to occur at the 
same time.
• Low viral activity in the first year of life was associated with clearance later on.
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• In summary, around 20% of vertically infected children may clear the virus, 50% 
will develop chronic asymptomatic infection with intermittent viraemia, usually 
normal ALT levels and rarely hepatomegaly, and about 30% will have chronic, 
active infection with persistent viraemia, frequent abnormal ALT and in some 
cases hepatomegaly.
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Chapter 7 Levels and patterns of im m unological param eters over age  in 
HCV infected and uninfected children
7.1 Introduction
Few data are available on immunological parameters in healthy children. Lymphocytes 
and neutrophils are included among the routine tests recorded on the EPHN study forms 
at each follow-up visit. Investigation of patterns of lymphocytes and neutrophils over 
age in uninfected children bom to HCV infected women could provide appropriate age- 
related standards which could be used assess immune function in a range o f paediatric 
diseases. Comparison of lymphocytes and neutrophils in HCV infected children with 
those in uninfected children may indicate possible differences in the immune response 
to maternal HCV infection and clarify the longer term effects of vertically acquired 
HCV infection on immune function.
7.2 Methods specific to this analysis
This analysis includes data for children enrolled in the EPHN prospective study and for 
older HCV infected children bom before 1999 (when the EPHN prospective study 
started) and followed up in EPHN centres.
Lymphocyte and neutrophil percentages were recorded on the study forms and 
converted into absolute lymphocyte (106/ml) and absolute neutrophil (106/ml) values 
using white blood cell counts from the same sample. Outlying values were checked 
against the original forms for data entry errors and white blood cell counts were 
converted to 106/ml where other units had been used.
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Statistical analysis
Absolute lymphocytes and absolute neutrophils were each plotted over age with scatter 
plots. The Lowess method was used to obtain a smooth curve of the changes in 
lymphocyte or neutrophil values over age (Cleveland and Devlin 1988). Lowess uses a 
locally weighted regression of lymphocyte or neutrophil value on age; here the running 
mean smoother option was used.
Absolute lymphocyte data for uninfected children up to 2 years of age were modelled in 
LMS (LMS 1.22, Institute of Child Health, London)(Cole and Green 1992). The LMS 
method summarises the changing age distribution of a variable by three curves 
representing the median (M), the coefficient of variation (S) and the skewness (L). The 
absolute neutrophil data for uninfected children up to 2 years of age were skewed to the 
right (i.e. there were many low values and a few high values so the peak of the 
distribution was to the left o f centre with a long tail to the right) so were logio 
transformed before modelling in LMS. Using the median (M), coefficient of variation 
(S) and skewness (L) values for each age from the LMS models, a z-score (standard 
deviation score) was calculated in Microsoft Excel for each of the absolute lymphocyte 
and absolute neutrophil values for infected and uninfected children up to 2 years of age 
with the formula, z=((Y/M)l' 1)/(L.S), where Y is the lymphocyte or neutrophil value. Z- 
scores indicate how much each absolute lymphocyte or neutrophil measurement varies 
from the mean and are adjusted for age.
Data for uninfected children in the EPHN were sparse beyond 2 years o f age because 
children are usually discharged from follow-up when absence of infection has been 
confirmed. Therefore data for uninfected children from the European Collaborative 
Study of children bom to HIV infected women (ECS) (Bunders et a l  2005b;European
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Collaborative Study 2004b;European Collaborative Study 1992) were used as a 
reference for lymphocyte and neutrophil measurements o f the EPHN HCV infected 
children up to 10 years of age. Lymphocyte and neutrophil z-scores for ECS uninfected 
children up to 2 years were compared to those for the EPHN uninfected children up to 2 
years of age to verify that the ECS were an appropriate reference group. Absolute 
lymphocyte and absolute neutrophil values for the ECS uninfected children were logio 
transformed to normalize the data. These data over age were modelled in LMS and the 
corresponding z-scores for the EPHN HCV infected children calculated using Microsoft 
Excel as described above.
For both analyses (up to 2 years and up to 10 years of age), linear regression was used 
to estimate the effect of infant and maternal factors on lymphocyte and neutrophil z- 
scores, accounting for repeated measures within child using a maximum likelihood 
random effects estimator (Leyland et al. 2001;Rabe-Hesketh et al. 2002).
To further investigate differences by HCV infection status, lymphocytes were compared 
in children who apparently cleared the virus with those who had persistent infection. As 
clearance occurs in most cases by 2 to 3 years o f age (Chapter 6, page 131), the early 
response to HCV infection was most relevant. The maximum (peak) absolute 
lymphocyte value in the first six months of life was therefore identified for each 
infected child and the median peak absolute lymphocyte value for the persistently 
infected children compared with the median peak absolute lymphocyte value for the 
children who cleared the virus, using the Wilcoxon rank sum test.
To investigate whether hepatomegaly was associated with lymphocyte levels, each 
absolute lymphocyte measurement for HCV infected children up to 10 years of age was
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defined as either coinciding with an episode of hepatomegaly (30 days either side o f the 
date hepatomegaly was reported) or not coinciding with an episode of hepatomegaly. 
The mean lymphocyte z-scores in each of these groups were compared using a t test and 
lymphocyte z-scores and absolute lymphocytes over age were plotted separately for 
each group.
7.3 Results
By July 2005, 1891 absolute lymphocyte measurements were available for 654 children 
and 1822 absolute neutrophil measurements were available for 638 children (Table 7.1).
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Table 7.1 Lymphocyte and neutrophil data for all children, all ages
All children HCV infected 
children
HCV
uninfected
children
Children with 
indeterminate 
infection status
Lymphocytes 
No. of children 654 119 468 67
Total no. of 1891 494 1300 97
measurements 
No. of measurements 2 (1 - 17 ) 3 (1 - 17) 3 ( 1 - 8 ) 1 ( 1 - 5 )
per child, median 
(range)
Age at first test, 6.3 weeks 2.1 years 5.3 weeks 7.1 weeks
median (range) (birth -  15.1 yrs) (birth -  15.1 yrs) (birth -  9.5 yrs) (birth -1.9 yrs)
Age at last test, 12.2 months 4.4 years 12.1 months 3.0 months
median (range) (birth -  17.0 yrs) (2 weeks -  17.0 yrs) (birth -  9.5 yrs) (birth -  3.1 yrs)
Neutrophils 
No. of children 638 106 469 63
Total no. of 1822 430 1302 90
measurements 
No. of measurements 2 ( 1 - 17 ) 3(1 - 17) 3 ( 1 - 8 ) 1 ( 1 - 5 )
per child, median 
(range)
Age at first test, 6.0 weeks 1.9 years 5.1 weeks 7.3 weeks
median (range) (birth -  15.1 yrs) (birth -  15.1 yrs) (birth -  9.5 yrs) (birth -  10.9
Age at last test, 12.2 months 4.0 years 12.1 months
mths) 
3.0 mths
median (range) (birth -  17.0 yrs) (2 weeks -  17.0 yrs) (birth -  9.5 yrs) (birth -  1.5 yrs)
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7.3.1 Absolute lymphocytes over age
The variation in absolute lymphocytes was greatest in the first year o f life with values 
ranging from 0.4 x l06/ml to 16.9 x l06/ml. Values and variation gradually decreased 
over age (Figure 7.1).
Figure 7.1
Absolute lymphocyte measurements over age in children born 
to HCV infected women with running mean smoother
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Figure 7.2
Absolute lymphocyte measurements over age by HCV infection 
status with running mean smoother
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7.3.2 Absolute lymphocyte z-scores and maternal and infant factors in the first 
two years of life
Beyond 2 to 3 years of age there were few measurements available for uninfected 
children (Figure 7.2) so the regression analysis was restricted to measurements up to 2 
years. 502 children with confirmed HCV infection status had at least one lymphocyte 
result in the first 2 years of life; 59 (12%)were infected and 443 uninfected, 259 (52%) 
were male (missing for 2) and 133 (28%) were bom to mothers with HCV/HIV co- 
infection (maternal HIV status missing for 19). Six children (1%) were HIV infected (of 
whom 2 were also HCV infected), 465 were HIV uninfected and 26 were of 
indeterminate HIV status (missing for a further 5). The median number of lymphocyte 
measurements per child was 3 (range 1 -  8) and the median age at first lymphocyte test 
was 5 weeks (range birth -  23 months). The infected children had a median 2 tests each 
(range 1 -  7) with the first test at a median 2.2 months (range birth -  23.2 months).
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Among the uninfected children the median number of tests was 3 (range 1 -  8) and the 
median age at first test was 5.0 weeks (birth -  22.0 months).
In both univariable and multivariable linear regression analyses, HCV infection, female 
gender and maternal HIV co-infection were significantly associated with higher 
lymphocyte z-scores (Table 7.2). For example, the adjusted coefficient for gender was 
0.293, that is, the mean z-score of the girls was 0.293 units higher than that of the boys. 
This coefficient corresponds to the 47th centile for the girls and the 40th centile for the 
boys.
Only 6 children were HIV infected and HIV infection was not associated with 
lymphocyte z-score univariably (coefficient = -0.287, 95% Cl -0.922 -  0.347, p=0.38) 
or when included in the multivariable model shown in Table 7.2 (adjusted coefficient = 
-0.434, 95% Cl -1.061 -  0.193, p=0.18). The estimates for the other variables in this 
model were not substantially altered by including child’s HIV status.
The association of lymphocyte z-score and maternal injecting drug use (IDU) during 
pregnancy, anti-retroviral (ART) prophylaxis to neonates bom to HCV/HIV co-infected 
women, prematurity and breastfeeding were also examined. Children bom to women 
who reported IDU during pregnancy had lower lymphocyte z-scores than those bom to 
women who were not current IDU although this difference was not significant in 
univariable analysis (-0.187, 95% Cl -0.451 -  0.078, p=0.17) and was only of borderline 
statistical significance when adjusted for HCV infection status, gender and maternal 
HIV infection (-0.237, 95% Cl -0.495 -  0.020, p=0.07). Including maternal IDU in the 
model shown in Table 7.2 did not substantially alter the estimates for HCV infection, 
gender or maternal HIV co-infection. In univariable analysis, receipt of ART neonatally
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was associated with higher lymphocyte z-scores (0.190, 95% Cl 0.036 -  0.343, p=0.02). 
However, the coefficient changed direction and was not significant when adjusting for 
HCV infection status, gender and maternal HIV co-infection (-0.263, 95% Cl -0.942 -  
0.416, p=0.45) because maternal HIV status and neonatal ART are collinear: nearly all 
children bom to HIV co-infected mothers (96%) received neonatal ART and none of the 
children bom to HIV uninfected women did. Maternal HIV co-infection was more 
important in the multivariable model than neonatal ART, based on improvement in 
likelihood when including maternal HIV co-infection instead of neonatal ART (log 
likelihood for model including maternal HIV co-infection = -1838.364; log likelihood 
for model including neonatal ART = -1838.930). Neither prematurity or breastfeeding 
were associated with lymphocyte z-score (adjusted coefficients were 0.047, 95% Cl - 
0.123 -  0.217, p=0.59 and -0.026, 95% Cl -0.217 -  0.164, p=0.79, respectively).
There was no evidence of interaction between HCV infection status, gender and 
maternal HIV co-infection except that HCV infection was not associated with 
lymphocyte z-score among boys (coefficient=0.021, p=0.92) although there remained a 
significant association among girls (coeffic ien ts.374, p=0.01). Figure 7.3 shows 
running smoothers separately by infection status and gender.
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Figure 7.3
Running mean smoothers for absolute lymphocytes 
up to 2 years by HCV infection status and gender
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7.3.3 Logio absolute lymphocyte z-scores and m aternal and infant factors up to 
10 years of life
The logio absolute lymphocyte z-scores of the ECS uninfected children up to 2 years 
(mean = 0.00, range -5.33 -  4.32) were similar to those for the EPHN uninfected 
children up to 2 years (mean = -0.00, range -3.56 -  4.00) (coefficient adjusted for 
gender = -0.032, 95% Cl -0.117 -  0.052, p=0.45), supporting the appropriateness of 
using the ECS uninfected children as a reference group.
106 HCV infected children were included in a regression analysis to investigate the 
effect of maternal and infant factors on lymphocyte z-scores up to 10 years of age, with 
1356 uninfected children from the ECS as the reference group for calculation of z- 
scores. Nearly two-thirds (65) were female and 36 were male (missing for 5). 42 
children (46%) were bom to HCV/HIV co-infected mothers (missing for 14) o f whom 9 
children (9%) were themselves HCV/HIV co-infected. The first lymphocyte
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measurement was at a median 18 months of age (range birth -  9.9 years) with the last 
test at a median 3.6 years (range 2 weeks -  10.0 years) and a median 3 tests per child 
(range 1 -17) .
The overall mean z-score for the HCV infected children was 0.092 compared to the 
reference group mean of zero (2 sided t test: t= - l.78, p=0.07). Girls had higher 
lymphocyte z-scores than boys although this difference was of borderline statistical 
significance and neither maternal or child HIV status were associated with lymphocyte 
z-score (Table 7.3). Adding an age group variable (with four groups of 2.5 years each) 
to the model in Table 7.3 did not substantially alter the estimates for gender, maternal or 
child HIV status, but there was some evidence of a decrease in lymphocyte z-score with 
increasing age group (adjusted coefficient = -0.097, 95% Cl -0.192 -  -0.002, p=0.05).
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Table 7.2 Infant and maternal factors and absolute lymphocyte z-scores in the first 2 years of life 
for 483 children with information available on all variables
n observations 
(N children)
Unadjusted coefficient 
(95% Cl)
P Adjusted coefficient 
(95% Cl)
P
HCV infection status
infected
uninfected
Gender
164 (52) 
1225 (431)
0.371 (0 .143-0.598) 0.001 0.267 (0 .041-0.493) 0.02
female
male
Maternal HIV co-infection
720 (234) 
669 (249)
0.318(0.178-0.457) <0.001 0.293 (0 .153-0.433) <0.001
infected
uninfected
525 (133) 
864 (350)
0 .217(0.065-0.369) 0.005 0.200 (0.051 -0 .349) 0.008
Table 7.3 Infant and maternal factors and logio absolute lymphocyte z-scores up to 10 years of age 
in 91 HCV infected children with information available on all variables
n observations 
(N children)
> Unadjusted coefficient 
(95% Cl)
P Adjusted coefficient 
(95% Cl)
P
Gender
female
male
Maternal HIV co-infection
242 (59) 
116(32)
0.280 (0 .003-0.557) 0.05 0.263 (-0 .013-0.539) 0.06
infected 
uninfected 
Child’s HIV status
212(41) 
146(50)
0.017 (-0 .249-0.284) 0.90 0.088 (-0.184-0.361) 0.53
infected
uninfected
28 (8) 
330 (83)
-0.306 (-0.761 -0 .150) 0.19 -0.303 (-0 .778-0.171) 0.21
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7.3.4 Absolute lymphocytes and clearance in HCV infected children
To further investigate differences in lymphocyte z-score by HCV infection status, 
lymphocytes in children who apparently cleared the virus were compared with those 
who had persistent infection. The median peak absolute lymphocyte value in the first 6 
months was significantly lower for the 11 clearers (6.23 x l0 6/ml) than for the 29 
persistently infected children (8.34 x l0 6/ml) (z=2.53, p=0.01). The median peak 
absolute lymphocyte value in the first 6 months for the 397 uninfected children was 
7.15 x l0 6/ml, not statistically significantly different to the median peak value for the 
clearers (z=-1.36, p=0.17). The clearers and uninfected children combined (n=408) had 
a significantly lower median peak lymphocyte value (7.14 x l0 6/ml) than the 29 
persistently infected children (8.34 x l0 6/ml) (z=-2.33, p=0.02).
7.3.5 Absolute lymphocytes and hepatomegaly in HCV infected children
The relationship between lymphocyte levels and episodes of hepatomegaly was 
investigated; hepatomegaly is one of the few clinical manifestations o f HCV infection 
observed in around 10% of children with vertically acquired HCV infection ((European 
Paediatric HCV Network et al. 2005c) Chapter 6). There was no evidence o f an 
association between hepatomegaly and lymphocytes. The mean lymphocyte z-score 
during periods of hepatomegaly was -0.113 (range -2.377 -  2.439) compared to 0.090 
(range -3.209 -  2.170) during periods without hepatomegaly, t test (2 sided) t= l .16, 
p=0.25. Examination of plots of lymphocyte z-scores and absolute lymphocytes over 
age did not reveal any differences in patterns between lymphocyte measurements which 
coincided with episodes of hepatomegaly and lymphocyte measurements which did not 
coincide with episodes of hepatomegaly.
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7.3.6 Absolute neutrophils over age
There was little variation in neutrophil values over age after the first 6 months o f life 
(Figures 7.4 and 7.5).
Figure 7.4
Absolute neutrophil measurements over age in children born 
to HCV infected women with running mean smoother
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Figure 7.5
Absolute neutrophil measurements overage by HCV infection 
status with running mean smoother
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7.3.7 Logio absolute neutrophil z-scores and maternal and infant factors up to 6 
months of age
Most of the variation in neutrophil measurements was in the first six months o f life so 
the regression analysis was restricted to this period. 435 infants with confirmed HCV 
infection status had at least one neutrophil measurement by 6 months of age. O f these, 
38 (9%) were HCV infected and 397 (91%) were uninfected, 223 (51%) were male and 
124 (29%) were bom to an HCV/HIV co-infected mother (missing for 8). Five children 
(1.2%) were HIV infected, 403 (93%) were HIV uninfected and 25 (5.8%) were of 
indeterminate HIV status (missing for 2). The median number of neutrophil 
measurements per child was 2 (range 1 -  6) with the first measurement at a median 5 
weeks of age (range birth -  5.9 months). Among the infected children the median 
number of measurements was 1.5 (range 1 -  4) with the first test at a median 4.4 weeks
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(range birth -  5.7 months) and the uninfected children had a median 2 tests each (range 
1 -  6) with the first at a median 4.7 weeks (range birth -  6.0 months).
Females had significantly higher neutrophil z-scores than males and HCV infected 
infants had lower z-scores than uninfected infants (Table 7.4). Maternal HIV co- 
infection was not significantly associated with neutrophil z-scores but infants who were 
themselves HIV infected had lower neutrophil z-scores than HIV uninfected infants, 
although this difference did not reach statistical significance (Table 7.4). There were no 
statistically significant associations between neutrophil z-score and maternal IDU 
during pregnancy, neonatal ART, prematurity or breastfeeding either univariably or 
when included in the multivariable model in Table 7.4, and the estimates for the 
variables in Table 7.4 were not substantially altered.
7.3.8 Logio absolute neutrophil z-scores and maternal and infant factors up to 10 
years of age
The logio absolute neutrophil z-scores of the ECS uninfected children up to 2 years 
(mean = -0.00, range -5.40 -  4.80) were very similar to those for the EPHN uninfected 
children up to 2 years (mean = -0.01, range -5.23 -  3.86) (coefficient adjusted for 
gender = 0.000, 95% Cl -0.077 -  0.077, p=0.99), supporting the appropriateness of 
using the ECS uninfected children as a reference group.
93 HCV infected children from the EPHN were included in a regression analysis to 
investigate factors associated with neutrophil z-scores up to 10 years of age, with 1226 
uninfected children from the ECS as a reference group. One-third were male (32, 35%) 
and 59 (65%) were female (missing for 2), half (40) were bom to HCV/HIV co-infected 
mothers (missing for 11) and 9 (10%) children were themselves HIV infected (missing
158
for 4). Children had a median three measurements each (range 1 - 1 7 )  with the first test 
at a median 14 months of age (range birth -  9.9 years) and the last at a median 3.2 years 
(range 2 weeks -  10.0 years).
The overall mean neutrophil z-score for the HCV infected children was -0.324, 
significantly lower than the mean neutrophil z-score of zero for the ECS uninfected 
reference group (2 sided t test: t=5.94, p<0.0001). Neither gender nor maternal HIV co- 
infection were associated with neutrophil z-score but HIV infected infants had 
significantly lower neutrophil z-scores than uninfected children (Table 7.5).
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Table 7.4 Infant and maternal factors and logio absolute neutrophil z-scores in the first 6 months of life 
for 401 children with information available on all variables
n observations 
(N children)
Unadjusted coefficient 
(95% Cl)
P Adjusted coefficient 
(95% Cl)
P
HCV infection status
infected
uninfected
Gender
63 (36) 
627(365)
-0.243 (-0 .538-0.051) 0.11 -0.321 (-0.621 -  -0.022) 0.04
female
male
Maternal HIV co-infection
363 (202) 
327(199)
0.193 (0 .025-0.361) 0.02 0.214(0.045-0.384) 0.01
infected 
uninfected 
Child’s HIV status
226 (98) 
464 (303)
0.036 (-0.148-0.220) 0.70 0.078 (-0.110-0.265) 0.42
infected
uninfected
10(5) 
680 (396)
-0.504 (-1 .232-0.224) 0.17 -0.508 (-1.243-0.226) 0.18
Table 7.5 Infant and maternal factors and logio absolute neutrophil z-scores up to 10 years of age 
in 81 HCV infected children with information available on all variables
n observations 
(N children)
Unadjusted coefficient 
(95% Cl)
P Adjusted coefficient 
(95% Cl)
P
Gender
female
male
Maternal HIV co-infection
203 (53) 
106 (28)
0.005 (-0.353-0.363) 0.98 -0.033 (-0.388-0.323) 0.86
infected 
uninfected 
Child’s HIV status
189 (39) 
120 (42)
0.043 (-0.292-0.379) 0.80 0.162 (-0.187-0.510) 0.36
infected
uninfected
29 (8) 
280 (73)
-0.551 (-1.088--0.013) 0.05 -0.639 (-1.206--0.072) 0.03
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7.4 Key points
• Based on measurements for HCV exposed children up to 2 years o f age, HCV 
infected children, girls and those bom to HCV/HIV co-infected women had 
significantly higher lymphocyte z-scores.
• The median peak absolute lymphocyte value in the first 6 months was 
significantly lower for infected children with evidence of clearance than for 
persistently infected children. The median peak value for the uninfected children 
was similar to that for the clearers.
• Lymphocyte z-scores were higher in girls than boys up to 10 years of age, but this 
association was of borderline statistical significance.
• HCV infected children had significantly lower neutrophil z-scores than uninfected 
children, based on measurements in the first 6 months of life.
• Neutrophil z-scores were significantly higher for girls than for boys in the first 6 
months of life, although there was no significant association with gender for 
measurements up to 10 years of age.
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Chapter 8 Care of children born to HCV infected wom en: the view s of 
parents and carers
8.1 Introduction
There has been little work to describe the characteristics of families affected by HCV in 
Europe, their views on the standard of care available and the impact o f HCV infection 
on their lives. As vertically acquired HCV infection is likely to be slowly progressive 
over decades, methods which are acceptable to affected families need to be developed to 
monitor the long-term consequences. The EPHN provided an ideal opportunity to 
undertake a survey of parents and carers of children bom to HCV infected women 
across a large number of clinical centres.
8.2 Methods specific to this analysis
Draft versions of the questionnaire were discussed with EPHN clinicians and with 
colleagues experienced in questionnaire design and shown to lay people to assess 
clarity. The final draft was piloted among five parents and carers at the EPHN centre in 
Edinburgh in March 2004. Following a few minor amendments the questionnaire was 
translated into Italian, Spanish, German, Norwegian and Swedish. The translations were 
checked against the English original by researchers fluent in both the relevant language 
and English.
When finalised, between 10 and 20 questionnaires (depending on the size of the centre) 
were sent to each participating EPHN centre. An envelope with the address o f the 
London co-ordinating centre was provided with each questionnaire and a log sheet 
supplied on which clinicians could record which parents/carers they had asked to 
participate, who had agreed, the reasons for refusal, and dates o f sending completed
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questionnaires to London (Appendices 8.1 and 8.2).SA11 questionnaires were anonymous 
with only the centre number provided.
Instructions were given to the clinician responsible for the survey at each clinic to ask 
the parent/carer of each child bom to an HCV infected woman attending the clinic for a 
routine visit to complete a questionnaire, preferably while waiting in the clinic. The 
invitation to participate was extended to all parents/carers and was independent o f the 
child’s HCV status. The purpose of the survey was explained and instructions for its 
completion provided, both verbally by the clinician and written on the questionnaire. 
Completed questionnaires were sealed in the envelope provided and handed in at the 
clinic. All questionnaires were sent to the London co-ordinating centre.
The questionnaire solicited information regarding age, sex, marital status, ethnic group, 
country of birth, relationship to the child and child’s date of birth, sex and HCV 
infection status. Section 2 was completed only if the respondent was the mother of the 
child (all of whom would be HCV infected) and included questions about her own 
health and how she was affected by her HCV infection. The next section was for 
completion by all respondents and comprised questions relating to visits to the 
paediatric clinic, including level o f satisfaction with the care provided, availability of 
information and suggestions for improvements and other services. The last section was 
completed only by parents and carers of HCV infected children and included questions 
on disclosure of the child’s infection status, provision of information and issues relating 
to the long-term consequences of vertically acquired HCV infection. There was space at 
the end of the questionnaire for additional comments for all respondents. Most questions 
had multiple choice answers with space for respondents to give details where 
appropriate.
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Statistical analysis
Completed questionnaires from each centre were numbered sequentially and entered 
onto a Microsoft Access database, x2 tests were used to compare proportions and the %2 
test for trend was used to assess trend in proportions. Where data were not normally 
distributed, the Wilcoxon rank sum test was used to compare medians and a non- 
parametric test for trend was used to assess trend in medians. Logistic regression was 
used to examine associations between the preferred method of long-term follow-up and 
respondent and child characteristics.
8.3 Results
Between June 2004 and September 2005, 333 completed questionnaires were received 
from 21 centres in Italy (14), Spain (3), Germany (1), UK (1), Sweden (1) and Norway 
(1). Nearly all respondents (327, 98%) completed the questionnaire at the clinic and the 
remaining 6 did so at home. The response rate was 96% (333/347); 4 mothers did not 
participate due to lack of time, one other parent/carer refused for unknown reasons and 
9 parents/carers agreed to take part but took the questionnaire home and did not return it 
to the clinic.
8.3.1 Characteristics of HCV affected families in Europe
The characteristics of the respondents are shown in Table 8.1. Three-quarters of 
respondents (248, 74%) were the mother of the child they had brought to the clinic and 
were white, mostly married (184) or co-habiting (64) and bom in their country of 
residence. Of the 28 male respondents, 26 were the father of the child and two were the 
adoptive father. The majority of respondents (313, 96%) were white and the 13 who 
reported other ethnic groups (6 asian, 4 black, 1 oriental, 2 South American) were bom
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outside Europe. The 29 respondents who were not bom in their country of residence had 
lived in Italy (24), Spain (4) and Norway (1) for a median 11 years (range 1 -  42 years).
Each questionnaire related to one child. The children of 99 (30%) respondents were 
HCV infected, a quarter (80) were uninfected and the HCV infection status of 154 
(46%) had still to be confirmed. The 99 parents/carers of infected children were older, 
less likely to be the mother of the child and therefore more likely to be male than the 
parents/carers of children who were uninfected or of indeterminate infection status 
(Table 8.1). Marital status, ethnic group and country of birth (Europe vs. other) were 
similar for the two groups. The older age of the parents/carers of infected children 
reflects that the infected children were a median 3.6 years old at the time of the survey 
(range 2 mths -  19 yrs), significantly older than the uninfected or indeterminate children 
who were a median 9 months old (range 2 days -  10 yrs) (z=10.81, p<0.0001).
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Table 8.1 Characteristics of the survey respondents
Characteristic All respondents 
n=333
n %
Parents/carers of 
infected children 
n=99
n %
Parents/carers of 
uninfected/ 
indeterminate 
children n=234 
n %
i t  P
Age (years)
<25 15 5 3 3 12 5 22.05, 0.001
25-29 61 18 17 17 44 19
30-34 107 32 22 22 85 37
35-39 81 25 25 26 56 24
40-44 54 16 22 22 32 14
>45 13 4 10 10 3 1
missing
Sex
female
2
305 92
0
84 85
2
221 94 8.32, 0.004
male 28 8 15 15 13 6
Relationship to child
mother 297 89 79 80 218 93 mother vs. other
father 26 8 14 14 12 5 relationship:
adoptive parent 4 1 3 3 1 0.5 12.89, <0.001
other relative 3 1 2 2 1 0.5
foster parent 3 1 1 1 2 1
Marital status
single 10 3 4 4 6 2.5 4.24, 0.37
co-habiting 79 24 23 23 56 24
married 229 69 66 67 163 71
divorced or separated 11 3 5 5 6 2.5
widowed 1 1 1 1 0 0
missing 3 3 3
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Table 8.1 continued:-
Characteristic All respondents 
n=333
n %
Parents/carers of 
infected children 
n=99
n %
Parents/carers of 
uninfected/ 
indeterminate 
children n=234 
n %
r f (d0, p
Country of birth
Italy 262 79 70 71 192 83 Europe vs. other:
Spain 33 10 18 18 15 6 0.02, 0.89
Germany 6 2 1 1 5 2
UK 3 1 1 1 2 1
Sweden 2 1 1 1 1 0.5
Other European (Switzerland, France, Portugal) 4 1 2 2 2 1
Eastern Europe, Russia 8 2 3 3 5 2
Africa (Egypt, Cote d’Ivoire, Equatorial Guinea) 5 1 1 1 4 2
Asia (Pakistan, Kyrgyzstan, Sri Lanka, Thailand) 6 2 1 1 5 2
South America 2 1 1 1 1 0.5
missing 2 0 2
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8.3.2 Characteristics of the HCV infected mothers
Of the 297 mothers, 292 completed the section about their own HCV infection. 
Women were asked how they thought they had become infected with HCV and could 
choose more than one option. 35% (101) reported not knowing how they became 
infected (Figure 8.1). Injecting drug use was reported by 17% of women (50) and a 
similar number reported either blood transfusion/blood products or sexual transmission 
as the most likely mode of acquisition. Among the 61 women who reported other 
modes of acquisition, 25 thought they had become infected through dental treatment 
(of whom 5 also reported either beauty treatment, surgery or tattooing), 7 reported 
intrafamilial transmission, 7 reported surgery, 5 occupational risk/needlestick injury, 
one tattooing, one nasal cocaine use and one reported beauty treatment as the route of 
transmission (not specified for 14). Of the 7 reporting intrafamilial transmission, 
vertical transmission was reported by three women, who were aged 35 -  45+, and a 
further two respondents (both aged 30 -  34) reported that their mother was HCV 
infected.
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Figure 8.1
Reported mode of acquisition of HCV infection
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It was likely that most mothers would have asymptomatic HCV infection so a general 
question was asked about the impact of HCV infection on their daily life rather than 
only questions relating to physical signs and symptoms. Women were asked about 
activities at home (cooking, cleaning and looking after the children were provided as 
examples) and activities outside the home (e.g. work). About half (138, 48%) of the 
289 women who answered at least one of the two questions reported that their HCV 
infection affects their daily life in some way, a little or a lot, at home and/or outside the 
home. 129 women (45%) said they were not affected at all at home or outside the 
home and 22 (7%) women were not at all affected for the one question they answered, 
either at home or outside.
Over half of the mothers (155 of 284 who answered this question, 55%) said that their 
HCV infection did not affect their daily life at all in terms of activities at home, but 99 
women (35%) said they were affected a little and 30 (10%) were affected a lot. 
Regarding activities outside the home, of 241 (83%) women who responded to this
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question 157 (65%) were not affected at all, 63 (26%) a little and 21 (9%) a lot. At 
least 16 of the 51 women who did not answer this question did not work.
There was space on the questionnaire for the women to give details about how HCV 
infection affects their day-to-day life. The major impact, reported by 61% of women 
(56 of those who provided details), was having to take precautions to avoid 
transmission of HCV to others, particularly when they had a wound and had close 
contact with their child or were preparing food. Other comments included feeling very 
tired or physically unwell or being anxious about their child and the future. However, 
11 women (12%) reported never having symptoms and living as an uninfected person 
would.
The median time since diagnosis, available for 288 (99%) women, was 6.6 years 
(range 1.6 months -  33.7 years). This was significantly associated with the extent to 
which HCV infection affected their daily activities at home; the longest duration of 
infection (median 7.6 years, range 3.5 mths -  34 yrs) was among women who were not 
affected at all and the shortest duration (median 3.6 years, range 7.4 mths -  16 yrs) was 
among women who were affected a lot (non-parametric test for trend z=-3.67, p<0.01). 
This association was not observed for the effect of HCV on activities outside the home 
(non-parametric test for trend z=-0.86, p=0.39).
Nearly a quarter of mothers reported either never seeing a doctor or nurse about their 
HCV infection (35, 12%) or less than once a year (32, 11%). 73 women (26%) 
attended the clinic for their HCV infection about once a year and 60 (21%) about twice
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a year. The remaining 30% of mothers (85) saw a health professional at least every 6 
months (question not answered for 7).
8.3.3 Satisfaction with services
Overall satisfaction
Only one respondent reported being dissatisfied with the care provided by the HCV 
clinic. 54% (174) were satisfied and 45% (147) were very satisfied with the care 
(missing for 11). The majority of the 128 respondents who gave specific comments 
found the clinic staff kind and friendly and were pleased with the expert professional 
care but 11 (9%) found the waiting time too long and 4 (3%) would like the waiting 
room to be improved. Despite the high level of overall satisfaction with the care 
provided, a fifth of respondents (56, 18%) made suggestions for changes or 
improvements to the clinic or the care provided. These mainly concerned reducing the 
waiting time (12) or improving the waiting areas by providing toys for the children and 
maintaining cleanliness (14).
A similar number (60, 20%) would like other services to be provided at or outside the 
clinic. These included support groups where affected families could share their 
experiences and offer advice to each other (13), psychological support (9), more 
information in general, especially during pregnancy or at the first visit (8), better care 
for HCV infected mothers (7), improved waiting areas and play facilities for children 
(5) and specialised centres in each district and better informed family doctors (4).
Whether respondents made suggestions for improvements to the clinic or other 
services to be provided was not associated with the age of their child.
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Practicalities of getting to clinic
The majority of respondents (197, 63%) reported that their child saw a doctor or nurse 
at the HCV clinic every 3 to 6 months. 34 children (11%) were seen more often than 
every 3 months, 59 (19%) visited the clinic about twice a year, 15 children (4%) had 
annual visits and the remaining 9 (3%) were seen less than once a year (not reported 
for 19). Children of indeterminate or unknown infection status visited the clinic more 
frequently than children with confirmed infection status (infected and uninfected) (x2, 
4 df= 14.42, p=0.006). As children with confirmed infection status tend to be older, 
frequency of visits was also associated with the age of the child; children attending the 
clinic every 3-6 months or more often were significantly younger than those who 
visited the clinic twice a year or less frequently (median 1 year, range 9 days -  19 
years vs. median 2 years, range 3 weeks -  18 years, z=5.60, pO.OOOl).
Nearly all parents and carers (300, 94%) were happy with the frequency o f visits to the 
clinic but 11 (3%) would prefer less frequent visits and 9 (3%) would prefer more 
frequent visits.
Most parents and carers did not have difficulties getting to the clinic (121, 37%) or 
found it easy (105, 32%) or very easy (44, 13%). 52 respondents (16%) found it 
difficult to get to the clinic while only 7 (2%) found it very difficult (missing for 4). 
The main reasons for difficulties were long distance to the clinic, poor public transport, 
traffic or parking problems and reliance on someone to drive them to the hospital. 
Some respondents who did not find it difficult to get to the clinic nevertheless 
mentioned problems of traffic, public transport and long distances to travel. 
Difficulties in getting to the clinic were not associated with a particular centre.
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41% of respondents (133) needed to take time off work to take their children to the 
clinic (a further 52 (16%) respondents did not work and the question was not answered 
in 5 cases) but only 21 (16%) found this difficult (19) or very difficult (2) to do. 52 
respondents (18%) reported that their child had to take time off school to attend clinic 
appointments (113, 40%, indicated that their child did not go to school, information 
missing for 51 respondents) and this was either very easy (20), easy (15) or OK (16) to 
do (missing for 1). Among the children aged 6 or older, 78% (29) had to take time off 
school for clinic visits.
Provision of information
Half of respondents (168, 50%) felt they needed more information about HCV 
infection in general. 114 (34%) would like more information about the different blood 
tests for HCV infection and 128 (38%) would like more information about how HCV 
infection is confirmed or excluded in their child. Most of the specific comments related 
to wanting more information about modes of transmission of HCV and precautions 
needed to avoid transmission to others or better information to be able to interpret their 
child’s test results.
Respondents from non-white ethnic groups were more likely to feel that they needed 
more information about HCV infection in general (10/13 (77%) non-white vs. 157/313 
(50%) white, x =3.58, Fisher’s exact p=0.09) and more information about the different 
blood tests for HCV infection (8/13 (62%) non-white vs. 105/313 (34%) white,
•y t
X =4.32, Fisher’s exact p=0.07), although these associations were of borderline 
statistical significance. However, the proportion of non-white respondents who needed
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more information about how infection is confirmed or excluded in their child was not 
significantly higher than for white respondents.
Compared to parents/carers of children with confirmed infection status (infected or 
uninfected), those with children o f unconfirmed infection status were significantly 
more likely to want more information on how the infection status o f their child is 
confirmed (81/154, 53% vs 47/179, 26%, x2=24.27, pO.OOl) and were more likely to 
feel they needed more information about the different blood tests for HCV infection 
(64/154, 42% vs 50/179, 28%, y£=6.$3t p=0.009). Nevertheless, in each case a 
substantial proportion of parents felt they needed more information even though their 
child’s infection status had been confirmed. The proportion of respondents who felt 
they needed more information about HCV infection in general was not significantly 
higher among those with a child of unconfirmed infection status.
Of the 95 parents/carers of infected children who completed the section relating to 
infected children, 52 (55%) respondents felt they needed more information about how 
their child’s health may be affected by HCV infection and 51 (54%) felt they needed 
more information about possible treatment for their child’s HCV infection. O f these, 
41 (43%) felt they needed more information about both. The children of respondents 
who felt in need of more information were significantly younger than the children of 
respondents who felt they had sufficient information [how child’s health may be 
affected: median age 2.9 years (range 2 months -  15 years) vs. 6.4 years (4 months -  
19 years), z=-2.16, p=0.03; possible treatment: median age 2.9 years (range 2 months -  
15 years) vs. 7.2 years (4 months -  19 years), z=-2.56, p=0.01].
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8.3.4 Long-term consequences for infected children
Disclosure of child’s infection status
The median reported age at diagnosis among the infected children was 8 months (range 
birth -  10 years). 25 o f 95 respondents (26%) said their child was diagnosed as 
infected at birth. Only 11 children were older than 2 years when diagnosed as HCV 
infected and, of these, 4 children were over 5 years old.
A quarter of infected children (23), who were median age 12 years (range 3 - 1 9  years) 
at the time of the survey, were aware of their HCV infection and 71 (75%) did not 
know they were infected, of whom the parents/carers of 53 thought they were too 
young to understand at a median age of 2.4 years (range 2 months -  14 years) (missing 
for 1).
Of the 71 respondents whose children were unaware of their infection status, 38 (61%) 
planned to tell their child when they were older, 23 (37%) had not thought about it and 
one said they would never tell their child about their HCV infection (missing for 9). 21 
of 38 specified the age at which they plan to tell their child which ranged from 5 years 
to 18 years, median 11.2 years. About half of respondents (35, 53%) would prefer to 
tell their child about their HCV infection on their own, 21 (32%) would like support 
from staff at the clinic in telling their child and 10 (15%) respondents would like a 
doctor or nurse at the HCV clinic to tell their child (missing for 5).
Views on long-term follow-up
Over half of the parents/carers (50, 57%) did not think their infected child would have 
health problems related to their HCV infection in adulthood, 4 (5%) said they hoped
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not and one said they cannot know (missing for 7). O f the 33 respondents (38%) who 
thought their child would have health problems in adulthood half (12) o f those who 
gave details mentioned liver problems.
Whether mothers thought their child would have health problems in adulthood was 
associated with the degree to which their own daily life was affected by HCV. Only 10 
of 37 (27%) women whose activities at home were unaffected by their HCV infection 
thought their child would have health problems compared to 9  of 19  ( 4 7 % )  who were 
affected a little and 6  of 8 ( 7 5 % )  who were affected a lot ( x 2 trend= 6 . 9 7 ,  p=0.008). 
Similarly, 10 ( 2 5 % )  of 40 women whose activities outside the home were unaffected 
by their HCV infection thought their child would have health problems compared to 11 
( 6 9 % )  of 1 6  who were affected a little and 4  of 5  (80%) who were affected a lot 
(x^ra<rll.36 ,p= 0 .0008).
All respondents strongly agreed (74, 81%) or agreed (17, 19%) with the statement ‘It is 
important to find out about the possible health problems that children with HCV 
infection may have in adulthood’ (missing for 4). Similarly, 67 (74%) strongly agreed 
and 23 (25%) agreed with the statement ‘A system is needed to find out about the 
possible health problems that children with HCV infection may have in adulthood’. 
However, one respondent disagreed with the second statement (missing for 4).
Of the five suggested ways to monitor the long-term consequences o f vertically 
acquired HCV infection (Table 8.2), most respondents (76, 88%) preferred the first 
option, to continue to see the paediatrician and then transfer to adult care when older. 
The main reasons given were to maintain continuity of care, to receive specialist care
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and to be seen by staff who they trust and who are aware o f their individual situation. 
Similar comments about continuity of care were given by those who would prefer the 
second option.
Associations between respondent and child characteristics and the preferred method 
for long-term follow-up were assessed in a multivariable logistic regression model. 
Mothers were significantly more likely to choose option one (continue to see the 
paediatrician) than options 2-5 compared to other carers (adjusted OR=7.05, 95% Cl 
1.34 -  37.16, p=0.02) and the parents/carers of younger children were more likely to 
choose option one than the other options compared to the parents/carers of older 
children (adjusted OR for each year increase in child’s age=0.83, 95% Cl 0.68 -  1.01, 
p=0.06). Whether the child was aware of their HCV infection and whether the 
parent/carer thought their child would have HCV-related health problems in adulthood 
were also included in the model but neither were significantly associated with 
choosing option one.
There was more variation in the least preferred option, with options 3, 4 and 5 the least 
favoured. The reasons given were mainly related to the lack of direct contact with 
clinicians which was thought to be detrimental. The least preferred option was 
significantly related to whether the child was aware of their HCV infection (x (4 
df)=11.85, p=0.02), with most parents/carers of children who were unaware of their 
infection choosing option 3 (researchers would keep in contact with the child) and 
most parents/carers of children who knew they were infected choosing option 4 (data 
linkage, no regular contact) as their least preferred option.
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Table 8.2 Options for long-term follow-up of infected children: 
respondents’ choices
Most preferred Least preferred
1 You continue to take your child to visit the 
paediatrician once or tw ice a year.
When your child becom es a teenager they 
w ould be seen by a liver specialist or another 
doctor who sees adults, once or tw ice a year, 
instead o f  seeing the paediatrician.
76 (88%) 1 (1%)
2 Doctors or nurses, from the hospital which you  
currently visit, w ould keep in contact with your 
child by post or telephone once a year and ask 
questions about their health.
6 (7%) 11 (15%)
3 Researchers w ould keep in contact with your 
child by post or telephone once a year and ask 
questions about their health.
1 (1%) 23 (32%)
4 Your child’s details w ould be added to a list o f  
children with HCV infection.
These details could be linked to sources o f  
information on specific health problems.
Your child w ould not be contacted directly on a 
regular basis
1 (1%) 18 (25%)
5 When your child is 20 to 30 years old they 
would be contacted by a health professional 
from a hospital or research centre.
They would be asked to attend hospital for a 
visit to check their health and have som e blood  
tests.
You would need to tell your doctor every time 
you change address.
2 (2%) 19 (26%)
missing 9 23
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8.4 Key points
• Most respondents were the mother of the child they had brought to the clinic and 
were white, married or co-habiting and bom in their country o f residence.
• A third of HCV infected mothers reported not knowing how they became infected.
• Around half of the mothers reported that their HCV infection impacts their daily 
life in some way with a similar proportion reporting that their infection did not 
affect their daily life at all.
• Nearly all respondents were satisfied with the care provided by the HCV clinic.
• A fifth of respondents made suggestions for improvements.
• There was evidence of a significant shortfall in provision of information; half of 
respondents felt they needed more information about HCV infection in general.
• Parents/carers of children with unconfirmed infection status were more likely to 
feel in need of more information about blood tests and diagnosis or exclusion of 
infection.
• Among the parents/carers of infected children, those with younger children were 
more likely to want further information about how their child’s health may be 
affected and treatment options than parents/carers of older children.
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• Over half of the parents/carers of HCV infected children did not think their child 
would have health problems in adulthood related to their HCV infection.
• The preferred option for long-term follow-up of infected children was to continue 
to see the paediatrician and transfer to adult care when older.
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Chapter 9 Discussion
9.1 Introduction
Hepatitis C virus infection is a major public health problem worldwide (WHO 
2002;Poynard et al. 2003;Butt 2005). As a relatively newly discovered virus which can 
cause slowly progressive disease, many previously undiagnosed chronic infections are 
now being detected and the full impact of the epidemic is being realised. The first 
reported case of mother-to-child transmission of HCV was in 1991 (Thaler et al. 1991). 
Over the past 15 years, mother-to-child transmission has replaced transfusion-acquired 
infection as the predominant route of paediatric HCV infection. During this period 
many small studies were conducted suggesting that the risk of vertical transmission was 
likely to be low. Much larger studies are therefore required to reliably estimate the risk 
of transmission and associated risk factors and to accrue detailed data on a sufficient 
number of vertically infected children to elucidate disease progression. The European 
Paediatric HCV Network was established in 1998 in response to this need and is the 
largest prospective study of HCV infected women and their children to date (European 
Paediatric HCV Network et a l  1999).
This thesis covers the major issues in mother-to-child transmission of hepatitis C virus; 
risk factors for transmission and temporal changes in these factors, markers of infection 
and progression of disease in vertically infected children, immunological parameters in 
infected and uninfected children and the views of parents and carers of HCV exposed 
children on current services and potential methods for long-term follow-up. This work 
provides a broad evidence base for future work on mother-to-child transmission of 
HCV, both research and the development of guidelines for clinical management of HCV 
infected women and their children.
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9.2 Strengths and limitations of the European Paediatric HCV Network
Most EPHN clinical centres are regional referral centres for paediatric infectious 
diseases with close collaboration between obstetric and paediatric colleagues (European 
Paediatric HCV Network et al. 1999). The women enrolled in the EPHN are likely to be 
representative of HCV infected pregnant women in western Europe, especially in the 
Italian centres where antenatal screening is usually routine (Decreto Ministeriale - 
Ministero della Sanita 1995). The large number of clinical centres in the EPHN across 
seven countries increases the generalisability of the findings.
Standardised data forms were designed to gather the essential obstetric, clinical and 
laboratory data to address the specific research questions posed. The forms were easy to 
complete and data collection was, of necessity, limited to ensure the response rate from 
participating centres was high. Extensive socio-demographic and maternal laboratory 
data could not be included.
With multi-centre observational studies there is the concern that centre-associated 
differences in background characteristics or variation in PCR assays used to determine 
infection status may affect the results. To investigate this, a random effect was included 
in the multivariable models in the risk factors analysis (Chapter 4). Although the 
goodness of fit o f the models improved after the inclusion of a random effect, 
suggesting there may be small centre-associated differences in vertical transmission 
risk, the estimated associations between the variables of interest and the risk of HCV 
vertical transmission did not change.
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9.3 The HCV epidemic among pregnant women in Europe
Estimates of the antenatal prevalence of HCV infection in Europe range from less than 
1% in the UK (Ades et al. 2000) to more than 2% in parts o f Italy (Conte et al. 2000). 
Investigation of factors associated with mode of acquisition of HCV infection among 
women enrolled in the EPHN (Chapter 4) showed that younger women, those with HIV 
co-infection and women from non-Italian centres were significantly more likely to have 
acquired their infection through IDU than through other routes such as contaminated 
blood transfusions. This indicates that at least two HCV epidemics exist among 
pregnant women in Europe; one driven by IDU and the other more widespread in the 
general population.
HCV/HIV co-infection in Europe is usually associated with IDU (Alter 2006). This 
reflects that both viruses are efficiently transmitted through contaminated needles in 
IDU but the risk of HCV sexual transmission is considerably lower than for HIV (Alter 
2006). A large and increasing proportion of HIV infection among women of 
childbearing age in western Europe is heterosexually acquired and related to migration 
from countries with high HIV prevalence, particularly sub-Saharan Africa (European 
Collaborative Study 2001;Hamers and Downs 2004). This contrasts with the HCV 
epidemic in Europe; only 6% (21) of the survey respondents were born outside western 
Europe and only 4% (13) were not white (Chapter 8).
There is evidence to suggest that some HCV infections in Italy are acquired through 
medical practices which could explain why non-IDU acquisition o f infection was 
associated with Italian centres. Montella et al. (Montella et al. 2003) showed a cohort 
effect in age-specific HCV prevalence in Southern Italy, with HCV prevalence of 
around 6% in adults aged 40-49 and 50-59 years compared to 2.3% in those aged 30-39
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years. The high prevalence in the 40-49 year age group was attributed to iatrogenic 
transmission during polio vaccination campaigns in the 1950s and 1960s which 
involved re-use of glass syringes, while the high prevalence among those over 50 years 
of age was thought to be due to HCV transmission through unsafe medical practices 
during World War II (Austin et al. 2000). Women in the EPHN were too young to have 
been infected during the vaccination campaigns but may have been at increased risk of 
infection due to HCV circulating at low levels in the general population as an indirect 
result of the campaigns. Although the risks of sexual, horizontal and vertical 
transmission are small, low level transmission through these routes could amount to a 
substantial number of infections if HCV were widespread in the general population. The 
history of vaccination campaigns in some regions, variation in initiating blood supply 
screening and differences in medical practices between regions would suggest that the 
HCV epidemic in northern Europe is predominantly in IDUs (Health Protection 
Agency, 2005) whereas in southern Europe it tends to be more widespread. However, 
the lack of reliable prevalence data for general populations hinders confirmation of this 
suggestion.
Regardless of the true distribution of risk factors for acquisition of infection in different 
regions of Europe, detection of asymptomatic HCV infected women in pregnancy 
depends on the antenatal screening policy. Routine antenatal screening o f all pregnant 
women will identify HCV infection outside specific high-risk groups. In Italy universal 
antenatal screening for HCV has been recommended by the Ministry of Health since 
1995 (Decreto Ministeriale - Ministero della Sanita 1995) whereas elsewhere selective 
testing of high-risk groups, such as IDUs, is more common. For example, a national 
policy of routine antenatal screening has not been introduced in the UK (Pembrey et al. 
2003a) and 90% of mothers of HCV infected children identified in a UK active
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surveillance study had a history of IDU (Gibb et al. 2000b) compared to 39% in the 
EPHN, reflecting the predominance of Italian centres with routine antenatal screening.
It has been widely reported that a substantial proportion of HCV infected women do not 
report a specific risk factor for infection (Ward et a l 2000;Conte et al. 2000), consistent 
with the results presented here from the prospective study (13%) and the survey (35%). 
Although the questionnaires were anonymous, under-reporting of IDU may have been 
more likely in the survey where questionnaires were self-completed. It is also possible 
that women completing the survey questionnaire were different from those enrolled in 
the EPHN; women participating in the survey were attending the clinic and the EPHN 
group would have included some women who did not attend follow-up appointments 
after delivery.
The substantial proportion o f women with no recognised risk factor has implications for 
prevention of HCV infection in women. Prevention programmes to reduce IDU-related 
infection focus on reducing risky injecting behaviours, such as sharing injecting 
equipment, including needle-exchanges and other harm reduction activities. The risk of 
transmission through blood transfusions and medical practices should now be negligible 
in Europe but reports of transmission through non-conventional routes emphasize the 
need to strictly implement universal precautions, particularly in non-medical settings 
such as tattooing and piercing salons and barber shops. There are several recent reports 
in the literature of HCV infection associated with dental or beauty treatment (including 
tattooing and barber shop shaving) (Chlabicz et al. 2004;Mariano et al. 2004). HCV 
testing of those who may be at risk of infection through non-conventional routes should 
also be encouraged and infected individuals treated to reduce the pool of infection in the 
general population and prevent ongoing transmission.
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9.4 Risk factors for mother-to-child transmission of HCV
The work in Chapters 4 and 5 contributes to the understanding o f risk factors for 
mother-to-child transmission of HCV. Some of the results confirm previous findings 
from smaller studies regarding the risk of vertical transmission, the lack of an 
association with breastfeeding and maternal IDU, and a possible increased risk 
associated with some obstetric factors. The most significant results, however, are the 
finding of an association between gender and risk of vertical transmission and the lack 
of a protective effect o f elective caesarean section despite a large sample size, which 
informs the current debate on this issue.
In addition to establishing an overall risk of transmission of 6.2% (95% Cl 5.0 -  7.5) 
consistent with estimates from other studies (Figure 1.1), trends over time were 
investigated. Although the risk of vertical transmission decreased significantly over 
time in the pooled analysis (Chapter 5), the effects of maternal HCV/HIV co-infection, 
mode of delivery or breastfeeding on risk of transmission did not change substantially. 
This suggests that the decrease in risk of vertical transmission was due to a reduction in 
the proportion of women at greatest risk of transmitting HCV to their infant.
These results confirm (Tovo et al. 1997;Resti et a l 2002a;Spencer et al. 1997;Polywka 
et al. 1999) that breast feeding does not increase the risk of HCV transmission in HCV 
infected women, although a very low risk cannot be ruled out. In the pooled analysis 
there was some evidence of an increased risk through breastfeeding among HCV/HIV 
co-infected women but this was restricted to the period before 1998 as subsequently, in 
line with European recommendations (Newell and Rogers 2002), very few co-infected 
women breastfed their infants.
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The finding of a significant association between the duration of rupture o f membranes 
and risk o f vertical transmission is consistent with others (Spencer et al. 1997;Mast et 
al. 2005), and suggests that prolonged contact with maternal blood and other fluids may 
increase the risk of transmission to the infant.
There has only been one report of a significantly increased risk o f HCV vertical 
transmission from mothers with a history of IDU (Resti et al. 2002a); this comes from 
the only other large prospective study and deserves further consideration. Although 
Resti et al. suggest that the increased risk through current IDU could be due to increased 
infection of peripheral blood mononuclear cells in IDUs (Resti et al. 2002b), IDU and 
HCV/HIV co-infection are closely correlated and HIV co-infection and the associated 
immunosuppression is a more biologically plausible risk factor for vertical transmission 
via increased HCV viral load. In the main analysis (Chapter 4) there was no evidence of 
an effect of maternal IDU on vertical transmission in univariable or multivariable 
analysis and in the pooled analysis (Chapter 5) it is clearly shown that the significant 
association between maternal IDU and vertical transmission observed in univariable 
analysis was confounded by maternal HIV co-infection and the adjusted odds ratio was 
close to 1. It is likely that the significant association between maternal IDU and vertical 
transmission seen by Resti et al. is confounded by some other factor(s) such as viral 
load (Armstrong et al. 2003), in addition to HIV co-infection. HCV viral load is likely 
to be higher in IDU mothers due to the immunosuppressive effects o f IDU and possible 
re-infection in active IDUs (Nikolopoulou et al. 2005). Although Resti et al. limited part 
of their analysis to HCV-RNA positive women, the range of viral load in these women 
was likely to be wide and no adjustment was made for viral load.
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Gender
This is the first report of a significant association between gender and HCV vertical 
transmission. Granovsky et al. reported an 8% transmission risk for girls and 3% for 
boys in a study of 122 mother-child pairs with 7 infected children, but this difference 
was not statistically significant (Granovsky et al. 1998). A significant higher 
susceptibility of females to vertically acquired infections has been observed for human- 
T-cell-leukaemia/lymphoma virus-type-I (Ureta-Vidal et al. 1999) and for HIV in 
Europe (European Collaborative Study 2004a;Galli et al. 2005) and in Malawi (Taha et 
al. 2005), although the risk of postnatal HIV transmission was significantly higher in 
males in a meta-analysis of African trials (The Breastfeeding and HIV International 
Transmission Study Group et al. 2004) but this analysis could not control for possible 
gender differences with regard to breastfeeding.
Alternative explanations for the association between gender and HCV vertical 
transmission were considered but there was no evidence of confounding or bias. 
Adjusted odds ratio estimates were similar to the unadjusted estimates, and girls and 
boys were followed up for similar periods and were equally likely to have their infection 
status confirmed. The male.female ratio in the EPHN was 1.20 (802:668), higher than 
the sex ratio in the general population (usually around 1.05) suggesting that this finding 
is unlikely to be due to excessive deaths of infected males in utero. It likely reflects 
hormonal or genetic differences in susceptibility or response to infection between males 
and females. Although auto-immune disease is more common in females, there is 
substantial evidence from humans and other species that males are more susceptible 
than females to infection caused by many parasites, fungi, bacteria and viruses (Klein 
2000b). This is thought to be mediated by sex hormones, either as a direct effect with 
androgens lowering immunocompetence (Klein 2000a) or indirectly via an effect of sex
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hormones on disease resistance genes and behaviour. Other steroid hormones and 
pituitary derived peptide hormones may also influence sex differences in infection.
There is some evidence to suggest a higher susceptibility o f males to HCV infection in 
adults. In a case-control study of 60 health care workers infected through percutaneous 
or mucocutaneous exposure to HCV and 204 HCV-exposed but uninfected controls, 
males were more likely to be infected than females (adjusted OR=3.1, 95% Cl 1.0 -  
10.0, p=0.06) (Yazdanpanah et al. 2005). A higher prevalence of HCV infection in 
males than females has been observed elsewhere (Coppola et al. 2000) and more rapid 
progression of fibrosis has been shown in males (Poynard et al. 1997;Freeman et al.
2003). In adults, however, it is often difficult to account for all confounders and 
untangle the effect of behavioural differences between men and women. The close 
contact between mother and fetus and the immature immune system may also reflect the 
different mechanisms acting in fetal or infant life and those in adulthood. For example, 
there is evidence that maternal infections increase fetal cortisol and 
dehydroepiandrosterone synthesis (Falkenberg et al. 1999) and human male and female 
fetuses exhibit differences in regulation o f the cytokine network (Romero et al. 1994).
Further immunological and physiological research is needed to elucidate the 
mechanisms involved in the increased risk of girls to vertically acquired infections. 
These mechanisms may act to influence transfer of HCV across the placenta resulting in 
different levels of exposure to male and female fetuses, or may influence susceptibility 
or response to HCV once exposed in utero, with males fetuses perhaps more able to 
effectively control and clear infection. Our findings suggesting gender differences are 
intriguing and of wider interest but have no impact on prevention o f mother-to-child 
transmission of HCV.
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Mode of delivery
These findings make an important contribution to the debate over the potential 
protective effect o f elective CS on risk of vertical transmission (European Paediatric 
HCV Network et al. 2001;Gibb et a l 2000a;Conte et al. 2000;0kamoto et al. 
2000;Tajiri et al. 2001;Paccagnini et al. 1995) and provide reliable evidence that mode 
of delivery does not influence HCV transmission in women with HCV infection alone 
or in HCV/HIV co-infected women. The proportion of elective CS was high in our 
study in HIV co-infected women, where a targeted recommendation exists (Newell and 
Rogers 2002), and also in those with HCV infection alone, especially in Italian centres 
where this practice is common in the general population (Tranquilli and Giannubilo
2004). The smaller studies which investigated mode of delivery were limited by a lack 
of statistical power to detect or exclude an effect. This study would have been large 
enough to detect a 60% reduction in risk of transmission associated with elective CS 
delivery from 6% to 2.5% (with 80% power and 5% significance). In the pooled 
analysis (Chapter 5) the sample size was increased further but no association was 
observed.
In fact, an association in the opposite direction, indicating an increased risk of 
transmission among elective CS deliveries, was observed among women with only 
HCV infection but further investigation revealed this to be a spurious finding. Most of 
the infected children bom by elective CS to the women in the group where the 
association was observed were from the same centre. This suggests that clinical practice 
in this, and possibly other, centres may have resulted in the observed association. 
Women who were symptomatic or had high HCV viral load in pregnancy may have 
been offered an elective CS if they were perceived to be at high risk of vertical 
transmission and elective CS was thought to be protective. High maternal HCV viral
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load could explain a higher risk of in utero transmission in these children which would 
be unaffected by mode of delivery. There were not sufficient data to investigate the 
effect of mode of delivery stratified by maternal HCV viral load. The recommendation 
for elective CS in HIV infected women and a high profile report o f a suggested 
protective effect for HCV vertical transmission (Gibb et al. 2000a) may have influenced 
some clinicians’ decisions over mode of delivery.
The lack o f a mode of delivery effect is consistent with the low risk o f sexual 
transmission of HCV (Rooney and Gilson 1998), which suggests that HCV is not 
usually present at high levels in the female genital tract, and contrasts with the high risk 
of HIV sexual transmission and protective effect of elective CS for HIV mother-to-child 
transmission. Evidence from a study which analysed cervicovaginal lavage fluid from 
HCV infected women suggested low HCV replication in the genital tract of women 
without HIV co-infection (Nowicki et al. 2005), similar to findings from Belec et al. 
(Belec et al. 2003) who did not detect replicating HCV-RNA in any cervicovaginal 
secretion samples from 15 chronically infected women who were HCV-RNA positive in 
serum.
Maternal HCV/HIV co-infection
Maternal HCV/HIV co-infection has been strongly and consistently associated with an 
increased risk of HCV vertical transmission (European Paediatric HCV Network et al. 
2001;Tovo et al. 1997;Zanetti et al. 1998), even in small studies. This association is 
thought to be mediated by higher HCV viral load in immunosuppressed HIV co-infected 
women than in women with HCV infection alone (Zanetti et al. 1995). There is also 
evidence that HCV replication may be directly enhanced by the presence o f HIV (Beld 
etal. 1998).
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The results in Chapter 4 indicate a more recent attenuation of the effect of maternal HIV 
co-infection on HCV vertical transmission. This may be due to widespread use o f 
HAART, which substantially improves HIV-induced immunosuppression and 
consequently may lead to better control of HCV replication. A similar finding was 
reported from a small study involving 15 HCV/HIV co-infected ART-treated women 
(Conte et al. 2000). Our results suggest that HAART may reduce both maternal HCV 
viral load and risk of HCV transmission. Since HAART has been associated with 
prematurity (European Collaborative Study 2003b), it also accounts for the apparent 
protective effect of prematurity on HCV vertical transmission, seen only in HIV co- 
infected women.
However, the results in Chapter 5 indicate that the effect of maternal HIV co-infection 
on risk of HCV vertical transmission has not changed significantly over time. The 
proportion of co-infected women in this study was only 15%, considerable lower than in 
earlier studies resulting in a loss o f statistical power to detect an effect o f maternal HIV 
co-infection even though the overall sample size was large. HAART could not be 
included in the multivariable models in the pooled analysis so it is unclear whether a 
change in the effect o f maternal HIV co-infection over time could have been shown had 
HAART been taken into account. A low proportion of HCV/HIV co-infected women 
can also account for the lack of an association in two other studies (Resti et al. 
2002a;Conte et al. 2000).
Maternal HCV viraemia
Maternal HCV viraemia is likely to be the most important factor in vertical transmission 
but is difficult to measure. Accurate estimation of the effect of viral load or the effect of 
viraemia as a qualitative variable on risk of vertical transmission requires regular
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measurements during pregnancy, ideally at least once in each trimester and at delivery, 
as viraemia may fluctuate throughout pregnancy (Gervais et al. 2000) and transmission 
can occur in utero or at delivery (European Paediatric HCV Network et al. 2005b). 
Although viraemia status is often available for the majority of women in the smaller 
single-centre studies, it is difficult to ensure that viraemia data are collected for all 
women in a large multi-centre study like the EPHN.
In this study, viraemia status, based on at least one measurement during pregnancy, at 
delivery or in the first week postpartum, was available for just over a third of women 
who were representative of the whole group; the data were not limited to particular 
centres or women. Although the risk of vertical transmission is likely to be substantially 
lower in non-viraemic women, our results confirm (European Paediatric HCV Network 
et al. 2000) that transmission cannot be ruled out, as a few children acquired infection 
from non-viraemic women. HCV RNA viral load may be a better predictor of 
transmission than a qualitative test. However, even where viral load data are available, 
interpretation is problematic, especially in multi-centre studies, due to inter-laboratory 
and inter-assay variations (Pembrey et al. 2003b).
9.5 Vertically infected children
In the natural history analysis presented in Chapter 6, the aim was to move beyond the 
description of laboratory markers of infection, symptoms and biopsy results which have 
characterised most of the studies published to date, to examine associations between 
laboratory markers and clinical manifestations to indicate likely predictors of disease 
progression and to identify predictors of persistent viraemia.
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This is the largest group of vertically HCV infected children described to date. All have 
been followed from birth, avoiding the referral bias present in some other studies where 
some infected children identified by paediatric hepatologists may be more likely to be 
symptomatic or with increased ALT.
A low prevalence of signs and symptoms among vertically HCV infected children was 
confirmed. Hepatomegaly was the most common clinical manifestation. Although a 
non-specific sign which can be observed in children without HCV infection, comparison 
with the uninfected children enrolled in the EPHN showed that hepatomegaly was 
significantly more common in HCV infected children while all the other signs and 
symptoms occurred at a similar prevalence in infected and uninfected children. These 
findings justified using hepatomegaly as a marker of disease progression, in the absence 
of any others, which likely indicates liver inflammation and an early stage o f HCV- 
related liver damage.
Our findings suggest three broad categories of vertically HCV infected children: 1) 
around 20% with apparent clearance of the virus, reflecting acute infection; 2) around 
50% with chronic asymptomatic infection, with intermittent viraemia, usually normal 
ALT levels and rarely hepatomegaly; 3) the remaining 30% with chronic, active 
infection, with persistent viraemia, frequent abnormal ALT levels and hepatomegaly in 
some cases. Similar distinctions have been made in adult HCV infection (Alter and 
Seeff 2000).
The extent of viraemia varied considerably and an estimated one fifth to one quarter of 
children may clear the virus. Our estimated clearance rate, although conservative as we 
did not include persistently PCR negative children who were antibody positive beyond
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18 months, is in line with reports by others (Table 2.1); for example, Resti et al. 
observed clearance in 12 of 62 children (19%) (Resti et al. 2003). Spontaneous viral 
clearance was initially estimated to occur in about 15% of HCV infected adults 
(Thomas et a l 2000). Loss of antibody is rarely observed in HCV infected adults who 
become persistently HCV-RNA negative (Alter et al. 1992) but has been reported 
(Lefrere et al. 2004). One might expect a higher clearance estimate among children 
followed from birth than among adults because adults clearing infection early without 
clinical symptoms are unlikely to ever be identified. In fact, in adult studies where 
patients are followed up after a defined exposure, higher clearance estimates of around 
25% are reported (Alter and Seeff 2000).
In our study, clearance had occurred by 3 years in most children, similar to a study of 
haemophilia patients who usually cleared 1-2 years after infection (Eyster et al. 2004). 
Early clearance explains the much lower proportion of clearers among the group 2 
children. Although all children in our study were followed from birth, PCR tests were 
not routinely performed in the early 1990s so some infected children may have been 
missed if not tested in the first two years of life and subsequent negative PCR tests or 
antibody negativity interpreted as absence of infection (Ketzinel-Gilad et al. 2000). 
However, in the group of children followed from birth, there were 4 children with 
apparent clearance after the age of 3 years, in line with the rate of clearance observed in 
group 2 with follow-up from a median age of 2.4 years.
In any multicentre study, reliability of HCV-RNA assays and potential inter-laboratory 
variation must be considered. In a recent quality assessment among EPHN laboratories, 
false positive qualitative RNA results were rare (Pembrey et al. 2003b), and it is 
unlikely that any clearers in our study were incorrectly identified as infected. False
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negative results were more common, particularly at low viral loads, suggesting that 
some children with evidence of clearance may remain infected but with viral load below 
the lower detection limit (Pembrey et a l  2003b).
Given that girls were at higher risk of acquiring HCV infection from their mothers than 
boys, markers of infection were examined by gender. A higher proportion of boys had 
evidence of viral clearance than girls but the number of children in each sub-group was 
small and this difference was not statistically significant. This trend may warrant further 
investigation. Resti et al. (Resti et al. 2003) did not find a gender difference in clearance 
but again, there was probably insufficient statistical power to detect an association. In 
adults the role of gender in HCV clearance is unclear. In a recent large population-based 
study in Egypt, females were significantly more likely to have cleared the virus than 
males (45% vs. 34%, OR=1.59, 95% Cl 1.21 -  2.08), even after adjustment for age, 
schistosomiasis treatment history and other iatrogenic exposures (Bakr et al. 2006). The 
highest clearance rates overall o f nearly 50% were seen in studies of women who were 
infected through receipt o f contaminated anti-D immune globulin (Wiese et a l 
2005 ;Kenny-Walsh 1999), also suggesting that women are more likely to clear than 
men. However, gender differences in clearance have not been confirmed in other studies 
(Watanabe et a l 2003;Mohsen and Group 2001).
Frequent abnormal ALT was significantly associated with hepatomegaly and could 
therefore be predictive of disease progression, although an attempt to investigate the 
temporal relationship between viraemia, ALT and hepatomegaly indicated that these 
tend to occur concurrently within each child so that peaks of ALT, for example, would 
not be predictive of an episode of hepatomegaly. However, a low proportion of positive 
PCR tests in first year was predictive of clearance, although further investigation of
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these associations is necessary before these markers can be used in the clinical 
management of infected children. In adults the value o f ALT as a predictor o f liver 
disease progression is still unclear (Freeman et al. 2003;Boyacioglu et al. 2004;Hui et 
al. 2003). In line with the higher risk of vertically acquired infection in girls, infected 
girls were significantly more likely to have hepatomegaly than boys. This may reflect a 
stronger immune response in girls resulting in immune-driven liver damage. Despite a 
large total sample, the analyses to investigate associations between markers of infection 
and hepatomegaly lacked statistical power, especially in multivariable models.
With increasing life expectancy among HIV infected individuals, co-infection with 
HCV has become increasingly relevant as individuals experience long-term liver 
damage (Mohsen et al. 2002). There is evidence to suggest that both HIV and HCV 
disease progression are adversely affected by co-infection (Soriano et al. 2002) but very 
little is known about paediatric HCV/HIV co-infection (England et al. 2006). 
Hepatomegaly was more common among the 26 HCV/HIV co-infected children in our 
study compared to children with only HCV infection and there was a trend towards a 
higher proportion o f positive PCR tests although the clearance rate was similar. 
However, patterns of HCV viraemia and ALT and prevalence of clinical symptoms are 
difficult to interpret due to the complex interactions between the two viruses (Talal 
2002). Although the number of co-infected children now being bom in Europe is very 
low with the HIV mother-to-child transmission rate reduced to less than 2% (Thome 
and Newell 2003), co-infection raises important issues relating to treatment with potent, 
hepatotoxic anti-retroviral therapies for HIV infection (Mohsen et al. 2002) and 
decisions regarding initiation of treatment for HCV infection and possible drug 
interactions (England et al. 2006).
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9.6 Immunological markers
In line with the vertical transmission and natural history results, gender differences were 
evident in levels o f lymphocytes and neutrophils in HCV infected and uninfected 
children (Chapter 7). Similar associations have been reported among children bom to 
HIV infected women (European Collaborative Study 2004b;Bunders et al. 
2005b;European Collaborative Study 2003a) and may indicate general gender 
differences in response to infections. Differences in lymphocytes between persistently 
infected children and those with evidence of viral clearance may contribute to an 
understanding of the infant immune response to maternal HCV infection. However, it is 
important to note that these data relate to overall lymphocyte levels rather than HCV- 
specific responses and should not be over-interpreted. Further research is needed to 
elucidate the relevance o f these findings in HCV-related immunological responses.
There was some evidence to suggest a longer-term impact o f vertically acquired HCV 
infection on immunological markers. Lymphocyte z-scores up to 10 years o f age were 
higher in HCV infected children compared to the reference group, and among the HCV 
infected children, levels were higher in girls than boys but these associations were only 
of borderline statistical significance, possibly due to the small sample size compared to 
the analysis relating to the first two years of life. HCV infected children had 
significantly lower neutrophils than the reference group although there was no effect of 
gender for the period up to 10 years of age. It is unclear whether the reduced neutrophil 
levels in HCV infected children are clinically relevant but may warrant further 
investigation. Although preliminary, these results suggest that the effect of gender on 
lymphocytes and neutrophils may diminish with age.
198
As few data are available on immunological parameters in healthy children, prospective 
data on uninfected children over age from studies like the EPHN can provide reference 
values for the assessment of immune suppression in several paediatric diseases such as 
HIV infection, rheumatoid arthritis and asthma (Shearer et al. 2003). Although in the 
EPHN data were only available up to 2 years of age for uninfected children (beyond this 
age the data are sparse as children who are confirmed as uninfected are usually 
discharged from follow-up), the greatest variation in lymphocyte and neutrophil 
measurements occurred within the first year of life, when paediatric values are likely to 
differ most from adult reference ranges and there is greatest uncertainty about what are 
‘normal values’. Although these children are uninfected, it is possible that exposure to 
maternal chronic infection could influence infant immunological parameters. 
Uninfected children bom to HCV infected women may be a more appropriate 
population to use for age-related standards than children bom to HIV infected women 
(Bunders et al. 2005a) as HCV does not directly target immune cells as HIV does.
However, no differences in lymphocytes or neutrophils were apparent between 
uninfected children bom to HCV infected women and uninfected children bom to HIV 
infected women at least in the first 2 years, when we compared the two groups to 
validate the use of ECS as a reference group for the HCV infected children. Shearer et 
al. report median absolute lymphocyte values for 800 HIV-unexposed healthy children 
from birth to 18 years from a cross-sectional study with at least 90 subjects in each of 7 
age strata (Shearer et al. 2003). The median values for the EPHN uninfected children 
for the same age ranges (a few observations for EPHN children were available up to 12 
years) tended to be higher but were all within 0.65 x l0 6/ml of the values reported by 
Shearer et al. Further work would be required to confirm the apparent limited impact of 
exposure to maternal chronic infection on lymphocytes in uninfected children.
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9.7 Care for children born to HCV infected women: views of parents and 
carers
Despite the public health importance of HCV infection, there have been relatively few 
studies to investigate the views of HCV infected women and the social and 
psychological impact of HCV infection on their lives. This is the first study to 
specifically address the views of parents and carers of HCV exposed children.
The response rate was very high at 96% and the survey was well received by parents, 
carers and clinicians. Many parents/carers commented that they were pleased their 
views were being sought and thought it important for clinicians and researchers to work 
with affected families. All parents and carers who attended each clinic over the 15 
month data collection period o f the survey were invited to take part. However, non- 
attenders were not included and may be different to clinic attenders. They may be more 
likely to have an uninfected child and/or find it harder to get to the clinic. One benefit of 
the survey continuing for a 15 month period was that infrequent clinic attenders were 
likely to have attended at least one appointment during this time. Despite the high 
response rate, the experience of parents and carers of children attending EPHN centres 
is unlikely to be representative of all HCV affected families in Europe. The findings 
may be influenced by the characteristics of the participating centres, for example, the 
predominance of Italian centres in the EPHN.
Overall, respondents were satisfied with the clinical care provided for their child and 
many commented on the kindness, expertise and dedication of the paediatricians and 
other health professionals. Despite this many had suggestions for improvements and 
other services.
200
A major outcome of the survey was evidence o f a significant shortfall in provision of 
information. About half of the parents/carers of children with indeterminate infection 
status would have liked more information about the different blood tests for HCV and 
confirmation or exclusion of infection in their child. Although parents/carers o f HCV 
infected children felt better informed about the diagnosis process, over half felt they 
needed more information about how their child’s health may be affected and treatment 
options. The results suggest that sufficient information was not provided early enough 
as the greatest shortfall was among parents of indeterminate children who tended to be 
younger and among parents/carers of the younger infected children. Poor provision of 
information was also identified in a survey of parents and carers o f HIV exposed 
children (Thome et al. 1999).
Passive transfer o f maternal antibodies, the distinction between antibody tests and HCV- 
RNA PCR tests and the need for more than one test to confirm or exclude infection are 
complicated issues to present to parents. Ideally, at the first clinic visit parents and 
carers should be given an information sheet to take away with them to refer to at home, 
as well as a verbal explanation with the opportunity to ask questions, as suggested by a 
few respondents. We did not collect data in the survey about whether clinics provided 
written information for parents and it is possible that this happens in some clinics. A 
survey of health professionals caring for HCV exposed children could address issues of 
information provision and its effectiveness.
The inadequacy of information available was apparent in the comments from HCV 
infected mothers about the impact of their own infection on their daily life. Taking 
precautions to avoid transmission of HCV to family members was the most common 
reported impact and was associated with considerable anxiety in many cases. Many
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respondents specifically mentioned modes of HCV transmission and necessary 
precautions to avoid transmission as issues about which they lacked knowledge. Up-to- 
date information sheets on modes of HCV transmission could provide reassurance that 
the risk of household transmission is likely to be very low with sensible precautions 
(Kim et a l 1998;Ackerman et a l  2000).
The results of the survey indicated that some HCV infected women may not be 
receiving adequate clinical care. Nearly a quarter of HCV infected mothers in the survey 
had limited contact with health services regarding their HCV infection. Several 
participants commented that while they were happy with the care their child had 
received, they felt that services for infected women were severely lacking. These 
findings are similar to an Australian study in which only just over half the women were 
seeing a doctor specifically for their HCV infection (Gifford et a l  2003).
Although interferon and ribavirin are contraindicated during pregnancy, women should 
be assessed for their suitability for treatment after delivery and should at least be 
monitored under the care of a hepatologist. An integrated approach to the care o f HCV 
affected families, perhaps involving other agencies who could take on the role of 
information provision and organisation of support groups, is likely to considerably help 
families and reduce their anxiety.
The research evidence relating to many issues in HCV infection is unclear, particularly 
for horizontal transmission, so it can be difficult to provide useful information for 
patients that is consistent; this may partly explain the lack of information available to 
parents/carers. The lack of a solid evidence base is particularly pertinent to the long­
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term consequences o f vertically acquired HCV infection and it is difficult to give a 
prognosis to parents and carers of infected children.
9.8 Monitoring the long-term consequences of vertically acquired HCV 
infection
All parents/carers of infected children agreed that it is important to investigate potential 
long-term consequences of vertically acquired HCV infection and all but one agreed 
that a system needs to be developed to do this, but over half the respondents did not 
think their child would have HCV-related health problems in adulthood. This may be 
based on mothers’ own experience of HCV infection; although about half of mothers 
reported that their daily life was affected by their infection to some extent, this was 
rarely due to health problems but to anxieties over transmission to others.
Nearly 90% of parents/carers wanted their infected child to continue to see the 
paediatrician six-monthly or annually and in the longer term transfer to adult care. It 
may seem obvious that parents would want to continue regular follow-up but because 
HCV infected children are usually asymptomatic and monitored but not treated, it was 
possible that some parents would feel that regular visits and blood tests were 
unnecessary. It is possible that the non-attenders to clinic, who were not represented in 
the survey, would be in favour of less frequent, indirect follow-up. Further work in 
conjunction with health professionals could establish how common non-attendance and 
loss to follow-up are among HCV infected children, and whether the non-attenders 
represent a substantial group whose views on long-term follow-up are likely to be 
different to the respondents of the survey.
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Issues concerning the most appropriate method for long-term follow-up are relevant for 
many conditions where fetal or childhood exposures may increase the risk o f disease in 
adulthood. In work with childhood cancer survivors now aged 16-25 who regularly visit 
clinical referral centres for follow-up, similar views were expressed with continued 
annual follow-up visits to the specialist clinician preferred to telephone or postal contact 
(Gibson et al. 2005). Most uninfected children bom to HIV infected women are now 
exposed to antenatal and neonatal antiretroviral therapy to reduce the risk o f vertical 
transmission of HIV. Long-term follow-up of these children is necessary as some ART 
drugs may be associated with mitochondrial abnormalities or malignancies (European 
Collaborative Study 2003b). A survey of parents and carers of HIV uninfected children 
again found similar views, with annual clinic-based contact thought to be the most 
acceptable method of follow-up (Claire Hankin, personal communication).
In decisions regarding the most appropriate approach to monitor the long-term 
outcomes of vertically acquired HCV infection, the distinction has to be made between 
following up infected children for their clinical management and collecting data for 
research to investigate the long-term consequences of vertically acquired HCV 
infection. In terms of clinical management of individual children, the current system, 
i.e. annual visits to the paediatrician and transfer to adult care when older, would seem 
appropriate. Theoretically, clinical and laboratory data from these visits could be 
collected for research purposes but funding would be required for co-ordination of data 
collection, management and analysis. Given the long latency time between infection and 
symptoms of 20 years or more in adults (Dore et al. 2002) and the lack of serious 
clinical manifestations among infected children in our study, it is likely that these 
studies will need to continue for decades to assess major clinical outcomes, which is 
unlikely to be feasible or cost-effective. In addition, regular follow-up may result in a
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non-representative sample o f vertically infected children, as non-attenders would be 
excluded, loss to follow-up could be substantial and some clinical centres may not be 
willing or able to participate in the long term. For these reasons, a bias towards 
inclusion and continued follow-up of children with symptoms or indications o f more 
serious disease might occur which could give a distorted impression o f the long-term 
prognosis. Early adult natural history studies based on symptomatic individuals seen in 
referral centres had similar limitations, often with the additional problem of unknown 
date of acquisition of infection (Alter 2005).
For public health purposes, data linkage between a register of vertically infected 
children and routine data sources such as hospital episode data, cancer and death 
registrations would be a more complete and sustainable option over many years but less 
detailed clinical and laboratory information would be available. This method would also 
depend on obtaining informed consent from parents and carers and the individuals 
themselves as they become adults, but could be acceptable to those concerned if this 
system was in addition to their continued clinical care. It could then be feasible, based 
on the infrastructure of a routine surveillance or data linkage programme, to conduct 
individually funded studies, each of a few years’ duration perhaps every decade, in 
which infected individuals would be contacted and asked to agree to clinical 
examinations and laboratory tests to obtain specific, more detailed data. However, this 
approach would not be possible in many European countries where adequate data 
linkage is not available.
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9.9 Management of HCV infected women and their children -  implications of 
the evidence from research for clinical practice and policy
The overall risk o f vertical transmission is low for women with HCV infection 
uncomplicated by HIV, but cannot be ruled out even in non-viraemic mothers. Given 
that there is no anti-viral treatment available for use during pregnancy, there are 
currently no interventions to prevent mother-to-child HCV transmission. In particular, 
there is no evidence to suggest that women should be offered an elective CS delivery or 
be advised to avoid breast feeding on the basis of their HCV infection alone. Although 
the evidence is limited, it would be prudent to avoid prolonged rupture o f membranes 
and invasive obstetric procedures where possible. HCV/HIV co-infected women should 
follow existing HIV guidelines (Newell and Rogers 2002). These include treatment with 
HAART during pregnancy to prevent HIV vertical transmission; this treatment may also 
have a beneficial effect on HCV vertical transmission.
All children bom to HCV infected women should be regularly followed up and tested 
for the presence of HCV-RNA and anti-HCV antibody to exclude or confirm infection. 
The first qualitative PCR test for HCV-RNA should be delayed until after the first 
month of life as sensitivity is low in the first weeks (European Paediatric HCV Network 
et al. 2006). The first antibody test can be done at 12 months as most uninfected 
children will have lost passively acquired maternal antibody by then (European 
Paediatric HCV Network et al. 2005a). A diagnosis of vertically acquired infection is 
confirmed by two or more positive HCV-RNA PCR results and/or persistence of 
antibody beyond 18 months. Intermittent viraemia is common in infected children and 
an estimated 20% -  25% have evidence of clearance of the virus, based on two 
consecutive negative PCR results with no subsequent positive tests. These children 
should remain in follow-up as negative PCR results may reflect very low viral load
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rather than real clearance. In adults there is evidence of HCV RNA persistence at very 
low levels many years after apparent complete spontaneous or therapy-induced 
resolution of chronic HCV infection; whether reactivation o f infection or risk of 
transmission is likely is unclear (Pham et a l  2004). As the majority o f children who 
clear the virus do so by 3 years o f age, and given the possible adverse effects of 
interferon on growth in children less than 3 years, decisions regarding initiation of anti­
viral treatment should be delayed until at least 3 years. The evidence on predictors of 
disease progression in vertically acquired infection is currently insufficient to further 
inform the management of infected children.
9.10 Future challenges in HCV infection
There have been considerable advances in the development of effective therapies for 
chronic HCV infection over the last few years. Alternative treatment options are needed 
for patient groups with poor response to pegylated interferon and ribavirin combination 
therapy, such as patients infected with genotype 1 for whom sustained viral response in 
only achieved in around 50% (Poynard et al. 2003). Novel antiviral drugs and 
immunomodulatory agents are under development (De Francesco and Migliaccio 2005) 
with the hope of attaining improved response rates with less side effects compared to 
the current interferon-based therapies. Given the genetic heterogeneity of HCV, drug 
resistance poses a problem and multiple drug combination therapy will be required for 
most patients. A further challenge is to find more cost-effective alternatives to the 
expensive interferon-based drugs. It is possible that some of the new drugs under 
development which target host rather than viral factors may be safe to use in pregnancy 
and in younger children.
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Despite many obstacles, the prospects for a preventive HCV vaccine now seem 
promising and potential therapeutic vaccines are also being investigated (Houghton and 
Abrignani 2005).
The future therefore looks optimistic for the developed world although primary 
prevention remains crucial. However, HCV infection is ‘a disease o f two worlds’ (Alter 
2005). In resource-poor countries HCV infection is often widespread in the general 
population and perpetuated through unsafe medical practices. Costly anti-viral therapies 
are not an option in many countries. In eastern Europe and central Asia HCV is 
spreading rapidly through the very high prevalence of IDU in some places (Aceijas et 
al. 2004;Rhodes et al. 2005). In these regions the huge potential public health impact of 
HCV infection is only just coming to light but will compete with many more pressing 
public health priorities.
9.11 Recommendations for future research
High maternal viral load is likely to be the best predictor of risk of mother-to-child 
transmission of HCV. If safe drug therapies are developed to reduce maternal HCV viral 
load during pregnancy, evaluation of these treatments for the prevention of vertical 
transmission would be required in clinical trials.
Further investigation of the immune response to maternal HCV infection and the gender 
differences observed here may indicate potential targets for future therapies.
The major focus of future work on mother-to-child transmission of HCV will be the 
infected children. As more data accumulate we will be better able to identify predictors 
of disease progression and characterise the medium and long-term natural history. It
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will be important to ensure that clinical and public health systems are established to 
manage these children appropriately and collect data for research. Mathematical 
modelling could be used to predict the long-term consequences and future burden on 
health services of mother-to-child transmission of HCV. Data on HCV infected adults 
and antenatal prevalence could be combined with the evidence on the risk of vertical 
transmission and the natural history of vertically acquired infection, including markers 
of immunological function, to estimate the number o f vertically HCV infected children 
bom annually and the likely morbidity, mortality and treatment costs. Similar work has 
been done to predict the outcome of IDU-related infection (Hutchinson et a l  2005) and 
to estimate future hepatitis C-related morbidity, mortality and costs for the Spanish 
population (Buti et al. 2005).
Accounting for the views o f parents, older infected children and health care 
professionals in decisions regarding the management and long-term follow-up of 
infected children will be essential. The survey was very much a preliminary assessment 
of the views and needs of parents and carers on the care of their children. The results 
raise some important issues, particularly the poor provision of information, which 
warrant further attention. A survey of the service providers would clarify the policies in 
place for the care of children bom to HCV infected women and the extent to which 
current practice reflects policy.
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Appendix 3.2 EPHN protocol
EUROPEAN PAEDIATRIC HCV NETWORK
P r o s p e c t iv e  St u d y  P r o t o c o l
Objectives o f  the prospective study
Work already carried out within the European Paediatric HCV Network (EPHN) has 
elucidated certain issues relating to perinatal HCV transmission. However, the 
information gathered is limited by various factors such as variation between centres in 
follow-up schedules, lack o f detailed data in some cases, and the retrospective nature of 
the analysis.
In this prospective cohort study aU children 1) with vertically acquired HCV infection 
or 2) bom to women known to be HCV infected at delivery will be followed-up 
according to a standard protocol, enabling the following issues to be addressed more 
satisfactorily:
Reliable estimates of vertical transmission risk
Timing of mother-to-child transmission
Maternal and obstetric risk factors for vertical transmission
Natural history of paediatric HCV infection
Development of laboratory diagnostic protocols
Eligibility
The children eligible for this prospective study are in one of two groups:
I) infected children with documented perinatal acquisition of infection 
prospectively followed from the first month of life. This includes children 
already notified to the EPHN through the retrospective natural history 
questionnaires and the infected children included in the meta-analysis. Although 
identified retrospectively they can be followed-up prospectively for this study 
starting now, from any age.
For the children and their mothers in group I it is not necessary to complete forms A, B 
and C, as we have sufficient information from the meta-analysis and natural history 
questionnaires. Only the paediatric follow-up forms (D and E) need to be completed at 
each visit.
II) newly identified mother-child pairs who are eligible to be enrolled in this 
study if:
- a) mother identified as HCV infected (by 2nd or 3rd generation ELISA or RIBA 
or by PCR) at or before delivery
and/or
- b) child identified as HCV seropositive within one month of delivery, 
provided that maternal HCV infection is confirmed.
Mother-child pairs who are seropositive for HIV should also be included.
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Guidelines on completing the form s
EPHN ID number: This is the unique identifier for each child and appears on every 
form. It is composed o f the centre number (2 digits), the mother number (3 digits), and 
the child number (3 digits). There is a mother number to identify siblings and so that a 
mother is not counted twice.
e.g. EPHN ID no. 05/003/001 is for Centre 5, mother 3, child 1
if mother 3 had another child their ID no. would be 05/003/002
FORM A -  Maternal Enrolment Information (Group II only)
Form A should be completed when the mother is enrolled. This may be any time during 
pregnancy or at delivery.
Please check with your local ethics committee whether informed written consent should 
be obtained from the mother at enrolment.
For each question on Form A please tick one box only.
FORM B -  Maternal Clinical and Laboratory Information during Pregnancy 
(Group II only)
This form should be completed at delivery.
HCV test results -  please give details of HCV tests performed on the mother during this 
pregnancy, starting with the most recent. If available, please also give details of earlier 
tests. It is assumed that all ELISA and RIBA tests are second or third generation (if not, 
please discuss this with the co-ordinators).
If identified early enough in pregnancy, the mother should be tested for HCV viraemia 
during the first, second and third trimesters, or as often as possible.
Viral load should be reported where available.
If possible, a 1 ml serum sample should be taken from the mother at or around the time 
of delivery and immediately stored at -80°C. This will be used to study variations in 
some biological characteristics of the virus over time in infected mother-child pairs.
FORM C -  Delivery Information (Group II only)
Mode of delivery: please tick one box only. Note that an elective Caesarean section is 
defined as occurring before onset of labour and before rupture of the membranes.
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FORM D -  Paediatric Follow-up: Clinical Examination (Groups I and II)
Children should be seen at or close to the following ages if possible and a form D filled 
in at each visit:
birth, 6 weeks, 3, 6, 9 ,12 ,18 , and 24 months
Then every six months if infected or every year if uninfected.
There are TWO D forms -  DI and D2.
Form DI should be completed at birth, at 6 weeks, and at 3 months of age.
Form D2 should be completed at 6 months and at all subsequent visits.
HCV treatment: If a decision is taken to treat the child for HCV infection, the EPHN 
treatment protocol should be followed if at all possible. There are questions about 
treatment on form D2. This information can be linked to the laboratory test information 
which is provided on form E.
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FORM E -  Paediatric Follow-up: Laboratory Test Information (Groups I and II)
There are TWO E forms -  El and E2.
As for the D forms; Form E l should be completed at birth. 6 weeks and 3 months of 
age
Form E2 should be completed at 6 months and at all subsequent 
visits.
We would encourage children to be seen at the following times and for blood to be 
taken and tested as indicated below, if at all possible:
Age at visit Tests to be done 
(in the routine way)
Extra samples to be taken and 
stored
0-3 days Qualitative PCR, ALT Guthrie card
6 weeks Qualitative PCR, ALT -
3 months Qualitative PCR, ALT Guthrie card
Serum or plasma sample in 3-5 
200pl aliquots
6 ELISA, Qualitative PCR, ALT -
9 ELISA, Qualitative PCR, ALT -
12 ELISA, Qualitative PCR, ALT, 
& test for presence of auto­
antibodies if child is infected*
Serum or plasma sample in 3-5 
200pl aliquots
18 ELISA, Qualitative PCR, ALT -
24 ELISA, Qualitative PCR, ALT Serum or plasma sample in 3-5 
200pl aliquots
If infected: 
Every 6 months ELISA, Qualitative PCR, ALT Serum or plasma sample in 3-5 
200pl aliquots every year
Note:
The date of test refers to the date that the blood sample was taken.
Genotyping need only be done once.
*The test for presence of auto-antibodies should be performed only in infected children 
and once a year, starting from one year o f age.
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Stored samples
Guthrie card (filter paper) and serum/plasma samples should be taken and stored at the 
ages indicated in the table above, i.e. Guthrie card at birth and 3 months; serum/plasma 
at 3 months, 12 months, 24 months, and then once every subsequent year for infected 
children.
Older Group I children should have a serum/plasma sample taken and stored at the first 
visit and then once every year.
If possible, a 1 ml serum/plasma sample should also be taken from the mother at the 
child’s first visit.
The ‘other tests’ listed on the lab form (E) do not have to be done at any specified times. 
However, the results of all tests that are performed should be reported on form E in the 
format indicated.
If it is more convenient, copies o f hospital lab reports can be sent rather than filling out 
EPHN forms. In this case please attach the lab report to an EPHN form E with just the 
EPHN ID number filled in.
Despatch of Completed Forms
Completed forms should be faxed if possible, or sent by post to the London co­
ordinating centre at appropriate intervals. Faxing the forms allows participating centres 
to keep the original form so that duplicate forms will not be necessary. If sending by 
mail, please keep a copy of the forms sent.
The forms are colour coded for easy identification.
There are also arrangements in place for the electronic transfer o f data in an Access 
database by email to the London co-ordinating centre. Please contact Lucy Pembrey if 
you would like to discuss the possibility of sending your data in this way.
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Appendix 3.3 EPHN data collection forms
Form A Maternal enrollment information
Form B Maternal clinical and laboratory information
Form C Delivery information
Form DI Paediatric follow-up: clinical examination (birth, 6 weeks & 3
months)
Form D2 Paediatric follow-up: clinical examination (6 months & older)
Form E l Paediatric follow-up: laboratory test information (birth, 6 weeks & 3
months)
Form E2 Paediatric follow-up: laboratory test information (6 months & older)
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FORMA
EUROPEAN PAEDIATRIC HCV NETWORK
Prospective Study
_______________MATERNAL ENRO LLM ENT INFORM ATION
EPHN ID number  / _____/ ______
centre no. mother no. child no.
Mother’s date of birth / /
Most likely mode of maternal acquisition of HCV infection
blood transfusion/blood products □
injecting drug use □
other □  please specify
not known □
Reason for HCV testing
mother’s request □
routine antenatal policy □
identified as high risk group □
(selective screening policy)
clinical (e.g. signs of hepatitis) □
other □  please specify
Has the mother used intravenous drugs?
yes, during this pregnancy □
yes, but not during this pregnancy □
never □
don’t know □
Is the mother HIV infected? Yes □ If yes, CDC stage: A1 A2 A3
No □ (please circle) B1 B2 B3
Don’t know □ C1 C2 C3
Has this mother been previously reported to the Network? Yes □
No □
If yes, please give EPHN ID number(s): / /
261
FORM B
EUROPEAN PAEDIATRIC HCV NETWORK
Prospective Study
MATERNAL CLINICAL AND LABORATORY INFORM ATION DURING  PR EG N ANCY
EPHN ID number  /   / __
centre no. mother no. child no.
HCV test results
Please give details of ALL tests carried out during this pregnancy and at delivery, 
starting with most recent.
If available, please also give details of earlier tests.
ELISA Date
Result
^RIBA Date
Result
PCR-RNA Date
Result
RNA
copies per ml
Date
Result
ALT
IU/L
Date
Result
Has the mother’s HCV genotype been determined? Yes □
No □
If yes, please specify genotype:
Has the mother received treatment during pregnancy or during delivery for HCV 
or HIV infection?
Yes □  If yes, name of drug dosage
No □  .....................................................
date treatment started   /
date treatment stopped _ _ _ /_  /_
Was a 1 ml serum sample taken and stored from the mother at or near delivery?
Yes □ Date: / /
No □ If not, why not:.....................................................................................................
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FORM C
EUROPEAN PAEDIATRIC HCV NETWORK
Prospective Study
_    DELIVERY INFO RM ATION
EPHN ID number /
centre no. mother no. “ cHiid no.
Date of delivery / /___
day month year
Mode of delivery
vaginal, spontaneous □ emergency Caesarean section □
vaginal, instrumented □ elective Caesarean section* □
*l.e. before onset of labour and rupture of membranes
unknown □
Total duration of labour:____ h rs______mins
Time from rupture of membranes to d e l i v e r y : _____hrs______mins
Were any obstetric interventions (e.g. fetal scalp monitors, forceps) used during
delivery? Yes □  If yes, please specify..................................................................
No □
Don’t know □
NEONATE INFORMATION
Birth weight (grams) ....................
Gestational age (weeks) ............
Gender male □
female □
Was any anti-retroviral treatment to reduce the risk of transmission of HIV 
administered to the neonate?
If yes, name of drug dosage
Yes □  .......................  ................
No □
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FORM DI
EUROPEAN PAEDIATRIC HCV NETWORK
Prospective Study
PAEDIATRIC FOLLOW -UP: CLINICAL EXAMINATION  
For examinations at birth, 6 weeks and 3 months of age
EPHN ID number  / _____ /   Date of examination /  /____
centre no. mother no. child no day month year
Date of birth / /____
day month year
Weight (kg )____ . ____
Height (cm)
Is this child HIV infected? Yes □
No □
Indeterminate □
If yes, CDC stage (please circle): N1 N2 N3 A1 A2 A3 B1 B2 B3 C1 C2 C3
Clinical manifestations
Has this child developed any of the following symptoms since the last visit?
Growth failure yes / no ..........
Please give details
Hepatomegaly yes / no ..........
Splenomegaly yes / no ..........
Nephropathy yes / no ..........
Cardio-pulmonary yes / no ..........
Skin disorders yes / no ..........
Haematological disorders yes / no ..........
Auto-immune disease yes /  no ..........
Other yes / no ..........
Was this child ever breast-fed? Yes □ If yes, age stopped (weeks)
No □
Don’t know □
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F0R M D 2
EUROPEAN PAEDIATRIC HCV NETWORK 
Prospective Study
PAEDIATRIC FOLLOW-UP: CLINICAL EXAMINATION 
________  For examinations at 6 months of age and older_________
EPHN ID number  / _____ /   Date of exam ination / /____
centre no. mother no. child no day month year
Date of birth / /______
day month year
Weight (kg)
Height (cm)
Is this child HIV infected? Y es □
No □
Indeterminate □
Ifyes, CDC stage  (p lease circle): N1 N2 N3 A1 A2 A3 B1 B2 B3 C1 C 2 C3
Clinical manifestations
Has this child developed any of the following symptoms since the last visit?
Growth failure yes / no ...........
Please give details
Hepatomegaly yes / no ...........
Splenomegaly yes /  no ...........
Nephropathy yes / no ...........
Cardio-pulmonary yes / no ...........
Skin disorders yes / no ...........
Haematological disorders yes / no ...........
Auto-immune disease yes / no ...........
Other yes / no ...........
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FORM D2
Has this child been vaccinated against:
hepatitis B? Yes □  
No □
If  yes, date o f first dose 1 /
hepatitis A? Yes □  
No □
If yes, date o f first dose I /
Has this child had an ultrasound since the last visit? Yes □
No □
If yes, date of ultrasound / /
result ...................................................................................................
Has this child had a liver biopsy since the last visit? Yes □
No □
If yes, date of biopsy /  /
reason for biopsy ............................................................................
result ..................................................................................................
Is this child receiving treatment for HCV infection? Yes □
No □
Date treatment started / /
Reason for starting treatment ......................................................
D ru g .......................................... Dosage................................
If child is no longer being treated, date treatment stopped /  /
Reason for stopping treatment ...................................................
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FORM El
EUROPEAN PAEDIATRIC HCV NETWORK
Prospective Study
PAEDIATRIC FOLLOW-UP - LABORATORY TEST INFORMATION 
For tests done at birth, 6 weeks, and 3 months o f age
EPHN ID number _ _ /
centre no mother no. child no.
Details o f laboratory tests carried out since the last visit: 
HCV PCR tests
Date o f test Result (positive/negative) Viral load* - copies per ml
*method used:
HCV Antibody tests
Date of test Type o f test
ELISA or RIBA,2nd or3fd 
generation
Result
positive/negative/
indeterminate?
no. o f bands
ALT levels
Date of test ALT level (IU/1)
Samples to be stored
W as a Guthrie card (filter paper) sam p le taken and stored (birth & 3 m ths)?
Y es □  D ate:_______ /______ /___________
No □  If not, why n o t : ................................................................................
W as a 1 ml serum or plasm a sam ple taken and stored (3 mths)?
Y es □  D ate:_______ /______ /___________
No □  If not, why not:.................................................................................
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FORM El
Other tests
Date of test Result
haemoglobin g/dl
g/dl
_____________ g/dl _
WBC 10 /ml
106/ml
10B/ml
lymphocytes %
%
%
neutrophils %
%
%
platelets /ml
/ml
/ml
coagulation screen
normal or abnormal:
if  abnormal please specify
IgG mg/dl
mg/dl
mg/dl
IgM mg/dl
mg/dl
mg/dl
igA mg/dl
mg/dl
mg/dl
igE lU/ml
lU/ml
lU/ml
total bilirubin mg/dl
mg/dl
mg/dl
albumin g/dl
g/dl
g/dl
alpha fetoprotein ng/ml
ng/ml
ng/ml
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FORM El
Is the HCV genotype of this child known? Yes □  If yes, genotype
No □
Have any other tests been carried out for this child? Yes □
No □
If yes, please give details below (date, type of test, result):
Date Type of test Result
FORM E2
EUROPEAN PAEDIATRIC HCV NETWORK 
Prospective Study
PAEDIATRIC FOLLOW-UP - LABORATORY TEST INFORMATION 
______ f o r  tests done at 6 months of  age and older______
EPHN ID number _ / _  _ /
centre no mother no child no
Details o f laboratory tests carried out since the last visit:
HCV PCR tests
Date of test Result (positive/negative) Viral load* - copies per ml
*method used:
HCV Antibody tests
Date of test Type o f test
ELISA or RIBA, 
generation
Result
positive/negative/
indeterminate?
no. o f bands
ALT levels
Date of test ALT level (IUA)
Samples to be stored
W as a 1 ml serum or plasm a sam ple taken and stored (at 12 mths, 24 mths, then on ce  
a year)?
Y es □  D ate:______ /______ /____________
No □  If not, why not:........................................................................................................
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FORM E2
Other tests
Date of test Result
haemoglobin g/dl
g/dl
g/dl
WBC 106/ml
106/ml
K^Tml
lymphocytes %
%
%
neutrophils %
%
%
platelets /ml
/ml
/ml
coagulation screen 
normal or abnormal: 
i f  abnormal please specify
IgG mg/dl
mg/dl
mg/dl
IgM mg/dl
mg/dl
mg/dl
igA mg/dl
mg/dl
mg/dl
igE lU/ml
lU/ml
lU/ml
total bilirubin mg/dl
mg/dl
mg/dl
albumin g/dl
g/dl
g/dl
alpha fetoprotein ng/ml
ng/ml
ng/ml
271
FORM E2
Has this child been tested for the presence of auto-antibody since the last visit?
Yes □  If yes, re s u lt_____________________________________
No □
Is the HCV genotype of this child known? Yes □  If yes, genotype
No □
Have any other tests been carried out for this child? Yes □
No □
If yes, please give details below (date, type of test, result):
Date Type o f test Result
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Appendix 3.4 Publications arising from the research
Chapter 4:
European Paediatric HCV Network (Tovo PA, Pembrey L, Newell ML.) A significant 
sex - but not elective cesarean section - effect on mother-to-child transmission of 
hepatitis C virus. Journal o f  Infectious Diseases, 2005; 192:1872-1879
Chapter 6:
European Paediatric HCV Network (Pembrey L, Tovo PA, Newell ML.) Three broad 
modalities in the natural history of vertically acquired hepatitis C virus infection. 
Clinical Infectious Diseases 2005;41:45-51
EPHN publications related to work in the thesis:
European Paediatric HCV Network (Mok J, Pembrey L, Tovo PA, Newell ML) When 
does mother-to-child transmission of hepatitis C virus occur? Archives o f  Disease in 
Childhood (Fetal and Neonatal Edition) 2005 ;90:F156-F 160.
European Paediatric HCV Network (Polywka S, Pembrey L, Tovo PA, Newell ML)
Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired
HCV infection. Journal o f  Medical Virology, 2006;78:305-310
European Paediatric HCV Network (Pembrey L, Newell ML, Tovo PA, EPHN 
collaborators) The management of HCV infected pregnant women and their children. 
Journal o f  Hepatology 2005;43:515-525
European Paediatric HCV Network (England K, Pembrey L, Tovo PA, Newell ML)
Excluding hepatitis C virus (HCV) infection by serology in young infants o f HCV
infected mothers. Acta Paediatrica 2005;94:444-450
European Paediatric HCV Network (England K, Pembrey L, Tovo PA, Newell ML) 
Growth in the first 5 years of life is unaffected in children with perinatally-acquired 
hepatitis C infection. Journal o f  Pediatrics, 2005;147:227-232
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Appendix 5.1 Questionnaire for EPHN 2001
European Paediatric HCV Network
Retrpspective questionnaire for individual meta-analysis on the effects of mode of 
delivery and type of feeding on mother-to-child transmission
EPHN ID n u m b e r  /________ Are any siblings of this child included in this study? Y es □
centre no. child no. N O  D
I f  yes, please give their EPHN ID numbers:
Delivery details
Date of delivery / /
day month year
M ode o f delivery vaginal, spontaneous □ em ergen cy  C aesarean  section  □
vaginal, instrumented □ elective C aesarean  section* □
* i.e. before onset of labour and rupture of m embranes
unknown □
W ere fetal scalp  monitors used  during delivery? Y es □  D on’t know □
No □
G estational ag e  (w eeks) .............
Birth w eight (grams) .....................
Maternal information
Maternal a g e  at delivery (years)
Date of first confirmation of mother’s HCV infection /__  /_______
day month year
Is the mother HIV infected? Yes □  If yes, CDC stage: A1 A2 A3 B1 B2 B3 C1 C2 C3
No □  (please circle)
W ere any other infections identified during pregnancy? Yes □  Don’t know □
No □
If  yes, please specify.....................................................................
Does the mother have a history of hepatitis? Yes □  Don’t know □
No □
Has the mother used intravenous drugs? Yes, during the pregnancy of this child □
Yes, but not during the pregnancy of this child □
Never □
Don’t know □
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Appendix 5.1 Questionnaire for EPHN 2001
Child information
Is this child HC V infected, according to our definition (see instructions)? Yes □
No □
Indeterminate □  see below
W as this diagnosis based on the results of antibody tests alone? Yes □
No □
W as this child tested by PCR within the first three days of life? Yes □
No □
Don’t know □
If yes, please give date of test and result:
Date of last clinical examination / /
day month year
Date of last laboratory investigation / /
day month year
W as this child ever breastfed? Yes □  If yes, age stopped (weeks)
No □
Don’t know □
Is this child HIV infected? Yes □
No □
Indeterminate □
Please return completed forms to:
Lucy Pembrey
Department o f Epidemiology and Public Health 
Institute o f Child Health 
30, Guilford Street 
London WC1N 1EH
Fax No: +44 1 71 242 2723
*  If the child is of indeterminate infection status, please give details of all HCV tests: 
Date of test Method (e.g. PCR, ELISA, RIBA II or III) Result
continue overleaf if necessary
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Appendix 5.1 Instructions for EPHN 2001
Individual data meta-analysis on the effects of mode of delivery and type 
t f  feedlhg oii mothertx>-ctiild transmission of HCV 
INSTRUCTIONS
At the EPH N workshop held in Turin in July it was agreed to undertake an individual 
m eta-analysis using the data previously collected by each centre to assess the 
impact of mode of delivery and type of feeding on perinatal H C V  transmission. This 
will enable clinicians to help infected wom en m ake better informed decisions about 
breastfeeding and mode of delivery.
P lease complete the enclosed questionnaire for each mother-child pair followed at 
your centre who fit the following inclusion citeria.
Inclusion criteria:
Mother must have been identified as H C V  infected with 2nd or 3rd generation  
ELISA, RIBA, or PC R  at or before delivery. Mother-child pairs can also be included 
in cases where the child was identified as seropositive within one month of delivery, 
provided that maternal H C V  infection was confirmed.
In order to avoid selection biases we have m ade the following restrictions:
All children born to H C V  infected mothers should be included if they were:
- born on or after 1st January 1992, and
a) at least 18 months old at the time of their last laboratory assessm ent, with 
definitive infection status, or
b) born more than 18 months ago and no longer in follow-up, irrespective of their 
infection status
Exclusion criteria:
History of blood transfusion in the child
Definitions of HCV infection s ta tu s  for th is m eta-analysis
The diagnosis of H C V  infection in the child is based on:
i) antibody positivity beyond 18 months and/or
ii) at least 2 positive PC R  tests (on 2 separate occasions)
Children are classified as uninfected if:
i) antibody negative at or after 18 months of age and had less than two positive 
PCR results, or
ii) born more than 18 months ago and are no longer in follow-up and had two 
negative antibody tests and less than two positive PCR results
Children are of indeterminate infection status if:
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Appendix 5.1 Instructions for EPHN 2001
i) born more than 18 months ago and antibody positive before 18 months of
age, and
•  with no PC R  analyses perform ed, or
•  no positive P C R  result, or
•  a single positive P C R  result
ii) born more than 18 months ago with a single antibody negative test before 18
months of age
For the few children who are of indeterm inate infection status, we would be grateful 
if you could give details of all their H C V  antibody and P C R  tests in the space  
provided at the end of the questionnaire. It is useful for us to know why each child is 
classified as indeterminate.
EPHN ID num ber
The EPH N  ID number is the sam e format that we used for the natural history 
questionnaires. The first 2 digits refer to the centre number. This is X X  for your 
centre. The last 3 digits identify the individual child. Children are num bered  
consecutively from 1 as they are included.
If you sent us natural history questionnaires for infected children at your centre these  
children will already have E PH N  ID numbers - please use the sam e num ber on 
these forms. W e  enclose a list of IDs for children of your centre for whom  w e already  
have information with the corresponding date of birth and any other reference that 
we have.
Transfer of data by com puter file
Som e of you who have patient records entered on com puter may find it more  
convenient to send us the relevant data by com puter file (e.g. as an A S C II file), 
rather than having to copy out data by hand onto each form. If this is the case  
please contact Lucy Pem brey to discuss the best way to do this. She will provide you 
with a list of the variables needed and the form at in which they should be provided.
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Appendix 8.1 Survey questionnaire (English version)
Centre no.
Children born to women with hepatitis C (HCV) infection: 
a questionnaire for parents and carers
We are researchers in the European Paediatric Hepatitis C Virus Network and are 
writing to ask for your help. Our Network carries out research on how hepatitis C 
infection (HCV) in mothers affects their babies. An important part of the research is 
to find out if children with HCV infection have any health problems.
We would like to ask you some questions about how HCV infection affects you and 
your child. We would also like to know what you think about the services provided 
for families affected by HCV infection.
We would be very grateful if you could complete this questionnaire which should 
only take about 10 minutes. You do not need to include your name or other 
personal details that could identify you. This information will be kept confidential. 
This means your answers will not be given to anyone else, including the doctors 
and nurses at the clinic.
When you have completed the questionnaire, please seal it in the envelope 
provided and give it to the clinic doctor or nurse who will send it back to us. We 
hope this study will help to improve the care of children affected by HCV infection.
Please say if you do not wish to take part. It will not affect you or your child’s care in 
any way.
Thank you very much for your help. To show our appreciation we will enable your 
clinic to buy something which will benefit the patients (e.g. something for the waiting 
area).
European Paediatric Hepatitis C Network
Centre for Paediatric Epidemiology & Dipartimento di Scienze Pediatriche e dell’
Biostatistics, Institute of Child Health Adolescenza
University College London Universita di Torino
30 Guilford Street P iazza Polonia 94
London W C 1N  1EH, UK 10126 Torino, Italy
For further information, please contact Lucy Pembrey 
(Email: L.Pembrev@ich.ucl.ac.uk. Tel: +44 20 7905 2734).
If you have a specific question about the questionnaire, please ask the doctor 
or nurse at your clinic and they will contact us if necessary.
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Children born to women with hepatitis C (HCV) infection: 
a questionnaire for parents and carers
W here did you complete this questionnaire? At the clinic □
At home □
Date completed: O th e r ...............................................
Section 1
About you
1. How old are you? less than 25 years □  please tick one box only
25-29 □
30-34 □
35-39 □
40-44 □
45+ □
2. Are you: fem ale □
male □
3. Are you: single □  please tick one box only
CO-habiting (living with your partner) □
married □
divorced or separated □
widowed □
4. How would you describe your ethnic group?
white □  please tick one box only
black □
asian □
oriental □
other (please spec ify ) ....................
5. In which country were you born?
6. How long have you lived in the country you are living in now?
since birth □ O R years
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About vour child
Please answ er these  questions abou t the child you have brought to the clinic today
1. Are you this child’s:
Mother □  please tick one box only
Father □
Adoptive parent □
Grandparent □
Other relative □
Foster parent □
Other (please specify) ..................................................
2. W hen was your child born?
Date: ______
day month year
3. Is your child:
male □
fem ale □
4. Does your child have H C V  infection?
Yes □
Not confirmed either way (indeterm inate) □  
Don’t know -  has not been tested □
If no, how old was your child when you w ere told that he/she does not have H C V  
infection?
....................years  months
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Section 2
• If you are the child’s  m other, we would like to ask  you a few questions abou t vour 
own health and how you are  affected by HCV infection.
• If you are not the child’s  m other, p lease  go to Section 3 on page 5.
1. W hen w ere you told that you have H C V  infection?
Date: _  _  / ______
month year
P lease give just the year if you cannot rem em ber the exact date.
2. How do you think you becam e infected with H C V?
For example,
Injecting drug use □  please tick a ll that apply
Blood transfusion/blood products □
Sex □
Other □  please say how  ....................................................
Don’t know □
3. How much does your H C V  infection (including any treatm ent you m ay currently be 
taking for it) affect your daily life?
Activities a t home Activities outside the hom e
(e.g. cooking, cleaning, (e.g. work):
looking after the children):
not at all □
a little □
a lot □
not at all □
a little □
a lot □
Please give details here
4. How often do you see a doctor or nurse about your H C V  infection?
About once a year 
About twice a year 
Every 3- 6 months
More often than every 3 months
Never
Less than once a year
□
□
□
□
□
□
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Section 3 Everyone should  answ er the questions in th is section
Visits to the clinic for vour child
1. How often does your child see a doctor or nurse at the H C V  clinic?
Less than once a year □
About once a year □
About twice a year □
Every 3- 6 months □
More often than every 3 months □
2. How easy is it for you to get to the clinic (e.g. distance to travel)?
Very easy □
Easy □
O K □
Difficult □
Very difficult □
Please describe any difficulties getting to the clinic
3. a) For your child’s appointment, do you or your child have to take time off work or 
school to go to the clinic?
You: Yes □  Your child: Yes □
No □  No □
I don’t work □  D oesn’t go to school □
b) If yes, how easy is it to do so?
Very easy □ Your child: Very easy □
Easy □ Easy □
OK □ O K □
Difficult □ Difficult □
Very difficult □ Very difficult □
Please describe any difficulties
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4. Overall, how satisfied are you with the care provided by the H C V  clinic w here your 
child is seen?
Very satisfied □  please tick one box only
Satisfied □
Unsatisfied □
Very unsatisfied □
Please write your comments h e re .......................................................................................
5. How often would you like your child to see a doctor or nurse at the H C V  clinic?
please tick one box only
More often than they do now □  ->  how o fte n .....................
The sam e as they do now □
Less often than they do now □  -»  how o fte n .....................
6. Do you feel you need more information about:
a. H C V infection in general Y E S □ NO □
b. the different blood tests for H C V  infection Y E S □ NO □
c. how it is confirmed that your child is Y E S □ NO □
H C V infected or not
If yes, please give details here
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7. Do you have any suggestions for changes or improvements to the clinic or the care 
provided by the clinic?
Y ES  □  NO □  I f  yes, please write your suggestions below
8. Would you like any other services to be provided at or outside the clinic (e.g. 
support groups)?
Y E S  □  NO □  If  yes, please write your suggestions below
• If your child is infected, p lease go to section  4 (page 8)
• Otherwise, please go to section 5 (page 11)
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Section 4
If your child is HCV infected, p lease  answ er the questions below
1. How old was your child when you w ere told that he/she has H C V  infection?
....................years  months
2. Does your child know that he/she has H C V  infection? please tick a ll that apply
Yes □  ->  please go to question 3
No □
He/she is too young to understand □
a) If no, when do you plan to tell your child about their H C V  infection?
W hen he/she is older □  ->  At what age? __  years
Never □
Have not thought about it □
Comments .......................................................................................................................................
b) Would you like help in telling your child about their H C V  infection?
I would like a doctor or nurse at the H C V  clinic to tell my child □
I would like to tell my child with the support of staff at the H C V  clinic □
I would like to tell my child on my own □
Comments ..........................................................................................................................
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3. Do you feel you need more information about:
a. how your child’s health m ay be affected Y E S  □  NO □
by H C V  infection
b. possible treatm ent for your child’s H C V  Y E S  □  NO  □
infection
If yes, please give details here ........................................................................................................
4. Do you think your child will have any health problems in adulthood because of his/her 
H C V  infection?
Yes □  please tick the box next to your answer 
No □
If yes, what do you think these health problems will be?
Please read the following sta tem ents and tick the box next to the answ er which best 
matches what you think.
5. It is important to find out about the possible health problems that children with
H C V  infection may have in adulthood.
Strongly agree □  please tick one box only
Agree □
Disagree □
Strongly disagree □
6. A  system is needed to find out about the possible health problems that children
with H C V  infection may have in adulthood.
Strongly agree □  please tick one box only
Agree □
Disagree □
Strongly disagree □
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7. Below are five possible ways w e could find out about the long-term effect of H C V  
infection on your child’s health. We do not yet know which of th ese  may be used  but 
would like to know what you think about them . Please read each one and think about 
which one you would prefer. Then write your answers in the space at the bottom.
1 •  You continue to take your child to visit the paediatrician once or twice a 
year
•  W hen your child becom es a teenager they would be seen by a liver 
specialist or another doctor who sees adults, once or twice a year, 
instead of seeing the paediatrician
2 • Doctors or nurses, from the hospital which you currently visit, would  
keep in contact with your child by p o st or telephone once a year and 
ask questions about their health
3 • R esearchers would keep in contact with your child by p o s t or 
telephone once a year and ask questions about their health
4 •  Your child’s details would be added to a list of children with H C V  
infection
•  These details could be linked to sources of information on specific 
health problems
•  Your child would not be contacted directly on a regular basis
5 •  W hen your child is 20 to 30 years old they would be contacted by a 
health professional from a hospital or research centre
•  They would be asked to attend hospital for a visit to check their health  
and have som e blood tests
•  You would need to tell your doctor every time you change address
a) Which option would you m ost prefer? Choose one and write in the num ber here: 
O p tio n _____
W h y ? ....................................................................................................................................
b) Which option would you like least? Choose one and write in the number here: 
O ption_____
W h y ? ....................................................................................................................................
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Section 5
Please use this page to write any though ts or com m ents you have abou t the 
issues in this questionnaire. Continue on another sh e e t if necessary .
THANK YOU VERY MUCH FOR YOUR HELP
Please put your completed questionnaire in the envelope provided and hand it to 
the paediatrician or clinic nurse who will send  it on to us.
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a questionnaire for parents and carers
Log sheet
• Please complete this list so you can keep track of which parents you have asked to 
participate and which questionnaires have been completed and sent to London.
• Please send the completed list to Lucy Pembrey at the end of the study. Please do 
not write any names on this list as the survey is anonymous.
• You will need to keep a separate list yourself to link the names with the number in 
the left-hand column.
CENTRE
Has the parent 
or carer agreed 
to complete 
questionnaire?
(Yes or No)
If they refused: If they agreed:
Please give reason, if known Have they 
given 
completed 
questionnaire 
back to you?
Please tick 
below
Have you sent the 
questionnaire on to 
Lucy Pembrey in 
London?
Please write in date 
sent to London
1
2
3
4
5
6
7
8
9
10
11
Please continue on another sheet if necessary
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